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Preface
PREFACE
The world-wide incidence of cancer increases, and this also holds for the incidence in adolescents 
and young adults (AYA). For the entire cancer population, much attention is paid to logistics 
and infrastructure of treatment of cancer patients, while the model of centralization of pediatric 
oncology has been active since decades. In contrast, the knowledge and awareness of the “AYA” 
cancer population was very limited up to recently, which was referred to as the AYA gap in cancer 
care. A few world-wide and local initiatives (e.g. development of Children’s Oncology Group AYA 
committee, opening of a number of AYA oncology units) have been undertaken to increase the 
awareness and facilitate centralization of care for this particular population of cancer patients 
with their specific needs. 
Two population-based epidemiological studies focusing on the AYA cancer population in the 
Netherlands are described to provide the fundamentals for the optimization of cancer care for 
this population in the Netherlands. Furthermore, this knowledge on incidence and survival is 
useful in the development of international initiatives, such as the design of collaborative studies. 
It furthermore provides essential population-based data on the incidence of second tumours in 
this cohort. These studies were conducted in collaboration with the Comprehensive Cancer Centre 
North-Netherlands (CCCN, E. Bastiaannet), and the Netherlands Cancer Registry (NCR, K. Aben). 
The following chapters of this thesis focus on of this thesis focuses on rhabdomyosarcoma (RMS) 
as an ultimate example of a tumour type overlapping the pediatric and AYA population. The first 
study provides a multi-centre retrospective study (1977-2009) which adds data to the negative 
prognostic effect of age on outcome in embryonal and alveolar RMS. This study was conducted 
in a collaboration between three medical centres in the Netherlands; the department of pediatric 
oncology (E. de Bont) and medical oncology (W. van der Graaf ) at the University Medical Center 
Groningen (UMCG), the department of medical oncology (S. Sleijfer) at the Erasmus Medical 
Center Rotterdam, and the department of pediatric oncology (J. Loeffen) and medical oncology 
(Q. van Hoesel, W. van der Graaf ) at the Radboud University Nijmegen Medical Centre (RUNMC). 
As survival rates for older patients as well as for particular high risk RMS subgroups remain 
poor and the aggressive multi-modality treatment regimens induce substantial late effects, we 
subsequently investigated novel potential treatment targets (ALK and IGF-1R) in RMS patient 
tumour samples and in vitro models. Tumour samples were collected from the previously 
described cohort, with additional samples collected via PALGA, the nationwide network and 
registry of histo- and cytopathology in the Netherlands. Diagnoses of all samples were confirmed 
by U. Flucke (department of Pathology, RUNMC) and all investigations were conducted by the 
preclinical sarcoma research group ((Y. Versleijen-Jonkers, W. van der Graaf ) of the department 
of medical oncology, which is embedded in the department of Pathology of the RUNMC, head: 
J. van Krieken).
This project was sponsored by the RUNMC and the Junior Scientific Masterclass (JSM, UMCG). 
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General Introduction
The basis to increase awareness and facilitate the development of tailored treatment and care 
of this young cancer population is a throughout description of the epidemiological features 
(e.g. incidence, distribution, survival) of cancers affecting this population. Another important 
feature to consider in both children and AYA with cancer is their generally long life-expectancy 
after surviving cancer, accompanied by an increased risk of development of long-term cancer 
related issues, including long term morbidity/mortality and second malignancies, due to previous 
anti-cancer treatment and/or genetic susceptibility (11-20). 
In Chapter 2, a population-based study concerning AYA patients (12-24 years) diagnosed in the 
Northern Netherlands and registered by the Comprehensive Cancer Centre North-Netherlands 
(CCCN) over the period 1989-2003 (N=1,118 patients) is reported. Cancer incidence and survival 
was the primary focus to get more insight in the age distribution of malignancies in this group 
with a special focus on the risk of second malignancies. 
In Chapter 3, an extended AYA cancer study is reported, concerning the Dutch nationwide 
population-based data of AYA cancer incidence (N= 23,161; 15-29 years) by the Netherlands 
Cancer Registry (NCR) over the period 1989-2009.
Rhabdomyosarcoma (RMS) is a rare type of soft tissue sarcoma that represents an ultimate 
example of a typical childhood malignancy which also occurs across the AYA age-spectrum and 
shows inferior survival rates in the older population (21-23). There are two main histological 
variants which can be distinguished; embryonal rhabdomyosarcoma (eRMS, 60-70% of RMS) 
and alveolar rhabdomyosarcoma (aRMS, 30% of RMS). These subtypes show unique age-related 
patterns of incidence. Although eRMS typically occurs in young children as 70% of the patients 
are diagnosed within the first decade of life, it shows a broad age range as it might occur in 
adults up to 70 years of age. In contrast, aRMS rarely occurs in young children, but shows an 
incidence peak in adolescents and young adults (24). 
The prognosis in children with RMS has improved dramatically during the last decades because 
of the introduction of multi-agent chemotherapy in consecutive multidisciplinary clinical trials 
and treatment in a centralized setting (25-29). The Intergroup Rhabdomyosarcoma Study Group 
(IRSG) publications demonstrated successive increases in five-year survival rates between 1972 
and 1997; from 55% on IRS-I (27) to 74% on IRS-IV protocols (29). In contrast, data on adults with 
RMS are scarce and in general show a worse outcome compared to children (30;31). Additionally, 
a recent Surveillance, Epidemiology and End Results (SEER) report of 2,600 RMS patients confirms 
that no survival improvements in adults have been made over the past decades (32). Also within 
the pediatric RMS population, survival was previously reported to be worse in older children 
when compared to younger children (with the exception of children <1 year of age) (32-35). 
The factors that are held responsible for this adverse effect of age on outcome of RMS can be 
divided in two theories; nature (tumour biology) and nurture (treatment). Concerning nature, 
RMS at the adolescent and adult age seems to act biologically more aggressive, shows more 
often the adverse alveolar subtype and tends to metastasize more early (30;36;37). With regard 
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Although cancer in children, adolescents and young adults (AYA) is relatively rare in comparison 
to the overall burden of cancer incidence, a world-wide increase in incidence of cancer and 
cancer-related deaths in young people is emerging (1). This is reflected by the fact that in children 
1-4 years, cancer represents the fourth most common cause of death, in children 4-15 years it 
is the second most common cause of death (2) and in adolescents 15-19 years, again, it is the 
fourth most common cause of death in developed countries (3). 
The development of a worldwide infrastructure for treatment of pediatric cancer patients in 
large comprehensive clinical trials and standardization of treatment took place over the past 
three decades. This resulted in a dramatic increase in survival rates among patients from 1 to 15 
years of age; the 5-year survival for all cancer combined has increased from approximately 60% 
in 1975–1978 to 80.6% in 1999–2002, as estimated by the Surveillance, Epidemiology, and End 
Results (SEER) Program of the National Cancer Institute in the United States (4;5).   
Despite a higher incidence of cancer in the adolescent and young adult (AYA) population 
compared to children, there has been a lack of awareness and centralization of patients in this 
age category over time (6). This is reflected by the relatively low accrual and participation of this 
subpopulation in clinical trials, which is held as one of the factors responsible for a consequent 
lack in survival benefit when compared to their younger counterparts (7-9). Importantly, the 
AYA cancer population is unique in ways of a typical tumour type distribution, overlapping 
both child- and adulthood cancers (1). Furthermore, the awareness of the AYA population 
being distinct in terms of specific needs and concerns (e.g. fertility, insurance, employment, 
and psychosocial issues) is rising (6). 
During the last years it has been recognized that cancer patients at the age of adolescence or 
young adulthood deserve more age specific attention resulting in initiatives that have been 
undertaken world-wide to improve care for these patients (10). In the United Kingdom, the 
teenager and adolescent cancer population (12-25 years) has been resurrected and it has a very 
active government funded national teenage cancer trust program with the first AYA cancer unit 
founded in 1990 in London. Now, there are eight comprehensive AYA centers, either under the 
guidance of pre-existing medical oncology or pediatric oncology units. This government-funded 
AYA cancer program has also been an example for Australian (15-25 years) and Canadian AYA 
cancer care programs (15-29 years, translated from the SEER database). Also, numerous European 
countries including Italy, Denmark and the Netherlands have followed the UK example by 
setting up tailored AYA programs/units (mostly patients 15-24 years). The United States’ National 
Cancer Institute (NCI) –(NCI) -funded the Children's Oncology Group AYA Committee formed 
an AYA Committee in 2000 (15-29 years), focusing on improving outcomes, access to care, and 
accrual to clinical trials, and subsequently the Adolescent and Young Adult Oncology Progress 
Review Group (AYAO PRG, 2006), extending the upper age limit to 39 years. To date, there are 
no dedicated physical AYA units in the United States, but several “virtual” AYA programs have 
been developed from 1999 up to now. 
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ALK’s 3rd intron yielding increased ALK transcription. In the same study, introduction of lentiviral 
shRNA against PAX3-FOXO1 into a PAX3-FOXO1 positive cell line consequently downregulated 
ALK mRNA levels in vitro (51). 
ALK overexpression and genetic alterations of the ALK gene have been previously identified 
in multiple malignancies including for example anaplastic large cell lymphomas (ALCL), non 
small cell lung cancer (NSCLC) (52;53), inflammatory myofibroblastic tumours (IMT)(54;55), 
neuroblastoma (56-59), as well as small subsets of rhabdomyosaroma (60). Differential underlying 
mechanisms are responsible for altered ALK expression in these tumours, including translocations 
(ALCL/NSCLC) (61-63), germline or somatic mutations (neuroblastoma) (56) and genomic gains 
or amplifications (neuroblastoma, NSCLC) (53;56). The exact underlying mechanism of ALK 
expression in RMS and its clinical and prognostic implications, however, are largely unknown.
In chapter 5, we focus on ALK expression and the underlying mechanism responsible for ALK 
(over)expression in RMS with special attention to clinical and prognostic implications. We 
analysed ALK protein expression by immunohistochemical analysis in 189 tissue samples of 
145 patients. Furthermore, in situ hybridization was performed to analyse ALK gene (2p23) copy 
number alterations and the presence of translocations. Additionally, mRNA sequencing of the 
ALK RTK domain was performed to detect genetic alterations.  
The insulin-like growth factor (IGF) system is a RTK signaling pathway previously implicated in 
RMS. The IGF system (which consists of the ligands IGFI and IGFII, the insulin-like growth factor-1 
receptor (IGF-1R), and 6 IGF binding proteins) was already identified in tumour samples and 
cell lines of RMS. Inhibition by using siRNA, monoclonal antibodies and receptor tyrosine kinase 
inhibitors resulted in diminished growth in multiple preclinical studies (64). However, clinical 
trials with monoclonal IGF-1R inhibitors show disappointing clinical response rates and only a 
temporarily anti-tumour effect (65). These disappointing results reflect the major pitfalls of these 
targeted therapies. First, the type of inhibitory agent determines its spectrum of cellular activity 
(e.g. on the cell membrane, intracellular, intra-nuclear, or a combination of these). Monoclonal 
antibodies are not capable of migrating over the cell membrane, however, small molecule 
inhibitors (generally less specific) have a broader area of activity as they are also capable of 
inhibiting intracellular/intranuclear molecules. Second, tumour heterogeneity (within the tumour 
or between primary tumour and metastatic lesions) might result in only a partial effect, which 
makes in vitro investigations less predictable for clinical effects. Third, recent investigations 
point out that certain tumour cells are capable to activate escape mechanisms in response 
to inhibition of a cell-surface receptor by the upregulation of other RTKs (66-69). A potential 
strategy to overcome this escape mechanism is to block multiple receptors simultaneously. 
In Chapter 6, we investigate the (co-)expression of the IGF-1R and ALK receptor signaling 
pathway, as well as the activation of downstream signaling by immunohistochemistry on tissue 
micro-arrays of 112 paraffin-embedded RMS primary tumour samples (86 eRMS, 26 aRMS). 
Furthermore we investigate the potential (synergistic) effect of ALK (NVP-TAE684) and IGF-1R 
(R1507) directed therapies in four RMS cell lines in vitro.  
to nurture, there is a lack of availability, accrual and participation in large international clinical 
trials in older patients. Furthermore, the tolerability of intensive chemotherapy schedules might 
differ between children and AYA patients and consequently there is a different opinion on the 
impact of these treatment regimens on patients by pediatric oncologists and adult oncologists. 
Unfortunately, reliable data on efficacy and toxicity of similar treatment schedules are hardly 
available in literature. 
In Chapter 4, a multi-center study concerning the effect of age on clinical presentation and 
outcome in eRMS and aRMS is reported. This effect of age and other prognosticators (including 
treatment modalities) was investigated in a multivariate survival analysis in a cohort of 169 
patients 0-73 years of age with complete data on follow-up. 
Despite the successive survival rates reported in children with RMS, the survival in particular 
subgroups of patients (e.g. those primarily diagnosed with alveolar histology, distant and/or 
lymph node metastases at diagnosis, diagnosed at older age, or with refractory/recurrent disease) 
remains disappointing (32;38-43). Survival in these subgroups is not exceeding 50%, which is 
particularly low compared to the overall survival of RMS exceeding 70-90% in one of the latest 
completely reported COG studies (IRS IV, conducted between 1991-1997) (29). Moreover, the high 
risk of treatment related/induced morbidity and mortality after aggressive chemotherapeutic/
radiotherapeutic/surgical treatment modalities as currently used in RMS (44), urges the need 
for new therapeutic options in RMS. 
‘Targeted treatment’ is an upcoming strategy that has made significant progress in many types 
of cancer over the past decade, including sarcomas. An important group of targets within this 
topic are ‘receptor tyrosine kinases’ (RTKs), a group of transmembranous signaling proteins, which 
can be activated by either ligand-binding or self-activation. Consequently, multiple intracellular 
downstream effector proteins are activated by phosphorylation processes including 1) the MAP 
kinase pathway (including the downstream signaling molecule ERK), and 2) the PIK3CA pathway 
(including downstream signaling molecules AKT and mTOR). These downstream effectors play an 
important role in cell cycle progression, proliferation and regulation of apoptosis. Deregulation 
of the receptors has been implicated in the oncogenic development of many types of cancer, 
including sarcomas (45). In contrast to the currently available cytotoxic strategies (inducing non-
selective destruction of rapidly dividing cells including normal cells), these ‘targeted’ agents aim 
at specific tumour cell death by interfering with specific molecules involved in tumour growth 
and progression, - ideally- without causing harmful effects to healthy tissues.
 
A receptor tyrosine kinase which represents a potential treatment target in RMS is Anaplastic 
Lymphoma Kinase (ALK) (46). In an attempt to identify genome-wide key players in oncogenesis 
as well as potential molecular targets for therapy, gene expression profiling studies recently 
identified the presence of distinct molecular signatures based on the presence or absence of the 
specific translocations in (PAX3/PAX7-FKHR) RMS (47-50). In these studies, translocation-positive 
aRMS was repeatedly associated with ALK overexpression (47-49). Moreover, whole genome 
analysis for PAX3-FOXO1 protein binding sites recently showed a very high affinity for binding to 
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Finally, Chapter 7 is a comprehensive review which highlights the similarities and differences 
between RMS in children and adults with regard to epidemiology, tumour biology, diagnosis, 
treatment approach, and accrual to clinical trials with new agents. It concludes with a concept 
to build a bridge between the two worlds (pediatric and adult oncology) in order to improve 
care for children, adolescents and (young) adults with RMS.
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INTRODUCTION
Malignancies in the young age group 15 to 24 years are uncommon, with an estimated incidence 
of 291 per million per year in the year 2000 in the United States (1). Within the total burden of 
cancer incidence (4203 per million in Europe 2003 (2), and 4723 per million in the USA 1996-
2000 (3)), the adolescent cancer patient population forms a minority, whereas malignancies 
in children (0-14 years) are even more uncommon (153 per million per year USA, 2000 (1) and 
130.9 per million per year in Europe (4)). 
Although the number of Adolescent and Young Adult (AYA) cancer patients remains low, reports 
have shown a marked increase in incidence. Over the past three decades, the cancer incidence 
among AYA's (15-24 years) in the United States increased with 0.85% per year, and European 
studies report an increase as well (1;5;6). 
Survival has improved considerably during the past three decades for young children treated by 
paediatric oncology groups in Western countries, probably as a result of large scale enrolment 
into international cooperative multicentre clinical trials investigating new treatment strategies 
including multi-agent chemotherapy. In contrast, adolescents and young adults had a less 
favourable improvement in clinical outcome (5;7). Surveillance Epidemiology and End Results 
(SEER) data showed an annual increase in 5-year relative survival of only 0.75% in adolescents 
(15-24 years), compared to 1.53% in children (0-14 years) between 1975 and 1997 (1). Notably, 
due to the relatively low incidence of cancer in this age group, patients are getting dispersed 
between large numbers of patients at oncology departments. 
Although improvement in survival in adolescents and young adults lags behind, the number of 
cancer survivors in this group has increased consistently over time. With the increasing age of 
survivors and more intensive treatment for cancer, awareness of an increased risk for developing 
second and treatment related secondary tumours in young cancer patients is important (8). 
We assessed recent trends in incidence and outcome of cancer, with special attention on second 
primary tumours, among adolescent and young adult cancer patients in a population-based 
cohort of 12-24 year olds diagnosed between 1989 and 2003 in the North-Netherlands. 
Cancer in AYA North Netherlands
ABSTRACT
Background: Lack of survival improvement in Adolescents and Young Adults (AYA) with cancer 
has led to increased awareness of this young population. 
Design: We performed a population-based study of incidence and survival of primary tumours 
and second primary tumours in patients aged 12-24 in North-Netherlands. Age-specific incidence 
rates per 100,000 and three-year moving means were calculated. Factors associated with 
incidence and survival were assessed using a Poisson model, log-rank test and multivariate Cox 
proportional hazard analysis.
Results: From 1989-2003 1118 patients were diagnosed. The total age-specific incidence rates 
per 100,000 were: Males: 13.4 (12-15 yrs), 26.9 (16-19 yrs), and 27.5 (20-24 yrs) and Females: 
13.9, 20.7 and 20.7. M/F ratio was 1.32. The overall estimated annual percent change (EAPC) in 
incidence was 2.15% (p<0.01). Five-year-survival was 80.8%, and did not improve during the 
study period. With median follow-up of 5.5 years (range 0.0-16.0) in our cohort the Standardized 
Incidence Ratio (SIR) of second primary tumours was 30.55 (95% CI 19.96-44-76, p<0.05)
Conclusion(s): The total incidence of cancer in AYA increased (EAPC 2.15%). Survival was 
unchanged. The SIR of a second primary tumour in this young cohort increased 31-fold. Further 
research is needed to study this increasing incidence and optimise treatment outcome in these 
young patients.
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with incidence was performed using a multivariate Poisson model. Survival rates at 3, 5 and 
10 years were calculated for all ages together by the life table method. Differences in survival 
rates were analysed using the log-rank test. Multivariate Cox proportional hazard analysis was 
performed to determine factors associated with survival for this age group. To asses the risk of 
second primary tumours a standardized incidence ratio (SIR) was calculated, which compares the 
observed number of secondary tumours with the expected number of tumours. The expected 
number of second tumours was calculated using age-, year- and gender specific incidence rates 
in the general population derived from the cancer registry. Cumulative incidence of second 
primary tumours over the study period and confidence intervals were estimated, with death 
as competing risks (12;13).
RESULTS
Patients
A total of 1118 patients aged 12-24 years were diagnosed with cancer in the period 1989-2003 
in the Northern Netherlands. In this cohort, 203 patients (18.2%) were 12-15 years, 385 (34.4%) 
were 16-19 years and 530 (47.4%) were 20-24 years at diagnosis, with a male:female (M:F) ratio 
of 1.32. Of these patients, 1055 were diagnosed and treated in the Northern Netherlands and 
the remaining 63 were treated in regions covered by other cancer registries. 
Incidence
Figure 1a shows the distribution of the tumour types by age-group and gender. Table 1a shows 
the age-specific incidence rates for the main tumour types, by age group, gender and time 
period. The annual cancer incidence (rate per 100,000) was lowest among 12-15 year-olds: 13.4 
(M) and 13.9 (F). This incidence increased to 27.3 (M) and 20.9 (F) in 16-19 year-olds and 27.9 
(M) and 20.8 (F) in 20-24 year olds. 
The highest incidence in males was seen for germ cell tumours with the highest incidence in 20-
24 year-olds (9.3). Non-seminomatous testicular cancer (ICD-9065, ICD-0-3) was the predominant 
morphological subtype (79.6%). Lymphomas were the second most frequent tumour type in 
males with the highest incidence in 16-19 year olds (7.4). In females, lymphomas represented 
the most frequent cancer type with a highest incidence of 7.2 for 16-19 year-olds. 
Cancer incidence increased markedly over time with an estimated annual percentage change 
(EAPC) of 2.15% (p= 0.001, unadjusted for age group and sex). The age-specific incidence (3-year 
moving means) of all cancer types in both sexes between 1989 and 2003 is shown in Figure 1b. 
We observed an increase in incidence in the age groups of 16-19 and 20-24 years for males. In 
females, the incidence increased for all age-groups, especially after 2000 for age-group 16-19 years.
Tables 1b and 1c explore the association of age, gender and year of diagnosis with incidence 
in a multivariate regression analysis. Increasing age was associated with increasing incidence 
in lymphoma (p<0.001), germ cell tumours (p<0.001), melanoma (p= 0.001), and carcinomas 
(p<0.001). While the incidence of leukaemia did not differ significantly by age group, it should be 
METHODS
Patients
Patients diagnosed between 1989 and 2003 in the Northern part of The Netherlands (covered by 
the cancer registry of the Comprehensive Cancer Centre North-Netherlands (CCCN)) aged from 
12 to 24 years were included in this study. Patients were classified by cancer type, age group 
(12-15, 16-19, 20-24 years) and gender for the periods 1989-1993, 1994-1998 and 1999-2003. 
These age groups were constructed because 12-15 year-olds are generally treated at a paediatric 
oncology unit and most 20-24 year olds are treated at a medical oncology unit, whereas 16-19 
year old patients form an intermediate group. Age-group therefore can be used as a proxy for 
treatment by a paediatric or adult medical oncology unit. Cancer type was defined using the 
ICD-0-3 classification (9) and classified by the Classification Scheme for Cancer in 15-24 years olds 
(version 5) according to Birch et al (10). Carcinoids of the appendix (mostly incidental findings) 
with malignant properties (ICD 8240-8245, ICD-0-3) were excluded from the analysis.
 
Data collection by the cancer registries
Data were collected by the regional cancer registry of the CCCN, covering the Northern Netherlands, 
a predominantly rural area with a population of about 2.2 million. The nationwide Dutch network 
and registry of histo- and cytopathology regularly submits reports of all diagnosed malignancies 
to the cancer registries. The national hospital discharge databank, which receives discharge 
diagnoses of admitted patients from all Dutch hospitals, completes case ascertainment. After 
notification, trained registry personnel collect data on diagnosis, staging, and treatment from 
the medical records, including pathology and surgery reports, using the registration and coding 
manual of the Dutch Association of Comprehensive Cancer Centres. Vital status was established 
either directly from the patient’s medical record or through linkage of cancer registry data 
with the municipal population registries, which record information on their inhabitant’s vital 
status. There were no death certificates only in the cohort. The closing date of the study was 
December 31st 2004, resulting in follow-up less than 5 years in 17.4% of the patients. A second 
primary tumour was defined as a new primary tumour registered in the regional cancer registry, 
as reported by the clinician or pathologist. Furthermore, when a second primary tumour was 
suspect to be a relapse (same histology) we checked medical files of the patients. A melanoma 
was considered a second primary only when its location was obviously different from the first 
tumour. Furthermore, a contralateral testicular tumour was considered to be a second primary 
tumour (11).
Statistical analysis
The population at risk for each year was retrieved from Statistics Netherlands (http://statline.cbs.
nl/StatWeb). The annual age-specific incidence rates for each tumour type were calculated per 
100,000 according to gender and period of diagnosis. In addition, three-year moving means of 
the incidence were calculated for patients aged 12-15, 16-19 and 20-24 years. Trends in incidence 
rates were estimated based on a linear regression of the log-transformed incidence rates with 
year of diagnosis as the regressor variable. The regression coefficient for year of diagnosis was 
used to estimate the Annual Percentage Change (EAPC). The association of age, year and sex 
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mentioned that with increasing age the contribution of acute lymphatic leukaemia (ALL) to the 
total of cases of leukaemia declined, whereas the contribution of acute myeloid leukaemia (AML) 
increased. For CNS tumours, incidence decreased significantly with increasing age (p=0.03). Later 
year of diagnosis was associated with an increase in incidence for lymphomas (p=0.008), germ 
cell tumours (p<0.001), and carcinomas (p= 0.002).  A remarkably high lymphoma incidence was 
found during the period 1999-2003 (11.7 and 9.9 among males and females, respectively), due 
to a high incidence of Hodgkin’s lymphoma in 16-19 year olds in the period 1999-2003. Germ 
cell tumour incidence was significantly lower for females (p<0.001), and incidence of melanoma 
and carcinoma was higher in females than among males (p<0.001 for both). This is largely due 
to the high incidence of thyroid cancer in females.
Table 1a: Age-specific incidence rates per 100,000 for different tumour types in Adolescents and Young Adults 
(AYA), males and females in the different periods in Northern Netherlands over the period 1989-2003. 
Figure 1a 
The distribution of all malignancies, displayed by age group and sex.
*CNS tumours = central nervous system tumours; **Lymphomas= Hodgkin’s lymphoma and non-Hodgkin 
lymphoma added up; Numbers are incidence rates, displayed per 100,000 within the figures. 
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Figure 1b 
Incidence rates per 100,000 for males (a) and females (b) 1989-2003. Three-year moving means.
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Survival
Survival (3-, 5-, and 10-year) of the most prevalent tumour types are shown by age group in 
Table 2a. The median follow-up time in the cohort was 5.5 years (range 0.0-16.0). The 5-years 
survival was 80.8% (CI 78.1-83.1). 
High survival rates were found for germ cell tumours, and melanoma, with 5-year survival rates 
exceeding 90%. Intermediate survival was found for carcinomas (87.1%), and lymphomas (87.0%). 
The 5-year survival rates were rather low for central nervous system (CNS) tumours, leukaemia, 
bone tumours, and soft tissue sarcomas (STS), not exceeding 70%. However, the numbers at 
risk for bone tumours and STS were small. 
Multivariate survival analysis adjusting for age group and gender did not show any increase 
in survival over time for the whole group (HR 0.96, CI 0.93-1.0, p=0.033), nor for the different 
tumour types (Table 2b and 2c).
This table displays 3-year, 5-year and 10-year survival for the different AYA tumours diagnosed in both sexes over 
1989-2003 with their 95%-confidence intervals. Survival was calculated using the life table method. * N=1118 
includes also patients with “other tumours”  (N=36)
Table 2a
Survival for the different AYA tumours diagnosed in both sexes.
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Second primary tumours
With a median follow-up time of 5.5 years (range 0.0-16.0), 26 patients developed a second 
tumour (table 3). This corresponds with a standardized incidence ratio (SIR) of 30.55 (CI 19.96-
44-76, p<0.05). The cumulative incidence of second primary tumours at 10 years was 2.83% 
(CI 1.7-4.3, cumulated over 1989-2003; figure 2). The median interval between first and second 
primary malignancy was 6.19 years (range 0.02-12.9 years).  Of the patients with a second 
malignancy, 21 patients are alive with a median follow up after the second tumour of 8.69 years 
(range 1.5-15.7 years).
Two patients developed a secondary tumour in the radiation field after treatment for Hodgkin’s 
Lymphoma. Five patients with melanoma developed a localized second melanoma at a distinct 
place. Only one patient with multiple melanomas was known with familial atypical multiple mole 
melanoma (FAMMM) syndrome. Four patients with a primary testicular tumour in adolescence 
developed a contralateral testicular tumour during follow-up.  
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Figure  2 
Cumulative incidence of second primary tumours in AYA over the period 1989-2003 including 95% Confidence 
Intervals (CI). 
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DISCUSSION
Interest in oncology in the AYA group is emerging (14-16). In order to better define the current 
magnitude of the cancer problem for this age group we started an inventory study on the 
incidence and survival of 12-24 year-olds, with emphasis not only on the primary tumour, but 
also on the second primary tumours.
The incidence of cancer in AYA (20.5 per 100,000 per year 1989-2003) was particularly low when 
compared to the overall cancer incidence, with a reported annual incidence of 415.8/100.000 
(European Standardized Rate (ESR) (17) in 2002 in the same district. 
Within the AYA group the incidence increases with increasing age from 13.7 in 12-15 year-olds 
to 24.1 and 24.4 in 16-19 and 20-24 year-olds, respectively. These age groups were constructed 
to be used as a proxy for treating unit. All 12-15 year-olds are generally treated at a paediatric 
oncology unit, 20-24 year olds at a medical oncology unit, whereas 16-19 year-olds will be seen at 
both departments. Most studies however routinely utilize five-year increments for their analyses, 
considering patients up to 14 years as children, and 15 years and older into the adolescent and 
younger adult group (1;5;18). 
When comparing our data with those from other countries the total incidence of cancer in 12-15 
year-olds greatly resembles SEER (USA)(1) (10-14 year-olds) and British data (18) (10-14 year-
olds), but the incidence in our 16-19 year-olds population is slightly higher than that reported 
in the USA as well as in Europe (24.1 compared to 20.3 in the USA 1975-2000 (1), and 18.6 in 
Europe 1988-1997 in 15-19 year-olds (19)).  This might be due to the difference in age group or 
study period. The incidence we showed in 20-24 year-olds (24.4) is lower than in the USA (35.2 
per 100,000 per year, 1975-2000 (1)) and comparable to British data (22.6 per 100,000 per year, 
1979-1997 (18)). 
We found a significant increase in incidence of all malignancies over time in 12-24 year-olds. 
When corrected for age-group and gender, increase in germ cell malignancies, lymphomas 
and carcinomas was found, confirming the findings from other recent reports in the Western 
countries (1;5-7;10;18;20). Increasing incidence for germ cell malignancies in males (e.g. testicular 
cancer) seems to be a world-wide phenomenon (1;21), and is not fully understood thus far. An 
increase in incidence for lymphomas was observed in both sexes. This increase in incidence was 
caused mainly by an increase in Hodgkin’s lymphoma in 16-19 year-olds, which was previously 
reported by Reedijk et al and Clavel et al (5;22). Interestingly, in England Birch et al observed a 
decrease for both Hodgkin’s lymphoma and Non-Hodgkin’s lymphoma in 15-24 year-olds in the 
same period (10). Moreover, SEER data show an Estimated Annual Percentage Change (EAPC) 
of 3.6% for Non-Hodgkin’s lymphoma, compared to only 0.2% for Hodgkin’s lymphoma in 20-
24 year-olds and a decrease in 10-19 year olds during 1975-2000 (1). The variation in reported 
trends for lymphomas over time might be due to improvement of the quality of data collection, 
uniformity in classification, and homogeneity in international coding and classification practices, 
as suggested by Clavel et al. (22). 
We found no improvement in survival between 1989 and 2003. When compared to children, AYA 
benefited less from the general survival improvement during the past decades as shown by several 
large studies in Western countries. As stated before, from 1975 to 2000, SEER data (USA) reported 
a twice higher annual increase of 5-year relative survival in children in comparison to adolescents 
(1). In contrast, Reedijk et al. reported equal 5-year survival increases in adolescents as well as in 
children (adolescents: 64 to 82%, children: 56% to 75% 1973-1999)(5). We performed our study 
on data from 1989 up to date, which might suggest that following the large improvements made 
in the seventies and eighties with the introduction of chemotherapy, the increase in survival of 
AYA has come to a steady state during the last 10 years.
The cooperation of experts in developing large comprehensive children’s cancer studies in the 
USA as well as in Europe has led to world-wide improvement in children’s cancer care. Whereas 
90% of children under the age of 15 are entered into a clinical trial, only 10% of adolescents 
(15-19 years) and 2% of young adults (20-24 years) in the USA are entered on to clinical trials 
of the paediatric or adult cooperative groups (23). Survival rates for specific tumour types in 
AYA are still less than 70%. These malignancies include Non-Hodgkin lymphomas, soft-tissue 
and bone sarcomas, CNS tumours and leukaemias. Treatment optimization, especially for these 
malignancies, is of great importance. Because of the rarity of these tumours, international 
cooperation and inclusion in clinical trials for these patients is warranted. 
Importantly, adolescents may access oncologic care from paediatric or adult medical centres. 
In adolescent patients with leukaemia, especially acute lymphoblastic leukaemia, childhood 
protocols improve survival (24-27). Furthermore, a recent study from Utah (USA) investigated the 
site of oncologic specialty care for older adolescents (15-19 years), concluding that 66% of these 
patients were never seen by a paediatric oncologist, and there was a trend to worse survival for 
adolescents not treated by a paediatric oncologist for all malignancies except non-Hodgkin’s 
lymphoma, germ cell tumours, and carcinomas (28). Unfortunately we were not able to assess 
the treatment unit for the patients in our cohort, as data concerning inclusion in clinical trials 
was incomplete in the cancer registry. 
Besides these treatment variables, other factors as patient and/or doctors delay in referral and/or 
diagnosis may play a role in the final outcome of the patients, presuming that AYA patients are 
diagnosed at a relatively higher stage of disease than children do. A very recent study from the 
Canadian Childhood Cancer Surveillance and Control Program also confirms this idea and shows 
a longer delay in both referral and diagnosis in 10-19 year-olds when compared to children <10 
years, due to both patients and  physicians (29). Furthermore, more aggressive tumour biology 
is also suggested to play a role in a disadvantage in outcome for adolescents (30). 
Remarkably, we observed an unexpectedly high risk of second malignancies in our cohort (SIR 
30.55) which has been not reported previously. Because the median time from first to second 
malignancy was longer (6.19 years) than the median follow-up (5.5 years), we might have 
missed the bulk of second malignancies in our study. This means that the observed SIR in our 
study might be even an underestimation of the actual risk. Since more young people survive 
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from cancer nowadays, the potential risk of late effects after primary cancer treatment have 
increasingly become a major topic of interest over time (31-33).  
A reasonable origin of these second tumours could be both intrinsic (genetic susceptibility) 
and/or extrinsic (environmental exposure, treatment induced). For example, melanoma of 
skin shows association with sun exposure but also with total and dysplastic nevi and genetic 
predisposition and this may lead to an increased risk to develop second or even third melanomas 
(34). In general, the younger sequential tumours become overt, the higher the chance that 
intrinsic –genetic- factors play an important etiological role. The occurrence of second tumours 
of the same histology in eight patients (melanoma and non-seminomatous testicular cancer), 
with only one patient known with a familiar predisposition for melanoma (FAMM syndrome), 
confirms the hypothesis that extrinsic factors as well as unknown genetic predisposition play 
an important role in carcinogenesis in these young patients and should be further investigated. 
Despite the growing interest in AYA oncology in general, population-based studies with an 
overview of all second primary tumours in this group are scarce. The only reported data found 
a SIR of 12.4 in 15-24 year-olds and a peak incidence in 15-19 year-olds (35). In contrast with 
the scarcity of data on AYA, data on second primary malignancies in childhood cancer survivors 
(up to 18-20 years of age) are widely available, reporting a 5- to 6-fold increased risk for second 
primary malignancies (8;36-38).
In conclusion, we found an increase in incidence of malignancies in AYA, with no survival 
improvement during 1989-2003. Large-scale enrolment and treatment of adolescents and 
young adults in international cooperative multi-centric clinical trials could be the solution 
in optimising care in this neglected group of young patients world-wide. The prevalence of 
survivors of adolescent cancer is increasing. In our cohort we showed that these survivors are 
at high risk for developing second primary malignancies. Further research is needed to study 
the increasing incidence of cancer in AYA and the incidence of second malignancies to optimize 
care for these young patients.
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ABSTRACT
Background: Cancer among adolescents and young adults (AYAs; 15-29 years old) is relatively 
rare but its incidence is increasing worldwide. To define the extent and nature of the AYA patients, 
this population-based study was performed to explore trends in cancer incidence, survival and 
risk of second primary cancers in AYAs.
Material and Methods: Data from all AYAs diagnosed with cancer between 1989-2009 were 
obtained from the Netherlands Cancer Registry. Age-standardized incidence rates with estimated 
annual percentage of change (EAPC) and 5-year relative survival rates were calculated. Relative 
survival was used as a good approximation of cause-specific survival. All analyses were stratified 
by gender, 5-year age-group and calendar period. In addition, Standardized Incidence Ratios 
were determined to evaluate the risk of second primary cancers.
Results: 23,161 AYAs were diagnosed with cancer between 1989-2009. Since 1989 the cancer 
incidence has increased significantly from 28 to 43 per 100,000 person years in males (EAPC: 
1.9) and from 30 to 40 per 100,000 person years in females (EAPC: 1.4). The most frequently 
diagnosed cancers in male AYAs included testicular cancer, melanoma and Hodgkin’s disease, 
whereas in females melanoma, breast cancer and Hodgkin’s disease were the most frequently 
occurring cancers. Five-year relative survival rates were 80% and 82% for males and females, 
respectively. Over time, the 5-year relative survival increased from 74% to 86% and from 79% 
to 86% in males and females, respectively. The risk of developing a second primary cancer was 
increased 3-6 times in males and 2-5 times in females, depending on rules for counting second 
primary cancers. 
Conclusions: Although the overall survival has improved over time, the progress made in AYAs 
for specific cancers is still less compared to improvements made in children and adults. This 
and the increasing incidence and high risk of second primary cancers warrants further research. 
BACKGROUND
Cancer in adolescents and young adults (AYAs) with an age at diagnosis between 15 and 29 years 
is relatively rare but its incidence is increasing (1-4). The age-adjusted incidence rate of cancer 
(European Standardized Rate; ESR) in AYAs in the Netherlands was 41 per 100,000 person years 
in 2009. Compared to the total incidence of cancer in the Netherlands, AYAs only represent a 
small part, i.e. slightly over 1%. However, compared to cancer incidence in children (ESR, <15 
years) which was 12 per 100,000 person years in 2009, the incidence among AYAs is more than 
3 times higher (http://www.cancerregistry.nl). 
Former studies showed that the progress made in survival of AYAs with cancer is limited as 
compared to the steadily increase in survival in adults and the large improvements that have 
been achieved in many childhood cancers (5;6). This lack of survival improvement might be 
due to differences in biological characteristics or etiology. Insufficient tailor-made professional 
attention for AYAs with cancer and lack of specialized guidelines may also be responsible for 
suboptimal outcome in this particular subset of young cancer patients. 
Furthermore, although the improvement in survival of AYAs with cancer lags behind, the 
majority of the patients survive their cancer and attention should be paid to their life time risk 
of developing second primary cancers. In a small Dutch study including patients diagnosed 
between 1989-2003 at the age of 12-24 in the Northern part of the Netherlands a strongly 
increased risk of developing a second primary cancer was found (standardized incidence ratio: 
31, 95% Confidence Interval: 20.0-44.8) (7). 
In order to improve the current care of AYAs with cancer and to develop services tailored to 
their needs, it is important to define the extent and nature of this patient population by use of 
analyses of population-based, accurate and recent data. As recent, population-based information 
on the cancer occurrence in AYAs is scarce, we performed the current study including all cancer 
patients diagnosed at the age of 15 till 29 years between 1989-2009 in the Netherlands in order 
to give an extensive overview. Cancer-specific trends in incidence, survival and risk of second 
primary cancers in the AYA population were evaluated by gender, age group and calendar period. 
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Risk of second primary cancers
All analyses on second primary cancers only included primary cancers, i.e. recurrences or 
progressive disease were not included in the analyses. In order to evaluate the risk of second 
primary cancers, Standardized Incidence Ratios (SIR) with 95% Confidence Intervals (CI) assuming 
a Poisson distribution were calculated. Person-years at risk were accumulated for each person 
in the cohort from the date of diagnosis of the first primary cancer up to the date of diagnosis 
of second primary cancer, date of death, date of emigration or 1-1-2010, whichever came first. 
The expected number of second primary cancers was calculated by applying the 5-year age, 
calendar year and gender-specific incidence rates for each cancer in the Netherlands to the 
person-years at risk among the AYA cohort. SIRs were calculated as the ratio of the observed 
number of second primary cancers and the expected incident number of given tumors in a 
specified gender- and age group. 
All analyses on second primary cancers were performed three times. Once including all second 
primary cancers, regardless of the time between first and second primary cancer and type of 
cancer. In this way we are able to evaluate the risk of developing a second primary cancer, 
including the contra-lateral or same site tumors (for example for testicular cancer, breast cancer 
and melanoma). Secondly, in order to exclude the effect of detection bias, cancers presented 
concurrently at the time of first diagnosis (rather than subsequent to the first diagnosis) and 
second primary cancers diagnosed within 3 months of the first cancer were excluded. Thirdly, 
in order to be able to compare the calculated SIRs with results reported by other studies, the 
International rules concerning multiple cancers as proposed by the International Agency for 
Research on Cancer / International Association of Cancer Registries (IARC/IACR) were applied (10). 
Using this latter definition the recognition of a second primary cancer is independent of time and 
only one primary tumor arising in an organ as defined by the three character topography code 
can be considered as primary cancer. Analyses were performed using the statistical software 
package SAS 9.2.
RESULTS
Overall 23,161 AYAs were diagnosed with cancer between 1989 and 2009 in the Netherlands. 
Fifty-one percent were male, 18% were diagnosed between 15-19 years, 30% between 20-24 
years and 52% between 25-29 years. 
Cancer incidence over time
Table 1 displays the cancer incidence rates by tumor type, gender and by period (table 1a) 
and age (table 1b). Incidence rates were based on tumor instead of patients (n=23,360 tumors 
diagnosed between 1989-2010, at age 15-29). Overall, the cancer incidence among males AYAs 
has increased sharply since 1989. The most prominent trend over time concerned testicular cancer 
(gonadal germ cell tumor) in males; testicular cancer incidence has doubled from 7 per 100,000 
person years in 1989-1995 to 14 per 100,000 in 2003-2009 (EAPC=4.90, p<0.01). When excluding 
testicular cancer a moderate rise in incidence is still evident. Significant rising trends (p<0.01) 
were seen for chronic myeloid leukemia (CML), Hodgkin’s disease, head and neck carcinomas and 
MATERIAL AND METHODS
Data were obtained from the Netherlands Cancer Registry (NCR), a nationwide population-based 
registry that includes all new diagnoses of cancer since 1989 except for basal cell carcinomas 
of the skin. The completeness of the Netherlands Cancer Registry since 1989 is estimated to 
be over 95%. All patients diagnosed with a primary malignant cancer at the age of 15 to 29 
in the period 1989 to 2009 were included. Benign tumors, tumors of uncertain malignancy 
(including borderline ovarian tumors, myelodysplastic syndrome, carcinoid of the appendix) 
were excluded. Patient- and tumor characteristics such as age at diagnosis, date of diagnosis, 
topography, morphology, invasiveness, WHO grade of differentiation, lateralization and stage 
as well as follow-up information concerning vital status and second primary cancers were 
retrieved. Vital status of all patients recorded in the NCR is updated annually by record linkage 
to the Dutch Municipal Personal Records Database which keeps information about vital status 
of all inhabitants in the Netherlands. All cancers in the NCR are classified using the International 
Classification of Diseases for Oncology (ICD-O). Cancers diagnosed between 1989-1992 were 
coded using the first edition of the ICD-O. Between 1993-2000 the second edition of the ICD-O 
was used and since 2001 the ICD-O third edition. Although, this classification on topography can 
be used for all cancers, it is largely satisfactory for late age of onset cancers, which mainly exist 
of carcinomas. As in young people the carcinomas only represent a small part of all diagnosed 
cancers a classification based on the histology is more appropriate to use. In the current study 
all primary tumors were therefore re-classified using the histology-based classification scheme 
as proposed by Birch et al. (8) which gives an accurate and balanced overview of cancers in the 
younger age groups.  
Cancer incidence
Cancer incidence rates were calculated by gender, 5-year age groups, and calendar period (1989-
1995, 1996-2002 and 2003-2009). Rates were age-adjusted by standardization to the European 
standard population (European Standardized Rates, ESR). Gender, age and calendar year specific 
population data were annually retrieved from Statistics Netherlands (http://statline.cbs.nl).  
Relative survival
Because the cause of death of the patients is not available in the cancer registry, disease specific 
survival could not be calculated. Instead, relative survival analyses were performed according 
to Dickman as a good approximation of disease-specific survival (9). This method adjusts crude 
survival rates amongst cancer patients for the expected mortality according to annual life tables 
of the general population matched on age, gender and calendar period (as annually retrieved 
from Statistics Netherlands). In the survival analyses end of follow-up was defined as date of 
death, date of emigration or 1-1-2010 whichever came first. Five-year tumor specific relative 
survival rates by gender and age group were calculated. To evaluate trends over time in survival, 
5-year survival rates were calculated for the top ten most frequently diagnosed tumors in males 
and females by calendar period (1989-1993, 1994-1998, 1999-2003, 2004-2009) as well. 
50 51
Cancer in AYA Netherlands
Cancer incidence by age
Within the AYA population, the incidence increased sharply with age. Each 5-year age category 
showed a different pattern of observed cancer types. In male AYAs with age 15 to 19 testicular 
cancer was the most frequently observed cancer (19%), followed by Hodgkin’s disease (15%) 
and non-Hodgkin lymphoma (9%). In 20-24 year olds testicular cancer comprised one-third 
of all cancers, followed by Hodgkin’s disease (13%) and melanoma (12%). In the oldest group 
(age 25-29), testicular cancer was still diagnosed in 35% of all patients. Melanoma (14%) and 
Hodgkin’s disease (9%) were second and third most frequent cancers. 
In female AYAs with age 15 to 19 Hodgkin’s disease (21%), melanoma (17%) and non-Hodgkin’s 
lymphoma (7%) were most frequently diagnosed. In females aged 20 to 24 melanoma accounted 
for 29% of all cancers, followed by Hodgkin’s disease (14%) and thyroid cancer (6%). In the oldest 
female AYAs (25 to 29) melanoma still represented the most frequent tumor (28%) with breast 
cancer (17%) and cancer of the genito-urinary tract (mainly cervical cancer) (13%) as number 
two and three. 
carcinomas of the respiratory tract. A decreasing trend was observed for astrocytoma. In females, 
a clear increase in cancer incidence is seen as well; significant increases were observed for CML, 
Hodgkin’s disease, melanoma, thyroid cancer and breast cancer. Astrocytoma and gonadal germ 
cell tumors were significantly decreased. In figure 1 the trends in cancer incidence over time by 
age and gender are presented. Over time the incidence of cancer among AYAs has increased 
significantly (EAPC=1.88, p<0.01 for males and EAPC=1.37, p<0.01 for females). 
Table 1: Incidence rates by tumor and gender
a) By period
Table 1 (continued)
b) By age 
* Only presented for males, a ESR: European Standardized Rate (per 100,000), b EAPC: Estimated Annual Percentage of Change
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chondrosarcoma, other bone tumors, fibrosarcoma, gonadal germ cell tumors, non-gonadal 
germ cell tumors, melanoma, non-melanoma skin cancer, thyroid cancer, head and neck cancer 
and cancer of the genito-urinary tract. Female patients with AML, central nervous system tumors, 
Ewing’s tumor, rhabdomyosarcoma, and unspecified malignant neoplasms have a fairly poor 
survival of less than 50%. In addition, the 5-year relative survival over time was evaluated (data 
not shown). Since 1989, a distinct improvement in the overall relative survival of approximately 
74% to 86% in males and 79% to 86% in females was observed. A clear survival improvement in 
patients with non-Hodgkin lymphoma in both males and females was seen. Among males, the 
survival of gonadal germ cell tumors and melanoma showed a slight but steady increase over 
time. The 5-year survival rates of the majority of other cancers (with the exception of Hodgkin’s 
disease and AML) seemed to be improved as well although the 95% Confidence Intervals are 
wide. In contrast to males, females showed a minor survival improvement for Hodgkin’s disease. 
The survival of female breast cancer patients improved significantly as well, though the survival 
of all other cancers among females remained similar or decreased. 
Overall, with a median follow-up time of 6.8 years, 884 patients (3.8% of all AYAs) were diagnosed 
with at least one second primary cancer. In 105 of these 884 patients (11.9%), the second tumor 
occurred within 3 months after diagnosis of the first tumor. A large part of the  remaining 779 
patients with non-simultaneous second primary cancers consist of melanoma, contra-lateral 
testicular cancer, and contra-lateral breast cancer. With the application of the IARC/IACR rules 
412 AYAs (1.8% of all AYAs) are defined to have a second primary tumor. In table 3 the SIRs are 
presented for all primary sites combined. Male AYAs diagnosed with cancer have a more than 6 
times increased risk of developing a second primary cancer. After application of the IACR/IARC 
rules, this risk is still more than 3 times increased. For females, the risk of developing a second 
primary cancer is almost 5 and 2 times increased, respectively. Overall, melanoma is the most 
frequently diagnosed second primary cancer among AYAs. The risk of developing a melanoma 
after a first primary cancer was 6 times increased for males and 8 times increased for females. 
This risk was even higher in patients with a melanoma as first primary cancer (females SIR: 22.8 
and males SIR: 27.2, not shown in table 3). After application of the IARC/IACR rules for multiple 
cancers, the most frequently diagnosed second primary cancers in males were hematological 
malignancies (n=40, SIR: 3.6, 95%CI: 2.6-4.9), gastrointestinal tumors (n=32, SIR: 5.2, 95%CI: 
3.6-7.4) and gonadal germ cell tumors (n=28, SIR: 1.9, 95%CI: 1.2-2.7). For females these second 
primary cancers included breast cancer (n=72, SIR: 1.8, 95%CI: 1.4-2.2), melanoma (n=25, SIR: 
1.2, 95%CI: 0.8-4.5) and hematological malignancies (n=23, SIR: 2.6, 95%CI: 1.8-4.0). We also 
explored the risks of second primary cancers after tumor-specific first primary cancers (data 
not shown). The most striking result was the more than 7 times increased risk of breast cancer 
after Hodgkin’s lymphoma (n=26 SIR: 7.4, 95%CI: 4.8-10.8).
Relative survival
In table 2, the 5-year tumor specific relative survival rates by gender and age are presented. 
Overall, the five year relative survival in males was slightly worse compared to females (80% 
versus 82%, p<0.001). A fairly good survival (at least 80%) was observed in male patients with 
Hodgkin’s disease, ependymoma, chondrosarcoma, other bone tumors, fibrosarcoma, gonadal 
germ cell tumors, melanoma, non-melanoma skin cancer, thyroid cancer, head and neck cancer 
and cancer of the genito-urinary tract (>80% was kidney or bladder cancer). Patients with acute 
myeloid leukemia (AML), acute lymphatic leukemia (ALL), other leukemia, other central nervous 
system tumors, Ewing’s tumor, osteosarcoma, rhabdomyosarcoma, and unspecified malignant 
neoplasms fare worse with a 5-year survival of approximately 50% or less. Largely similar to 
males, a 5-year survival of at least 80% was seen in female patients with Hodgkin’s disease, 
Figure 1
Trends in incidence of cancer in AYAs over time (1989-2009) by age (5-year age groups and total) and gender
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AML and rising incidence of CML. Concerning soft tissue and bone cancers a shift is seen as 
well; younger AYAs are more frequently diagnosed with ‘childhood and adolescent types’ such 
as osteosarcoma, Ewing’s tumor and rhabdomyosarcoma whereas older AYAs are diagnosed 
with other types of soft tissue and bone cancers. Non-Hodgkin lymphomas are diagnosed in 
children, AYAs and adults, but a different distribution of histological subtypes has been reported 
(16). Frequently diagnosed carcinomas in adults such as colorectal, lung and prostate cancer are 
very rare among children and AYAs (8), with the exception of breast cancer and melanoma in 
females. However, the underlying etiology might be different in AYAs compared to older women. 
The overall 5-year relative survival of AYAs diagnosed with cancer in the Netherlands is 80-82%. 
This is better compared to survival rates for AYAs in the US (US female AYAs have a similar survival 
but US male AYAs have a 5-year survival of approximately 70%) (1), but these figures relate to 
a more distant time period (1975-1999). The EUROCARE study reported a 5-year survival rate 
of 87% for patients diagnosed at age 15-24 (6). Time trends were studied as well in EUROCARE 
and a small improvement in the 5-year survival rate in the period 1995-1999 versus 1990-1994 
was reported. In our study, we observed an improvement in the 5-year survival in males as well 
as females since 1989, from 74% to 86% in males and from 79% to 86% in females. Part of the 
survival improvement in males might be caused by the increased proportion of patients with 
testicular cancer which have a very good prognosis. Therefore, survival over time was assessed 
after exclusion of these tumors as well. A similar trend and improvement in survival was observed 
(5-year survival of 67% in the period 1989-1993 and 79% in the period 2004-2009). It can be 
concluded that the progress made in survival is not due to the strongly increased number of 
patients with testicular cancer. The most prominent survival improvement is seen in patients 
with non-Hodgkin lymphoma. This is in line with findings from EUROCARE in which a significant 
increased survival was reported in these patients as well (6). In general the 5-year survival rates 
of the most frequently diagnosed tumors in male AYAs seem to improve over time. As the 
number of patients by tumor site are relatively small, observed trends should be interpreted 
with care. During the study period there might have been influence of changing clinical practice, 
with more centralization and more patients discussed in multidisciplinary teams and a better 
adherence to tumor directed guidelines. However whether these factors have played  a role in 
our study population is unclear as literature on this topic in AYA cancers is very scarce. Also, stage 
migration over time might have had a positive effect on survival. An elaborate discussion on stage 
migration was beyond the scope of this overview paper. In female AYAs time trends by tumor 
site are less clear; next to non-Hodgkin lymphoma, only survival of breast cancer and Hodgkin’s 
disease patients has clearly improved over time. In the most recent period the survival of AYAs 
with breast cancer seems similar compared with the survival of adult breast cancer patients (5-
year survival of 84% versus 86%) (http://www.cancerregistry.nl). The survival improvement seen 
in young breast cancer patients was also observed in other European countries (6). However, 
a US study based on SEER data reported 5-year survival rates of young breast cancer patients 
which were less than 80% and stated that improvement over time was less compared to the 
adult breast cancer population, probably because of age-dependent biological differences (17).
DISCUSSION
Recent, population-based data about cancer among AYAs is scarce. This study was performed to 
provide insight in cancer incidence, survival and risk of second primary cancers among AYAs in 
the Netherlands. This information is necessary to define the extent and nature of the AYA patient 
population and provides input for further research to improve quality of care in this specific group 
of patients. Similar to earlier findings, the incidence of cancer in AYAs has increased significantly 
between 1989 and 2009 in the Netherlands (1-4). A comparison with incidence data from the 
SEER registry shows a slightly higher cancer incidence among AYAs in the US (http://seer.cancer.
gov/) (1). The most prominent observed trend over time in male AYAs concerned testicular cancer 
which incidence has more than doubled in the period 1989-2009. This increase in testicular cancer 
has been reported worldwide (11). An accumulating body of evidence suggests that testicular 
cancer may originate already during fetal life, possibly associated with impaired spermatogenesis, 
cryptorchidism and hypospadias. As a common causal factor for this combination (also called 
Testicular Dysgenesis Syndrome) exposure to endocrine disrupting chemicals has been postulated 
(12). The other most striking result is the observed steep increase in melanoma incidence 
among older adult females (and males) as well, which is probably largely due to a combination 
of more UV exposure (sun bathing and sunbed use) and increased awareness (13;14). The same 
explanation might be underlying the observed rise in melanoma in female AYAs. A recent study 
performed in Australia, including patients with melanoma between 18-39 years old, found that 
sunbed use during adolescence and early adulthood was associated with increased risk of early 
onset melanoma (15). No obvious explanation is available for the observed increase in breast 
cancer over time in AYAs. The known life style factors associated with breast cancer risk such as 
age at birth of first child, number of pregnancies, hormonal therapy, breast feeding are in these 
AYAs not very likely causes, as in our analyses AYAs only include women younger than 30 years. 
A decreasing trend in astrocytomas is observed. This was also reported by Bleyer and colleagues 
(1) but no clear explanation is available. Next to variation in incidence over time, considerable 
variation exists in the incidence of specific cancer types across the AYA continuum. Within the 
male AYA population, the gonadal germ cell tumors are the most frequently diagnosed cancer 
at each age, but the proportion of these tumors increased strongly with increasing age (from 
19% to 35%). In the youngest males, Hodgkin’s disease, non-Hodgkin lymphoma and ALL jointly 
represent over 30% but this proportion decreased towards the older age groups. Melanoma, on 
the other hand, showed a clear increase with increasing age. Similar to males, in young female 
AYAs Hodgkin’s disease and non-Hodgkin’s lymphoma represented the majority of diagnosed 
cancers but with increasing age, the predominant cancers become melanoma and breast cancer. 
Similar patterns are reported in the US by Bleyer and colleagues (1).
This study showed a typical distribution of cancer types among AYAs, very different from the 
pattern reported for children and older adults. Frequently occurring cancers during childhood such 
as neuroblastoma, nephroblastoma (Wilm’s tumor), other embryonal tumors and retinoblastoma 
are uncommon among AYAs. ALL is the most common hematological malignancy among children 
(5). The different types of leukemia in AYAs reflect a clear transition of a childhood pattern, with 
ALL as most frequently diagnosed in the AYAs aged 15-19, to an adult pattern dominated by 
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Compared to the earlier performed Dutch study from van Gaal et al (7), the reported risk on 
second primary cancers is much lower (i.e. 5-6 fold increased risk versus 31 fold). Our data are 
more recent and much more precise due to a 20 year national coverage of all AYA tumors in 
The Netherlands. However, it should be mentioned that due to fact that the NCR is complete 
since 1989, first primary tumors prior to 1989 may not be recorded and therefore, secondary 
primary tumors may not be identified as such. Although, all available information before 1989 
was incorporated to identify first primary cancers, this could have led to an underestimation of 
the risk of secondary primary cancers.
As far as we know no studies have been performed in this age group evaluating the risk of 
second primary cancers. Studies including children with cancer reported on average a 6-fold 
increased risk of second primary cancers (26;27). 
In conclusion, this study demonstrates that the incidence of cancer at AYA age is rising. In 
general, the survival has improved over time, but for specific tumor sites survival still lacks behind 
compared to children. The risk of second primary cancers is high and might even increase in the 
future as a result of survival progress. Cancer specific studies are needed to explain these unique 
features and to translate the figures into useful prognostic information for patients. Specialized 
treatment and follow-up of all AYAs after treatment of the primary tumor is needed to diagnose 
second primary cancers in a stage where cure can still be reached. Finally, tailor made treatment 
regimes should be developed for this age group as AYAs with cancer live in a completely different 
psycho-social context compared to older cancer patients, with specific dynamics in education, 
careers, social networks, sexual relations and family life. 
A relatively poor survival is noted among AYAs diagnosed recently with ALL (5-year survival of 50-
52%), AML (5-year survival of 44-48%), astrocytoma (5-year survival of 54-57%), rhabdomyosarcoma 
(5-year survival of 36-39%), Ewing’s tumor (5-year survival of 40-46%) and osteosarcoma among 
males (5-year survival of 45%). The survival of these cancers in children (0-14 years) in the 
Netherlands is much better: Children with ALL have a 5-year survival of approximately 80%, 
with AML 53%, with astrocytoma 76%, with rhabdomyosarcoma 65%, with Ewing’s tumor 
65% and with osteosarcoma (63%) (unpublished data from the Netherlands Cancer Registry, 
notably from a later part of the whole time period than this AYA analysis has been performed, 
2003-2007). Similar survival rates in children were reported by Linabery and Ross (2008) (18) 
and by the EUROCARE study (6). The poor survival among AYAs with these cancers which are 
also prevalent among children may be partly explained by the low participation rate of AYAs in 
clinical trials (19;20) but tumor biology may be different as well (21). Another explanation might 
be that AYAs are diagnosed at a more advanced disease stage due to patient’s and doctor’s 
delay (22). There is an ongoing debate about the question whether to treat AYAs with cancer 
as children or as adults (23). For ALL adolescents have better survival in case they are treated 
with pediatric rather than adult protocols (24). 
In this study we had to use relative survival as an approximation for disease-specific survival 
because disease-specific survival cannot be estimated as no information on the cause of death 
was available to the Netherlands Cancer Registry due to specific legislation concerning Statistics 
Netherlands, holder of information on causes of death in the Netherlands. This relative survival 
adjusts for the general survival of the Dutch population taking gender, age, and calendar year 
into account. This might be interpreted as a limitation of this study, however, it can be argued 
that relative survival is the most appropriate method to use in population-based cancer survival 
studies, as misclassification of cancer specific deaths, result in biased estimates for cancer-specific 
survival (25). Furthermore, it should be noted that Death Certificate Only (DCO) registrations are 
not available in the Netherlands Cancer Registry due to the same reason as mentioned before. 
However, these patients would not affected the survival results as they would be excluded from 
the  analyses.
Next to incidence and survival, we assessed the risk of second primary cancers in this study. A 
striking result was that AYAs with cancer have a more than 6 times (in case of male AYAs) or almost 
5 (in case of females) increased risk to develop a second primary cancer. A large part of these 
second primary cancers are bilateral or of the same type (breast cancer, testicular cancer and 
melanoma). But also after excluding these bilateral/same-type- tumors, the risk of developing a 
second primary was approximately 3 times increased in males and 2 times in females. Although 
in the current study the mean follow-up time was almost 10 years and the median follow-up time 
was almost 7 years, part of the second primary cancers may occur later in life. The reported risk 
of second primary cancers may therefore be an underestimation. Several explanations can be 
given for the increased risk of second primary cancers: patients could be genetically susceptible 
for (different types of ) cancer; environmental factors early in life may account for both the first 
and the second tumor; the second primary cancers may be treatment-induced; and/or general 
survival improvement of the first primary cancer may result more second primary cancers. 
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INTRODUCTION
Rhabdomyosarcoma (RMS) is a soft tissue sarcoma (STS) that occurs predominantly in children; 
70% of cases are diagnosed within the first decade of life (1, 2). There is a second peak in incidence 
during adolescence (age 15-19 years), with RMS accounting for 1.7% of all malignancies in this 
age group (3). In adulthood, RMS is extremely rare, given that STS accounts for fewer than 1% 
of all malignancies, and as RMS comprises only 3.3 % of all STS (4). 
The two main histological subtypes of RMS that occur in both adults and children are embryonal 
and alveolar RMS. Alveolar RMS, which occurs mostly in older children and adolescents, has a 
worse outcome compared to embryonal RMS, which is more common in young children. 
The prognosis in children with RMS has improved dramatically during the past decades because 
of the introduction of multiagent chemotherapy in consecutive multidisciplinary clinical trials and 
treatment in a centralized setting (5-9). The Intergroup Rhabdomyosarcoma Study Group (IRSG) 
publications demonstrated successive increases in five-year survival rates between 1972 and 
1997; from 55% on IRS-I (5) to 74% on IRS-IV protocols (8). In contrast, data on adults with RMS 
are scarce and in general show a worse outcome compared to the disease in children (10, 11). 
Additionally, a recent Surveillance, Epidemiology and End Results (SEER) report of 2,600 patients 
with RMS, confirms that no improvements in adults have been made over the past decades (12). 
The reasons underlying the worse outcome in adult patients with RMS compared to children 
remain to be revealed. From larger pediatric studies, several prognostic factors have been 
established, such as site of the primary tumor (8), size below or above 5 cm diameter (12), 
histological subtype (14), stage of disease (15) and age at diagnosis (16, 17). In the scarce data 
on adult RMS, nearly identical factors have been described (10-12, 18-22). 
To further substantiate the differences in outcomes between children and adults with RMS, the 
present Dutch multicenter study was conducted to investigate the role of age and other putative 
prognostic factors on outcome in a large cohort of both children and adult patients with RMS. 
ABSTRACT
Background: The prognosis of rhabdomyosarcoma (RMS) in children and adolescents has 
improved since the introduction of multiagent chemotherapy. However, outcome data of 
adults with RMS are scarce. This multicenter retrospective study investigated the effect of age 
on outcome of RMS. 
Patients and Methods: Data were collected from three Dutch University Medical Centers between 
1977-2009. The effect of age and clinical prognostic factors on relapse-free and disease-specific 
survival (DSS) were analyzed.
Results: Age as a continuous variable predicted poor survival in multivariate analysis. Five-year 
DSS was highest for non-metastatic embryonal RMS, followed by non-metastatic alveolar RMS 
and was poor in metastatic disease. Higher age correlated with unfavorable histological subtype 
(alveolar RMS) and with metastatic disease at presentation in embryonal RMS. In non-metastatic 
embryonal RMS and all alveolar RMS, higher age was an adverse prognostic factor of outcome. 
Conclusion: This study indicates that age is a negative predictor of survival in patients with 
embryonal and alveolar RMS. Whether this is due to nature (biological make-up) or nurture 
(treatment) deserves further research. 
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Statistical analyses
Follow up data was collected in a database and statistical analyses were performed by Statistics 
16.0 (SPSS, Chicago, IL, USA). Frequency distribution of patient characteristics and prognostic 
factors for the different histological subtypes were assessed with Chi-square test. The relation 
between age and prognostic factors was assessed using non-parametric testing with Kruskal 
Wallis, or Mann Whitney U-test when appropriate. 
Overall survival (OS) probabilities were assessed using the Kaplan Meier method and compared 
with log-rank test. OS was defined as the time from onset of disease until death from any cause. 
A multivariate Cox proportional hazards analysis including age and other prognostic factors was 
used to analyze whether age was an independent prognostic factor in disease-specific survival 
(DSS) and relapse-free survival (RFS), using a backward conditional model. Furthermore, we 
tested interaction between the effect of age and histological subtype on DSS and RFS. Treatment 
modalities were selectively tested based on clinical relevance. DSS was defined as the time 
from disease onset until death due to disease. RFS was defined as the time from the end of 
treatment with complete remission (CR) until local and/or distant recurrence. CR was defined 
as no evidence of residual disease at the end of treatment, confirmed by radiography and/or 
histopathology. Patients who never experienced an event were censored at the last contact 
date with the hospital and/or medical correspondence. 
RESULTS
Patients
A total of 169 patients were eligible for analysis. The median age at diagnosis was 8 years (range 
0-73 years). Because all patients younger than 16 years were treated by a pediatric oncologist in 
all centers, we separated our patients into age groups <16 and ≥16 years. Patients’ and tumor 
characteristics are summarized in Table 1.
A significantly higher rate of alveolar subtype and tumors arising at unfavorable sites (mainly 
involving parameningeal and extremity sites), more lymph node involvement, a higher rate 
of distant metastasis, a lower probability of CR, a higher rate of relapse, and a trend towards 
higher IRS stage was demonstrated in patients ≥16 years in comparison to patients <16 years.
Pre-treatment prognostic factors
Age was significantly related to histological subtype (p<0.001, Table 1, Figure 1A and B). Embryonal 
RMS occurred mainly in young children (median age=7 years). Botryoid RMS mostly occurred 
in infants and toddlers (median age=4 years). Alveolar RMS (median age=15 years) showed 
two peaks in incidence: one in young children and one in adolescence and young adulthood. 
Because of this strong correlation, we compared prognostic factors for the different histological 
subtypes (Table 2). Embryonal RMS was characterized by a significantly higher rate of favorable 
primary sites, absence of regional lymph node involvement and metastatic disease, with a 
consequently lower IRS stage at diagnosis when compared to alveolar RMS. 
Patients 
We selected all patients with RMS in PALGA, the Dutch National Histopathological Database 
System, treated at either the Pediatric Oncology Unit of the Department of Pediatrics or the 
Department of Medical Oncology at the University Medical Center Groningen, the Erasmus 
Medical Center Rotterdam, or the Radboud University Nijmegen Medical Centre diagnosed 
between 1977 and 2009 (N= 226). Patients were excluded if medical files were not available 
(N=10), or histological diagnoses were other than embryonal or alveolar RMS (N=47) as pathology 
reports were reviewed. 
Data collection
The following data were collected: age at diagnosis, gender, site and size of the primary tumor, 
presence of metastases at diagnosis, metastatic site, lymph node involvement, treatment 
modalities (intention-to-treat principle), and follow-up status. Histological subtype was defined 
as embryonal or alveolar RMS. Botryoid RMS (a subtype of embryonal RMS occurring almost 
exclusively in infants and toddlers with a superior outcome) was analyzed separately.   
Staging
Staging at diagnosis started with physical diagnosis. Evaluation of the location, size and local extent 
of the tumor was additionally evaluated with computerized tomography (CT) and/or magnetic 
resonance imaging (MRI). Regional lymph nodes were considered positive when suspicious at 
physical examination, and when confirmed by CT scanning and/or histological or cytological 
evaluation. Further staging included chest X-ray and/or CT scan, bone scintigraphy and bone 
marrow aspiration. Pre-treatment staging in children was based on the IRSG classification (23). 
Adult patients were staged according to the TNM classification, based on local tumor extension 
and/or fixation to surrounding tissues (T), tumor size <5 cm of ≥5 cm, lymph node involvement 
(N) and presence of metastatic disease (M), and were translated into IRSG classification to facilitate 
comparison. Favorable locations of the primary tumor included the orbit, head and neck but 
not parameningeal, and paratesticular sites, whereas unfavorable locations included all other 
sites, as stated by the IRSG studies. Postsurgical clinical grouping (CG) staging was based on the 
extent of residual tumor after the initial resection, according to the IRSG clinical grouping system. 
Treatment
Most children were treated according to the Children’s Oncology Group (COG) or International 
Society of Paediatric Oncology (SIOP) guidelines (24, 25). Local control consisted of primary 
surgery or surgery after neoadjuvant chemotherapy and/or radiotherapy. Adjuvant systemic 
treatment consisted of combinations of vincristine, D-actinomycin, and either iphosphamide 
or cyclophosphamide. Anthracyclines were added in the case of advanced disease. Treatment 
of adults consisted of surgery and/or radiotherapy for local control following the STS protocols. 
Additionally, chemotherapy, mainly consisting of anthracyclines in combination with one or 
more of vindesine/vincristine, iphosphamide, and etoposide, was administered to the majority 
of adult patients. 
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In the largest group, namely embryonal RMS, higher age was related to a higher rate of metastatic 
disease at diagnosis (p=0.001) and IRS stage (p=0.002). Within the group of alveolar RMS, higher 
age was related to IRS stage (p=0.026), and there was a trend for a relation between higher 
age and more lymph node involvement (p=0.079). Tumors arising at unfavorable primary sites 
(p=0.068), such as parameningeal versus other primary locations (p<0.001), were also related 
to higher age.
Treatment
Of all 169 patients, six patients did not receive any treatment due to varying reasons (supplementary 
Table 1). Of the remaining  patients (N=163), 22 did not complete treatment. 
Surgery was performed slightly more frequently in patients <16 years (p=0.051), whereas 
radiotherapy was more frequently administered to patients ≥16 years (p=0.003, Table 3).  A 
significantly lower number of patients ≥16 years underwent chemotherapy when compared to 
Table 1
Patient characteristics.
Table 2
Pre-treatment prognostic factors by histological subtype. 
aChi-square test; bnon-prostate, non-bladder; cEvaluated by either histological evaluation, by CT scanning or by 
clinical examination; dIRS: Intergroup Rhabdomyosarcoma Study Group (IRSG) pre-operative staging; eComplete 
remission (CR) was defined as no evidence of residual disease at the end of treatment, confirmed by radiography 
and/or histopathology; fTime to relapse is defined as the time from the end of treatment with CR until disease 
relapse; gFollow-up time is the time between time of diagnosis until death or the last contact moment to the hospital
aChi-square test; bIRS stage: Intergroup Rhabdomyosarcoma Study Group (IRSG) pre-operative staging.
This table displays the frequency distribution of the prognostic factors by histological subtype.
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Figure 1A
Frequency distribution by age and histological subtype. 
Figure 1B
Age distribution by histological subtype.
This figure shows the box plots of the age distribution by histological subtype. Stepwise non-parametric 
testing was performed. Age differed significantly between patients with alveolar (median=15 years) 
and those with embryonal RMS (median=8 years, p<0.001) and botryoid RMS (median=4 years, 
p<0.001). There was a trend for a difference in age between embryonal and botryoid RMS (p=0.084).
patients <16 years (p=0.003). The reason why not all patients received chemotherapy could not 
be retrieved in all cases. Some patients were in a poor clinical condition, impairing administration 
of chemotherapy; others had had a resection of a small tumor and were apparently deemed to 
have been optimally treated in earlier years of this retrospective study.
Most children received multiagent chemotherapy but no anthracyclines (63.5%), with the 
addition of anthracyclines only to patients with advanced disease (29.6%). Adults mainly received 
anthracycline-based multiagent chemotherapy, resulting in a more frequent use of anthracyclines 
in patients ≥16 years when compared to patients <16 years (p<0.001).
Survival
Five-year OS for the whole cohort was 52.0±4.0%. Patients ≥16 years had a disadvantage in 
outcome when compared to patients <16 years (5-year OS 21.4±6.4% versus 64.8±4.5%, p<0.001, 
Figure 2A). 
A significant difference in survival was seen for the different histological subtypes (Figure 2B). 
Botryoid RMS had the best 5-year OS (78.3±11.1%), whereas alveolar RMS demonstrated poor 
outcome (5-year OS=21.9±6.1%). Patients with embryonal RMS had an intermediate 5-year OS 
of 63.7±4.9%. 
For embryonal RMS, a superior survival was seen in patients <16 years (5-year OS=71.3±5.2%) 
versus patients ≥16 years (5-year OS=37.4±11.0%, p=0.001, Figure 2C). For alveolar RMS, an 
advantage in survival for patients <16 years when compared to patients ≥16 years was also 
seen (5-year OS=35.8±9.7% versus 8.5±5.8%, p=0.020, Figure 2D). In Figure 2E, we show OS in 
non-metastatic embryonal RMS (5-year OS=69.1±5.0%), non-metastatic alveolar RMS (5-year 
OS=34.1±9.5%), and metastatic embryonal and alveolar RMS (5-year OS=11.7±5.9%). Furthermore, 
within the subgroup of non-metastatic embryonal RMS, there was a significant disadvantage in 
survival for patients ≥16 years (5-year OS=40.0±13.0%) when compared to 
Supplementary table 1 
Treatment intention and follow-up.
aNED=no evidence of disease. This table displays the number of patients included in the study and the treatment 
intention, as well as data on completement of treatment and follow-up. 
76 77
Table 3
Treatment characteristics by age group.
aChi-square test. bTreatment regimens were divided into vincristine and actinomycin (VA)-containing 
and non-VA-containing. VAC/VAI(A), vincristine, D-actinomycin, cyclophosphamide/ iphosphamide, 
(doxorubicin); DIME, doxorubicine, iphosphamide, mesna, etoposide; EVI, etoposide, vindesine/vincristine 
and iphosphamide. cClinical group was based on the extent of residual tumor after the initial surgical 
resection, according to the clinical grouping system of the Intergroup Rhabdomyosarcoma Study Group. 
Percentages of treatment modalities (chemotherapy, radiotherapy, surgery and clinical group) were 
calculated as the percentage of all patients treated with curative intention of treatment (N=163).
Age in rhabdomyosarcoma; a multi-centre report
children <16 years (75.9±5.1%, p=0.002, Figure 2F). Exclusion of patients who did not receive 
chemotherapy resulted in a 5-year OS 49.2±15.4% in patients ≥16 years versus 78.1±5.0% in 
patients <16 of age (p= 0.021). 
Prognostic factors
In all RMS patients (Table 4), increasing age (p<0.001, HR=1.028), unfavorable primary site 
(p=0.012, HR=2.51), lymph node involvement (p=0.023, HR=1.94) and the presence of metastatic 
disease (p=0.009, HR=2.16) were multivariate predictors of poor DSS. Increasing age (p<0.001, 
HR=1.031) was the only significant multivariate prognostic factor of poor RFS, along with a trend 
towards a negative prognostic effect of alveolar subtype (p=0.057, HR=1.96) and metastatic 
disease (p=0.094, HR=1.89). To further exclude the interaction between the effect of age and 
histological subtype on outcome, we analyzed embryonal and alveolar RMS separately.
Embryonal RMS
In embryonal RMS (Table 5), increasing age (p=0.001, HR=1.038), unfavorable primary site 
(p=0.006, HR=4.21), and lymph node involvement (p<0.001, HR=5.47) were significant multivariate 
predictors of poor DSS, whereas a trend was seen for metastatic disease (p=0.063, HR=2.45). 
Higher age (p<0.001, HR=1.043), unfavorable primary site (p=0.033, HR=2.50), and lymph node 
involvement (p=0.015, HR=3.47) were multivariate predictors of poor RFS. 
To eliminate a possible effect of metastatic disease in older patients as mentioned before, non-
metastatic embryonal RMS was analyzed separately (Table 6). Increasing age (p=0.001, HR=1.045), 
unfavorable primary site (p=0.011, HR=4.00), and lymph node involvement (p<0.001, HR=6.44) 
were significant multivariate predictors of poor DSS, whereas higher age (p<0.001, HR=1.043), 
and unfavorable primary site (p=0.045, HR=2.52) were predictors of poor RFS.
Furthermore, we investigated the effect of treatment modalities (chemotherapy, radiotherapy, 
surgery, and Clinical Group I-IV) on DSS in non-metastatic embryonal RMS. In univariate analysis, 
no administration of chemotherapy (p=0.011, HR=5.19, 95% CI=1.47-18.63), no surgery for 
primary tumor and/or metastases (p=0.004, HR=3.66, 95% CI=1.515-8.83), and Clinical Group 
III versus I (p=0.013, HR=5.06, 95% CI=1.41-18.20) predicted poor DSS. In a multivariate model 
including age, lymph node involvement, primary tumor location, Clinical Group, radiotherapy, 
chemotherapy and surgery (N=79), higher age (p=0.005, HR=1.07, 95% CI=1.019-1.115), lymph 
node involvement (p=0.003, HR=6.51, 95% CI=1.90-22.25), Clinical group III versus I (p=0.021, 
HR=23.45, 95% CI=1.61-342.34), and no radiotherapy (p=0.048, HR=3.68, 95% CI=1.01-13.37) 
were predictors of poor DSS. 
Alveolar RMS
In alveolar RMS (Table 7), there was a trend for poorer DSS with increasing age (p=0.078, HR=1.02), 
and metastatic disease (p=0.095 HR=1.82). A nearly identical result was seen for RFS.
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Figure 2 (continued)
Rhabdomyosarcoma survival. 
Kaplan-Meier overall survival 
(OS) curves for patients with 
rhabdomyosarcoma (RMS) by 
age group (A), patients <16 years: 
N=118 patients, N at 5 years=51, 
patients ≥16 years: N=50 patients, 
N at 5 years=7; by histological 
subtype (B), embryonal RMS: 
N=102 patients, N at 5 years=41, 
botryoid RMS: N=15 patients, N 
at 5 years=8, and alveolar RMS: 
N=51 patients, N at 5 years=9; by 
age group for embryonal RMS (C), 
patients <16 years: N=78 patients, 
N at 5 years=36, patients ≥16 years: 
N=24 patients, N at 5 years=5; by 
age group for alveolar RMS (D), 
patients <16 years: N=26 patients, 
N at 5 years=7, patients ≥16 years: 
N=25 patients, N at 5 years=2; for 
non-metastatic embryonal RMS, 
non-metastatic alveolar RMS and 
metastatic embryonal and alveolar 
RMS (E), non-metastatic embryonal 
RMS: N=90 patients, N at 5 years 40, 
non-metastatic alveolar RMS: N=27 
patients, N at 5 years=8, metastatic 
embryonal and alveolar RMS: N=35 
patients, N at 5 years=2; and by 
age group for non-metastatic 
embryonal (F), patients <16 years 
at diagnosis: N=72 patients, N at 
5 years=36, patients ≥16 years at 
diagnosis: N=18 patients, N at 5 
years=4.
Figure 2
Rhabdomyosarcoma survival. 
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DISCUSSION
In this multicenter retrospective clinical study, we demonstrated in multivariate analysis that 
increasing age as a continuous variable is a strong prognostic factor of a poor therapeutic 
outcome in patients with embryonal and alveolar RMS aged 0-73 years. Moreover, histological 
subtype and clinical presentation at diagnosis (e.g. tumor location, lymph node involvement 
and presence of metastatic disease) were prognosticators of outcome in the whole cohort.  
Whereas prognostic factors in children with RMS have been investigated extensively over the 
past decades (5-8), until recently, data on prognostic factors in adult patients were scarce, most 
likely due to the rarity of these tumors and the dispersion of patients treated in adult oncology 
centers (11). 
Our study confirms previous findings in cohorts aged 0-75 years, with additional correction for 
treatment modalities. La Quaglia et al. were the first who described both adults and children 
with RMS and found age, TNM stage, and histological subtype as prognostic factors of survival 
(22). Furthermore, a population-based study including 2,600 patients of all ages with RMS was 
published recently (12), indicating that age, histological subtype, primary site location, stage, and 
local control with surgery and/or radiation were significant predictors of survival. In contrast to 
this large study, we attempted to add in this present study an analysis of chemotherapy schedules 
that were administered and excluded pleiomorphic RMS, which occurs exclusively in adults. 
Histological subtype is an established prognostic factor of survival in RMS in children. This holds 
true with the present findings for the whole cohort in univariate analysis. Moreover, results of our 
multivariate model for the whole cohort indicate that this disadvantage in outcome for alveolar 
RMS might have a stronger relation to an unfavorable clinical presentation (e.g. unfavorable 
primary site and the presence of lymph node and distant metastases) than to alveolar histology 
itself, as reported by Sultan et al (12). In addition, a trend for unfavorable primary location (i.e. 
parameningeal) and lymph node involvement at a higher age in alveolar RMS was found, which 
might explain the worse outcome in older patients. However, it should be mentioned that the 
documentation and assessment of lymph node involvement was suboptimal during the early 
time period. Nevertheless, the reported effect of lymph node involvement on survival in the 
current study is in line with a recent report, and supports the view that lymph node involvement 
should be considered as an important prognosticator, especially in alveolar RMS (26). Regarding 
histological subtype, it should be taken into account that refinement of the histological diagnosis 
of RMS with molecular and genetic diagnostic techniques has taken place over time during our 
study (7, 27). 
Metastatic disease is a strong adverse prognostic factor in all patients with RMS, leading 
to poor survival not exceeding 30% (11, 12, 28, 29). In our cohort, 5-year overall survival of 
patients with metastatic disease hardly exceeded 10%. Importantly, the presence of metastatic 
disease correlated with higher age at diagnosis, even in the restricted group of embryonal RMS. 
Unfavorable clinical presentation with increasing age was also reported by others (11, 20, 21). 
Importantly, we found age was a prognosticator of DSS in non-metastatic embryonal RMS. 
Although age as a prognostic factor in this particular subset of patients has been previously 
reported (22), to our knowledge, the present study is the first that has evaluated age as a 
continuous factor in multivariate analysis including treatment modalities. 
Apart from tumor-specific factors, treatment-related aspects play a role in the final outcome of RMS 
patients. Pediatric patients (up to 21 years) are generally treated on study protocols developed 
by, for example, the SIOP (Europe) and COG (formerly IRSG, United States), including systemic 
treatment for all patients. In adults, we show that systemic treatment is administered, although 
less frequently and comprising other agents, as was mentioned above. Of note, anthracyclines 
were applied more frequently as part of the primary treatment for adult patients. The underlying 
reason for this discrepancy in treatment approach is not fully clear. The lack of international 
protocols for the elder RMS population and the rarity of the disease within the adult oncologic 
population may play an important role (30). Although we found that age remained of prognostic 
significance after including treatment modalities in a multivariate model, we were not able to 
correct for the different regimens and dose intensities given.  Whether these observed differences 
in chemotherapy schedules might play a role should be further investigated. Importantly, Ferrari 
et al. previously hypothesized that survival in adults would be comparable to that of children, if 
they received the appropriate treatment as prescribed in the current childhood regimens (11).
Other suggested explanations for poor survival of adults with RMS are differences in oncogenesis 
and biological behavior. Advanced clinical presentation with increasing age, as well as age per se 
being a prognostic factor in uniformly treated children, support this idea (17, 26, 31, 32). Despite 
investigations focusing on understanding oncogenesis and biological behavior, limited data 
are available with regard to age-related biological differences of RMS. Younger onset of RMS is 
associated with several rare syndromes that harbor specific genetic alterations, including of the 
germline p53 tumor-suppressor gene, HRAS oncogene, and neurofibromin (NF1) gene, suggesting 
a different genetic background for early RMS genesis within these patients (33). Furthermore, 
the PAX7/FKHR translocation t(1;13)(p36;q14) in alveolar RMS, is associated with younger onset 
of disease, primaries of the extremity, localized disease, and better outcome, whereas the more 
common PAX3/FKHR translocation t(2;13)(q35;q14) is associated with higher age at diagnosis 
and represents a highly malignant phenotype with a predilection for bone marrow involvement 
and worse outcome (34, 35). However, although a recent study confirmed the relation of PAX3/
FKHR with a higher age and metastatic potential, it did not confirm a higher rate of bone marrow 
involvement and worse outcome for patients with these tumor types (36). A higher expression 
of drug-efflux pumps in adult RMS, thereby potentially contributing to worse response to 
chemotherapy, was also proposed to explain differences in terms of biological behavior (37).
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CONCLUSION
In conclusion, age is a strong adverse prognostic factor of survival in patients with embryonal 
and alveolar RMS. Whether the dismal outcome is caused by a biological or treatment effect 
remains to be elucidated. With the introduction of more homogeneous treatment protocols 
for both children and adults, the contribution of age-related biological factors can be further 
explored. Given the presumably lower tolerance of adults to the high doses of chemotherapy 
administered in childhood RMS (20), dose schedules should be adapted. Based on the results of 
our study and the recently published SEER data, collaboration between pediatric and medical 
oncologists regarding patients with RMS is urgently needed, and should ideally take place at a 
global level, given the rarity of these tumors (30).
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INTRODUCTION
Rhabdomyosarcomas (RMS) are the most common soft tissue sarcomas of childhood (1, 2). The 
two main histological subtypes are embryonal RMS (ERMS, 60-70%) and alveolar RMS (ARMS, 
20-30%) (1). ARMS is typically characterized by the specific t(2;13) translocation (PAX3-FOXO1, 
55%), or a variant t(1;13) translocation (PAX7-FOXO1, 22%) and is known for its aggressive clinical 
behavior (3). Although dramatic survival improvements have been reached with the introduction 
of intensive chemotherapy schedules, survival rates for  patients at high risk to develop metastatic 
disease or already having metastases at initial diagnosis, remain disappointing (<50%) (4-9). 
In an attempt to identify genome-wide key players in oncogenesis as well as potential molecular 
targets for therapy, gene expression profiling studies recently identified the presence of distinct 
molecular signatures based on the presence or absence of the specific translocations in RMS 
(10-14). In these studies, translocation-positive ARMS was repeatedly associated with anaplastic 
lymphoma kinase (ALK) overexpression (10-12). Moreover, whole genome analysis for PAX3-
FOXO1 protein binding sites recently showed a very high affinity for binding to ALK’s 3rd intron 
yielding increased ALK transcription. In the same study, introduction of lentiviral shRNA against 
PAX3-FOXO1 into a PAX3-FOXO1 positive cell line consequently downregulated ALK mRNA levels 
in vitro (15). 
In line with these gene expression data, ALK protein expression was reported in RMS, predominantly 
in ARMS but also in ERMS (16, 17). In addition, FISH analysis of a small subset of ALK overexpressing 
ARMS points towards the presence of ALK copy number gain/amplification in RMS (17). 
The ALK receptor is a member of the insulin receptor family of receptor tyrosine kinases (RTKs) 
which is capable of activating the STAT3 (18, 19), AKT/PI3K (20), and RAS/ERK (21) pathways. These 
pathways are involved in biological processes including cell proliferation, migration and survival. 
In normal tissues, ALK expression is essentially limited to the central and peripheral nervous 
system, where it plays a role in neuronal differentiation during embryogenesis (22). However, 
multiple malignancies are known to harbor ALK alterations, for example anaplastic large cell 
lymphomas (ALCL), non small cell lung cancer (NSCLC) (23, 24), inflammatory myofibroblastic 
tumors (IMT) (25, 26), and neuroblastoma (27-31). These alterations encompass translocations 
(ALCL/NSCLC) (32-34), germline or somatic mutations (neuroblastoma) (27) and genomic gains 
or amplifications (neuroblastoma, NSCLC) (24, 27). Impressive anti-tumor activity of an agent 
targeting ALK in NSCLC (35) underlines the clinical relevance that ALK can play in certain tumor 
entities.
Although the previous investigations point towards ALK as an important factor in RMS, there 
are limited data concerning expression and genetic alterations of ALK in this disease. The aim of 
the present multi-center cohort study is to investigate ALK protein expression and underlying 
genetic aberrations in RMS, with special attention to clinical and prognostic implications in a 
representative cohort of RMS patients with complete clinical follow-up data.  
ABSTRACT
Purpose: The aim of this study is to investigate anaplastic lymphoma kinase (ALK) protein 
expression and underlying genetic aberrations in rhabdomyosarcoma, with special attention 
to clinical and prognostic implications.
  
Patients and methods: A total of 189 paraffin-embedded rhabdomyosarcoma tumor specimens 
of 145 patients were collected on tissue microarray. ALK protein expression was evaluated by 
immunohistochemistry. ALK gene (2p23) copy number and translocations were determined by 
in situ hybridization. cDNA sequencing of the receptor tyrosine kinase domain of the ALK gene 
was assessed in 43 samples. 
Results: Strong cytoplasmic ALK protein expression was more frequently observed in alveolar 
rhabdomyosarcoma (ARMS) than in embryonal rhabdomyosarcoma (ERMS) (81% versus 32%, 
respectively, p<0.001). ALK gene copy number gain was detected in the vast majority of ARMS 
(88%), compared to 52% of ERMS (p<0.001). ALK copy number correlated with protein expression 
in primary tumors (N=107). We identified one point mutation (2%) and seven tumors harboring 
whole exon deletions (16%). In ERMS, specific ALK gain in the primary tumor correlated with 
metastatic disease (100% in metastatic versus 29% in non-metastatic disease, p=0.004), and 
poor overall survival (OS) (5-years OS 62% versus 82%, p=0.046).
Conclusion: As ALK aberrations on genomic and protein level are frequently found in 
rhabdomyosarcomas, in particular ARMS, and are associated with disease progression and 
outcome in ERMS, ALK may play a role in tumor biology and may provide a potential therapeutic 
target for these tumors. Future research should aim at the oncogenic role of ALK and the potential 
effect of ALK-inhibitors in rhabdomyosarcoma. 
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preclinical testing program, Nationwide Children’s Hospital, Columbus, OH) were analyzed by 
cDNA sequencing (primers and sequencing method are explained in supplementary methods). 
Mutations were confirmed by repeat amplification/sequencing and by consensus among two 
investigators.
Statistical analysis
A possible relation between categorical data was calculated using Chi-2 testing or Fisher’s exact 
test when appropriate. Differences in median age and median ALK copy numbers for different 
IHC groups were assessed using Kruskal Wallis with close-testing. Linear correlation between 
two continuous parameters was evaluated using Spearman correlation. Kaplan-Meier survival 
analyses with Log-rank test were performed to evaluate the effect of ALK protein expression and 
ALK copy number on disease-specific survival (DSS). DSS was defined as time from diagnosis 
until tumor-specific death. Patients who never experienced an event were censored at the last 
contact date to the hospital. A p<0.05 was considered significant. All statistical analyses were 
performed using SPSS version 16.0. 
RESULTS
ALK protein expression
A total of 183 (97%) samples were evaluable for ALK protein expression. ALK protein staining 
showed a dot-like or diffuse cytoplasmic staining pattern (figure 1A). Nuclear staining was 
occasionally observed (7% overall). (Moderately) strong ALK protein expression was identified 
in tumor samples of different origins (primary 51%, distant/lymph node metastases 56%, 
postchemotherapy resections 29%, and local recurrences 42%). Strong ALK protein expression 
was predominantly seen in ARMS (81% overall, 93% primary tumors) and to a lesser extent in 
ERMS (32% overall, 38% primary tumors, p<0.001). 
ALK as emerging target in rhabdomyosarcoma
MATERIAL AND METHODS
Patients and tissue samples
A total of 189 RMS tissue samples of 145 patients were included. One-hundred-thirty-seven 
samples of patients diagnosed between 1979-2009 were retrieved from the files of the Pathology 
Departments from the author’s affiliations. Fifty-two additional samples were selected from 
PALGA, the nationwide network and registry of histo- and cytopathology in the Netherlands 
(36). The study was performed in accordance with the Code of Conduct of the Federation of 
Medical Scientific Societies in the Netherlands (http://www.federa.org/?s=1&m=99). Slides were 
reviewed by an expert pathologist (U.E. Flucke) and the diagnosis was based on histological 
and immunohistochemical (IHC) criteria according to the WHO classification (37). Translocation 
status could be evaluated by reverse transcriptase polymerase chain reaction (RT-PCR) in 84.4% 
of ARMS, showing a PAX3-FOXO1 translocation in 65.8%, PAX7-FOXO1 translocation in 5.3%, 
PAX3/7-FOXO1 translocation in 18.4%, and 10.5% were translocation negative. Paraffin-embedded 
tumor specimens were collected on tissue micro-arrays (TMAs) containing 1-3 cores of 1-3 mm 
diameter for each sample. 
Immunohistochemistry 
ALK IHC was performed on 4 µm thick formalin-fixed, paraffin-embedded TMAs using the mouse 
monoclonal antibody CD246 (ALK protein, clone ALK1, Dako, Denmark). A selected positive RMS 
case was used as positive control and substitution of the primary antibody with 1% BSA-PBS was 
used as a negative control. The IHC protocol is discussed in more detail in the supplementary 
methods.  ALK IHC score was categorized as - (negative), +/- (weak), + (moderately strong), and 
++ (strong), with a minimum cut-off at 10% of tumor cells. IHC was scored by three independent 
investigators. Additionally, a binary scoring system was used for statistical analysis, in which 
negative or weak staining was considered negative, whereas (moderately) strong staining was 
considered positive. 
Chromogenic / Fluorescence in situ hybridization (CISH/FISH)
FISH procedures were performed on identical TMAs using an ALK (2p23) split-signal FISH DNA 
probe (Dako) to detect alternative rearrangements involving the ALK gene and to determine copy 
numbers. The TMAs were subsequently DuoCISH-stained (Dako DuoCISH kit, Dako, Denmark) 
and analyzed using bright field microscopy. ALK copy number was counted in 30 cells per core 
and categorized as normal (0-4 copies), low level gain (>4-6 copies), high level gain (>6-10 
copies) and amplification (>10 copies) with a minimum cut-off at 10% of the cells. A MYCN 
(2p24) and LAF (2q11) Repeat-Free control probe (Kreatech Diagnostics) was used as reference 
for chromosome 2(p) alterations in cases with abnormal ALK copy number (>4 copies of ALK in 
>10% of cells). Cut-off points used were ALK/LAF or MYCN/LAF ratio <1.5, 1.5-2 and >2. A ratio 
>1.5 was considered a specific ALK or MYCN gain.
ALK RTK domain sequence analysis
Fresh-frozen tissue samples with an amount of tumor cells ≥60% (n=43;24 ERMS, 19 ARMS) 
and four cell lines (RD, Rh18, Rh30 and Rh41, kindly provided by Dr. Peter Houghton, pediatric 
Figure 1A (color figure page 196)
ALK protein expression by IHC with the ALK1 antibody (Dako) in RMS. 
Upper row: 1. ALK negative staining in ERMS, 2. ALK weak staining inERMS, 3. ALK moderately strong staining in ARMS, 4. ALK 
strong staining in ARMS. Lower row: corresponding heamatoxylin and  eosin (H&E) staining. Magnification: 20x 
96 97
ALK as emerging target in rhabdomyosarcoma
ALK copy number alterations
ALK gene copy numbers could be evaluated in 167 (88%) samples (figure 1B). There was no 
evidence for the presence of ALK translocations. Copy number gain was present in tumor 
specimens of different origin (primary tumors 59%, distant/lymph node metastases 72%, 
postchemotherapy resections 65%, and local recurrences 78%). ALK copy number gain was 
observed more frequently in ARMS (88% overall, 92% primary tumors) compared to ERMS 
tumors (52% overall, 49% primary tumors, p<0.001) (table 1). 
A close-up on copy numbers in primary tumors of ARMS histology, revealed two cases (8%) 
showing normal ALK copy number, 14 cases (58%) showed low level gain, six cases (25%) showed 
high level gain and two cases (8%) showed true amplification. In ERMS primary tumors, 42 (51%) 
showed normal ALK copy numbers, 32 (39%) showed low level gain, 9 (11%) showed high level 
gain, and no amplifications were observed. Characteristics of all 17 primary tumors with high 
level gain or amplification are summarized in table 2.
True amplification of the ALK gene was limited to six specimens of unique patients (4%, 
table 2), including two primary ARMS, one ARMS lymph node metastasis, and three ERMS 
postchemotherapy resections.
Specific ALK gain and MYCN alterations
In primary tumors with evidence of ALK gain/amplification, we evaluated LAF (near-centromere; 
2q11) and MYCN (neighboring gene; 2p24) signals as a reference for the specificity of ALK 
aberrations. No difference in the mean ALK/LAF ratio between ARMS and ERMS was seen, ranging 
from 1.10-2.72 in ERMS (median 1.58 N=36) and from 0.95-12.59 in ARMS (median 1.47 N=20, 
p=0.584). 
In ERMS, 61% (22/36) of the evaluated samples showed specific ALK gain (ALK/LAF ratio >1.5), 
which corresponds to an overall rate of 28%. Also, 14% (5/36) showed an indication for whole 
chromosome 2 gain (defined as >10 % of cells harboring >4 LAF copies), involving a single case 
with an additional specific ALK gain. MYCN aberrations were absent in ERMS. 
Figure 1B (color figure page 196)
Chromogenic in situ hybridization (CISH) of the ALK gene in RMS.
1. low level ALK gain up to 6 copies per nucleus (marked by black arrows) 2. Primary ARMS showing ALK amplification in all cells 
3. Amplification of the ALK gene with >30 ALK copies in an ERMS lymph node metastasis during treatment. Magnification: 40x.
Table 1
Patient characteristics and ALK immunohistochemistry (IHC) score and ALK gene copy number by 
Chromogenic In Situ Hybridization (CISH) 
NOTE missing data were excluded from the analysis. T= Tumor invasiveness; T1= non-invasive, T2= invasive to 
surrounding tissues, Tx= unknown. N= lymph node involvement; N0= no clinical/CT/histological evidence for lymph 
node involvement, N1= evidence for lymph node involvement. M= metastatic disease; M0= no distant metastases, 
M1= distant metastases present. IRS= pre-treatment staging system. Clinical group= post-surgical clinical group.
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Sequencing of the ALK RTK domain
Eight out of 43 (19%) investigated tumors harbored genetic alterations in mRNA encoding for the 
ALK RTK domain. One patient showed a missense mutation c.3673G>A; p.Asp1225Asn. Matched 
germline DNA was not available to determine whether this was a germline or a somatic mutation. 
We furthermore identified a solitary exon 23 deletion (n=2 patients, and Rh18), a solitary exon 
27 deletion (n=3 patients and Rh41), a combined exon 23 and 25 deletion (n=1 patient) and 
a combined deletion of 2 nucleotides in exon 25 and a whole exon 27 deletion (n=1 patient). 
Assuming there are no alterations of ALK outside the sequenced domain, these deletions will 
result in the formation of an unglycosylated ALK protein of ~130 (exon 23), ~140 (GA deletion 
exon 25 and exon 27), and ~170 (exon 25) kDa. ALK copy number and protein expression data 
of these patients and their clinical characteristics are summarized in table 3 and 4. No obvious 
relation between these genetic aberrations and protein expression was observed.
Longitudinal ALK expression 
Paired tumor samples of single patients (primary tumor/chemotherapy effect/lymph node or 
distant metastasis/local recurrence) were analyzed for longitudinal changes in ALK expression. 
ALK protein expression (n=47 pairs, (moderately) strong versus weak/negative) was similar in 
68.1%, whereas ALK copy number (n=40 pairs, normal versus gain/amplification) was identical 
in 80.0%. ALK protein expression was lower in postchemotherapy resections than in the related 
primary tumor (n=21, p=0.02, z=-2.333) and a tendency for decreased ALK copy number in 
post-chemotherapy resections compared to the related primary tumor was observed (n=17, 
p=0.08, z=-1.732).
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Figure 1c
ALK IHC by mean ALK copy number.
In ARMS, ALK specific gain was observed in 45% (9/20), which corresponds to an overall rate of 
41% in all primary ARMS (9/22). Whole chromosome 2 gain was present in 25% (5/20) of ARMS, 
including one case with an additional specific ALK gain. MYCN amplification was observed in 
three cases, all without specific ALK gain. 
Relation between ALK copy number and protein expression 
The mean ALK copy number distribution by protein expression was evaluated in primary 
tumors (figure 1C). There was a significant positive correlation of mean ALK gene copy number 
and protein expression (Spearman’s rho p<0.001, correlation coefficient (cc) 0.352, N=107). No 
significant correlation between mean copy number and protein expression was found in ARMS 
(N=24, p=0.109, cc 0.335), and ERMS (N=83, p=0.085, cc 0.190) separately. Specific ALK gain was 
not related to protein expression.
Table 2
ALK characteristics of the primary tumors with high level gain or amplification and non-primary tumor samples with amplification
(RMS89 represents a lymph node metastasis, RMS 15, RMS154 and RMS5 postchemotherapy specimens). *whole chromosome 2 gain was defined 
as a minimum of ≥10% of nuclei containing more than 4 LAF signals. Hlg= high level gain ampl= amplification n.a.= could not be assessed
This figure displays the distribution of the mean ALK copy number in RMS tumors showing negative (-), weakly (+/-), moderately 
strong (+), or strong (++) ALK staining in primary tumors. P-value’s calculated by Kruskal-Wallis test and close-testing of the 
separate groups by Mann-Whitney-U test. 
100 101
ALK as emerging target in rhabdomyosarcoma
Ta
bl
e 
3
A
LK
 c
ha
ra
ct
er
is
tic
s 
in
 c
as
es
 w
ith
 g
en
et
ic
 a
lte
ra
tio
ns
 o
f t
he
 A
LK
 R
TK
 d
om
ai
n.
Ta
bl
e 
4
Cl
in
ic
al
 c
ha
ra
ct
er
is
tic
s 
of
 th
e 
ca
se
s 
w
ith
 g
en
et
ic
 a
lte
ra
tio
ns
 in
 th
e 
AL
K 
RT
K 
do
m
ai
n.
FA
V=
 fa
vo
ra
bl
e 
lo
ca
tio
n 
of
 th
e 
pr
im
ar
y 
tu
m
or
, U
N
FA
V=
 u
nf
av
or
ab
le
 lo
ca
tio
n 
of
 th
e 
pr
im
ar
y 
tu
m
or
. T
= 
Tu
m
or
 in
va
si
ve
ne
ss
; T
1=
 n
on
-in
va
si
ve
, T
2=
 in
va
si
ve
 to
 su
rr
ou
nd
in
g 
tis
su
es
, T
x=
 u
nk
no
w
n.
 N
= 
ly
m
ph
 n
od
e 
in
vo
lv
em
en
t; 
N
0=
 n
o 
cl
in
ic
al
/C
T/
hi
st
ol
og
ic
al
 e
vi
de
nc
e 
fo
r l
ym
ph
 n
od
e 
in
vo
lv
em
en
t, 
N
1=
 e
vi
de
nc
e 
fo
r l
ym
ph
 n
od
e 
in
vo
lv
em
en
t. 
M
= 
m
et
as
ta
tic
 d
is
ea
se
; M
0=
 n
o 
di
st
an
t m
et
as
ta
se
s, 
M
1=
 d
is
ta
nt
 m
et
as
ta
se
s 
pr
es
en
t. 
IR
S=
 p
re
-t
re
at
m
en
t s
ta
gi
ng
 s
ys
te
m
. C
lin
ic
al
 g
ro
up
= 
po
st
-s
ur
gi
ca
l c
lin
ic
al
 g
ro
up
. C
R=
 c
om
pl
et
e 
re
m
is
si
on
. D
F=
 d
is
ta
nt
 fa
ilu
re
, L
F=
 lo
ca
l f
ai
lu
re
. E
FS
= 
ev
en
t f
re
e 
su
rv
iv
al
 (m
on
th
s)
. F
U
= 
fo
llo
w
-u
p;
 N
ED
= 
no
 e
vi
de
nc
e 
of
 d
is
ea
se
, D
O
C 
= 
de
ad
 d
ue
 to
 o
th
er
 c
au
se
, D
O
D
= 
de
ad
 o
f d
is
ea
se
. 
LL
G
= 
lo
w
 le
ve
l g
ai
n,
 H
LG
 =
 h
ig
h 
le
ve
l g
ai
n,
 A
M
PL
=a
m
pl
ifi
ca
tio
n.
 W
ho
le
 c
hr
om
os
om
e 
2 
ga
in
 w
as
 d
efi
ne
d 
as
 a
 m
in
im
um
 o
f 1
0%
 o
f n
uc
le
i d
is
pl
ay
in
g 
>4
 L
A
F 
co
pi
es
. n
a=
 n
ot
 a
ss
es
sa
bl
e.
 C
N
 =
 c
op
y 
nu
m
be
r N
o.
 3
 (I
D
11
6)
 re
pr
es
en
ts
 a
 ly
m
ph
 n
od
e 
m
et
as
ta
si
s 
at
 d
ia
gn
os
is
, w
he
re
as
 th
e 
ot
he
r s
am
pl
es
 w
er
e 
al
l p
rim
ar
y 
tu
m
or
s.
102 103
DISCUSSION
The identification of novel therapeutic targets in RMS is of major clinical importance. In this 
study, we provide a descriptive characterization of ALK protein expression and underlying 
genetic aberrations in RMS. Furthermore, the clinical and prognostic implications of ALK status 
were explored in a representative subset of patients with complete follow-up data.  
We demonstrated ALK protein expression in the vast majority of ARMS (81%, n=58) and in a 
significant number of ERMS (32%, n=125), which is higher than previously described in smaller 
series; 45-52% in ARMS and 15-23% in ERMS (16, 17). 
As reported earlier in a small number of cases (n=6) selected for their high ALK protein expression 
(17), a high frequency of ALK copy number gains was found in our extensive cohort (ARMS 88% 
n=51 and ERMS 52% n=116; respectively). True amplification of the ALK gene was observed in 
only 4% of RMS in the present study, which is lower than the single amplification (17%, n=6) 
reported by Corao et al (17). 
Previous studies also identified MYCN (ALK neighboring gene; 2p24) overexpression in ARMS 
(mainly in PAX3-FOXO1 positive) and to a lesser extent in ERMS (10, 15, 38-40). However, ALK 
copy number gain in our series was not associated with gain/amplification of a larger area on 
chromosome 2p (including both ALK and MYCN), as was previously reported in neuroblastoma 
(27). Of note, the number of cases with MYCN amplification was particularly low (n=3 ARMS). 
Interestingly, the presence of ALK translocations/rearrangements as previously found by 2p23 
break-apart FISH analysis (2/19) (17, 26, 41), was not confirmed in our study population. 
We detected a high rate of genetic aberrations on mRNA level in the RTK domain of ALK; in ERMS 
more often than in ARMS. Seven tumors harbored whole exon deletions and one missense 
mutation was detected. To our knowledge, exon deletions have not been described before and 
we found that these deletions potentially lead to variable ALK isoforms. A 140 kDa variant of the 
ALK protein was earlier reported in neuronal tissues as well as in two neuroblastoma cell lines 
(UKF-NB3 and IMR-32) (22, 42, 43). Although it was earlier proposed that proteolytic cleavage of 
the extracellular domain is responsible for the presence of a shorter variant of ALK (44), our data 
indicate that alternative mRNA splicing is the mechanism behind the existence of variable ALK 
isoforms in RMS, as was postulated by Morris et al (32). Although activation by phosphorylation 
of the shorter variant protein was observed in neuroblastoma cell lines (43), the consequences 
of the existence of ALK splice variants remain to be revealed. We furthermore postulate that the 
identified point mutation might alter protein function, but this should be further elucidated. 
There is an ongoing debate with regard to the optimal ALK detection method in different 
malignancies (45). Although the current study underscores the feasibility of ALK protein detection 
(IHC) and copy number evaluation (ISH) in RMS, there are some issues that should be considered. 
Importantly, the variant ALK isoforms might not be detected using the ALK1 antibody since it 
binds distal to the end of the isoforms (bp 1359-1460), leading to a potential underestimation 
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Clinical and prognostic implications of ALK
The clinical characteristics investigated for a potential relation with ALK in primary tumors are 
summarized in table 1. We could retrieve the clinical follow-up data of 73 patients (median follow-
up of 46.5 months). In all patients, a significant relation between ALK protein expression and 
ARMS histology (p<0.001), metastatic disease at diagnosis (p=0.033), and higher median age at 
diagnosis (p=0.041) was observed. ALK copy number gain/amplification was significantly related 
with ARMS histology (p<0.001), and the presence of metastatic disease at diagnosis (p=0.022). 
In ERMS, we observed a significant relation between specific ALK copy number gain and 
metastatic disease (5/5 of metastatic versus 13/45 of non-metastatic patients displayed ALK 
copy number gain, p=0.004) and worse survival (n=49, 5-year DSS 61.9 ± 12.3% versus 81.6 ± 
7.5%, p=0.046) (figure 2). 
In ARMS, we did not observe any relations between ALK protein expression or copy number 
alterations and clinical presentation or outcome, due to the nearly absence of cases without 
protein expression or copy number gain. However, DSS for the whole group of ARMS was 
particularly low (n=17, 5-year DSS 31.2 ± 11.3%).
Figure 2
Effect of specific ALK gain on ERMS survival.
This figure shows a significant poorer survival in patients with ALK specific gain in the primary tumor (N=18, 5-year survival 61.9 
± 12.3%) versus non-specific gain or no gain (N=31, 5-yr DSS 81.6 ± 7.5% p=0.046 N at 5 yrs 17) 
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APPENDIX
ALK IHC supplementary data
ALK immunohistochemistry was performed on 4 µm thick formalin-fixed, paraffin-embedded 
TMAs using antigen retrieval by heating in a pressure cooker in a 10 mM citrate buffer (pH 6.0). 
The slides were blocked with 3% hydrogen peroxide and 20% normal horse serum (Vector 
Laboratories Inc., Burlingame, USA). Mouse monoclonal antibody CD246 (ALK protein, clone ALK1, 
Dako, Denmark) was applied overnight in a humidified chamber at 4°C at a dilution of 1:10 in 1% 
bovine serum albumin–phosphate buffered saline (BSA-PBS). The sections were incubated with 
a secondary biotinylated horse-anti-mouse IgG antibody (Vector Laboratories Inc., Burlingame, 
USA) followed by incubation with an avidin-biotinylated horseradish peroxidase complex (ABC) 
using Vectastain ABC kit (Vector Laboratories Inc., Burlingame, USA).  The catalysed reporter 
deposition (CARD) technique was used to enhance staining results and antibody binding was 
visualized with PowerVision DAB (3,3’-diaminobenzide) (ImmunoLogic, Duiven, the Netherlands).
Sequencing additional data
Fresh-frozen tissue samples with an amount of tumor cells ≥60% (n=43 ;24 ERMS, 19 ARMS) 
and four cell lines (RD, Rh18, Rh30 and Rh41, kindly provided by Dr. Peter Houghton, pediatric 
preclinical testing programm) were analyzed by cDNA sequencing. Total RNA was prepared 
using the RNA-Bee isolation reagent according to the manufacturer’s protocol (Tel-Test Inc., 
Friendswood, TX). cDNA was transcribed from 1µg RNA using SuperScriptII reverse transcriptase 
(Invitrogen Life Technologies, Breda, the Netherlands). A region of 1.7 kb including the RTK 
domain of the ALK gene was PCR amplified. PCR analysis was performed using AmpliTaq Gold 
DNA polymerase (Applied Biosystems), with the following program: 94°C 10 min;  92°C 1 min, 
60°C 45 sec, 72°C 1 min, 35 cycles; 72°C 10 min. PCR primers are listed in supplementary table 1. 
The sequencing reaction was performed using the BigDye Terminator reaction mix and samples 
were analyzed on the 3730 DNA Analyzer (Applied Biosystems). Mutations were confirmed by 
repeat amplification/sequencing and by consensus among two investigators.
of protein expression in the current series. Additionally, the interpretation of gene copy number 
gain/amplification is complex. ALK copy number cut-offs in the present study were arbitrarily 
defined. By our cut-off strategy (>4 copies per nucleus in ≥10% of tumor cells) we aimed to 
prevent for overestimation of ALK copy number caused simply by DNA duplication in highly 
proliferative tumor cells. However, this strategy might lead to underestimation of low level copy 
number gains and impairs the detection of specific ALK losses. 
Although the functional role of the observed ALK alterations remains unknown, the high rate of 
both copy number changes and protein expression in mainly ARMS and also progressive ERMS 
suggest a potential role for ALK in the tumor biology of these tumors. This is further supported by 
previous data reporting ALK overexpression on mRNA level in (translocation positive) ARMS (10-12) 
as well as the potential of the chimeric PAX3-FOXO1 protein to influence ALK transcription (15). 
Although it is too early to draw firm conclusions concerning the potential effect of ALK inhibitors 
in RMS, the observed relation between specific ALK copy number gain and metastatic disease 
at diagnosis and poor outcome in ERMS encourages the need for investigations concerning 
the potential effect of ALK inhibitors in RMS patients with progressive disease. As the clinical 
and outcome data concerned only a limited subpopulation of our cohort, the relation of ALK 
with progressive disease and outcome should be further validated in a future cohort of RMS 
patients. Small molecule inhibitors of ALK are currently under (pre)clinical investigation and 
recent data have shown impressive clinical responses in ALK overexpressing NSCLC, ALCL and 
IMT (35, 46, 47). Mutations and amplification of the ALK gene have previously been shown to 
modify the response to ALK inhibitors (29, 30, 48, 49). We suggest that the evaluation of genetic 
changes is therefore essential in the development of predictive and selective models for future 
ALK inhibitory treatment. The observation that ALK RTK deletions are also apparent in RMS cell 
lines, indicates that potential modifying effects of these alterations can be studied further in 
vitro and in xenograft models of these cell lines. As ALK expression was shown to decrease after 
chemotherapy, the optimal sequence of ALK-inhibitors in combination with chemotherapy 
should be further investigated in preclinical models.
In conclusion, our study shows that ALK protein expression as well as copy number gain is a 
common feature in ARMS and progressive ERMS. Future (pre)clinical research should aim at the 
functional role of ALK and the potential effect of ALK-inhibitors in RMS, with special attention 
to the observed genetic aberrations. 
Supplementary table 1
Primers for PCR and sequencing analysis
* All primers contain a M13 sequence (underlined) introduced as a site to initiate sequencing.
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INTRODUCTION
Rhabdomyosarcoma (RMS) is an aggressive soft tissue sarcoma. Although it is relatively rare 
with an estimated incidence of 4.5 per million, it is the most common pediatric soft tissue 
sarcoma, and accounts for 3-7% of all malignancies in children (1). Its two most common forms 
are embryonal (eRMS) and alveolar RMS (aRMS). The Children’s Oncology Group (COG) reported 
dramatic increases in 5-year survival on chemotherapeutic regimens between 1972 and 1997 
(55% to 73%) (2-3). However, the prognosis for the high-risk subset of RMS patients (e.g. alveolar 
histology, lymph node involvement, distant metastases, recurrent disease, and higher age) 
remains poor, not exceeding a 5-year survival of 50% (4-7). Therefore, there is an urgent need 
for new therapeutic strategies.  
The specific targeting of receptor tyrosine kinases is an upcoming treatment strategy for many 
tumour types, including sarcomas (8). The insulin-like growth factor (IGF) system is probably 
the most extensively studied treatment potential in sarcomas over the past decade (9). As IGF 
pathway signaling is believed to play an important role in oncogenesis and progression of RMS, 
this seems a potential treatment target (9-10). This is supported by overexpression of both IGF-
1R and mainly IGFII in RMS tumours, cell lines and xenograft models (11-14). Furthermore, IGF 
pathway inhibition by antisense and small interfering RNA, monoclonal antibodies (mAbs) and 
small molecule tyrosine kinase inhibitors (TKIs) against IGF-1R were shown to result in decreased 
RMS growth in vitro and in vivo (15-18)
Despite promising preclinical evidence of an anti-tumour effect of IGF-1R inhibitors in RMS, the 
results of clinical trials remain unsatisfactory because of the modest and temporarily anti-tumour 
effect (19-21). Since altered activation of the same intracellular survival pathways via alternative 
receptors was observed upon IGF-1R directed treatment (22-25), simultaneous targeting of these 
receptors could be a potential strategy (26).  We hypothesize that the anaplastic lymphoma 
kinase receptor (ALK) is a potential candidate for simultaneous therapy, as high expression rates 
were observed previously (27-28), and as ALK downstream activation overlaps that of IGF-1R, 
involving the PI3K and MAPK pathways (29). 
The aim of the current study is to investigate the (co-)expression of IGF-1R and ALK in RMS tissue 
samples and correlate this with outcome in a representative multicenter cohort study. Furthermore 
we investigate the effect upon (simultaneous) targeting of IGF-1R and ALK in RMS in vitro. 
ABSTRACT
Background: Rhabdomyosarcoma (RMS) is an aggressive soft tissue tumour mainly affecting 
children and adolescents. Since survival of high-risk patients remains poor, new treatment 
options are awaited. The aim of this study is to investigate anaplastic lymphoma kinase (ALK) 
and insulin-like growth factor-1 receptor (IGF-1R) as potential therapeutic targets in RMS.
Methods: One-hundred-and-twelve primary tumours (embryonal RMS (eRMS) 86; alveolar RMS 
(aRMS) 26) were collected. Expression of IGF-1R and ALK was evaluated by immunohistochemistry. 
The effect of ALK inhibitor NVP-TAE684 (Novartis), IGF-1R antibody R1507 (Roche) and combined 
treatment was investigated by MTT assays in cell lines (aRMS Rh30, Rh41; eRMS Rh18, RD).
Results: IGF-1R and ALK expression was observed in 72 and 92% of aRMS and 61 and 39% of 
eRMS, respectively. Co-expression was observed in 68% of aRMS and 32% of eRMS. Nuclear 
IGF-1R expression was an adverse prognostic factor in eRMS (5-yr survival 46.9±18.7% versus 
84.4±5.9%, p=0.006). In vitro, R1507 showed diminished viability in Rh41. NVP-TAE684 showed 
diminished viability in Rh41 and Rh30, and to a lesser extent in Rh18 and RD. Simultaneous 
treatment revealed synergistic activity against Rh41. 
Conclusion: Co-expression of IGF-1R and ALK is detected in eRMS and particularly in aRMS. As 
combined inhibition reveals synergistic cytotoxic effects, this combination seems promising 
and needs further investigation.
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PATIENTS AND METHODS
Patients and tumour samples
Tumour material consisted of 112 therapy-naïve biopsies (86 eRMS, 26 aRMS) retrieved from the 
authors’ (referral) files (UEF, AJHS) and PALGA, the nationwide network and registry of histo- and 
cytopathology in the Netherlands. The current cohort largely overlaps the cohort as we described 
in our previous publication (27). Clinical characteristics are summarized in table 1. Tissues and 
follow-up data were retrieved according to the Dutch Code on Proper Use of tissue (http://www.
federa.org/gedragscodes-codes-conduct-en). RMS diagnosis was reviewed and reclassified by an 
expert pathologist (UEF), based on criteria according to the WHO classification (30). 
Tumour specimens were collected on tissue micro-arrays (TMA), containing 1-3 cores of 1-3 
mm diameter for each sample. 
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Cell lines 
RMS cell lines (RD, Rh18, Rh30 and Rh41) were generously provided by Dr. Peter Houghton 
of the Pediatric Preclinical Testing Program (Columbus, OH). RD cells were cultured in DMEM 
medium (PAA Laboratories GmbH, Pasching, Austria), Rh18 cells in McCoy’s 5A medium (Lonza 
Benelux BV, Breda, the Netherlands) and Rh30/Rh41 cells in RPMI 1640 medium (PAA Laboratories 
GmbH). All media were supplemented with 10% fetal bovine serum (PAA Laboratories GmbH) 
and 1% Pen-Strep (Lonza Benelux BV) and cells were cultured in a humidified atmosphere of 
5% CO2/95% air at 37°C. For IHC analysis, the cells were fixed with Unifix (Klinipath, Duiven, The 
Netherlands) and processed into AgarCytos.
Immunohistochemistry 
Immunohistochemical staining was performed to evaluate the expression of ALK and the IGF1 
receptor ß (IGF-1R). The specifications are listed in table 2. Immunohistochemical staining of ALK 
and IGF-1R on tumour samples was performed as described previously (27;31). For ALK staining 
in RMS cell lines, 4 μm sections were pretreated with EDTA buffer by heating in a microwave 
oven. Endogenous peroxidase was then blocked (3% hydrogen peroxide) and sections were 
incubated with the primary antibody overnight at 4°C. Next, sections were incubated with 
Poly-HRP-GAM/R/R IgG (ImmunoLogic, Duiven, the Netherlands) and antibody binding was 
visualized with PowerDAB (3,3’-diaminobenzidine; ImmunoLogic). Slides were counterstained 
with haematoxylin, dehydrated and coverslipped.  Positive control tissues were used as listed 
(table 2). Substitution of the primary antibody by 1% BSA-PBS served as negative control.
Table 1
Patient characteristics
Table 2
Immunohistochemistry methods
Favourable locations included: orbit, head and neck non parameningeal, urogenital and hepatobilliary tract tumours. All other 
primary locations were unfavourable. N0= no lymph node involvement N1 = lymph node involvement present; M0= no distant 
metastases M1= distant metastases present; IRS stage = pre-treatment staging system according to the Intergoup rhabdomyosarcoma 
Study Group (IRSG) study IV. Missing data is due to inavailability of clinical and follow-up data of the cohort of patients included 
via PALGA. Follow-up time is mentioned as median (ranges) for the different subtypes.
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(RFS) and overall survival (OS) was tested by the Kaplan-Meier method with Log Rank test. The 
relation between ALK and outcome was described in our earlier publication (27). A p-value <0.05 
was considered statistically significant. All analyses were performed with SPSS version 16.0.
RESULTS
Immunohistochemical staining patterns
Staining frequencies for all (primary) tumours and subdivided by histological subtype are 
summarized in table 3. Immunohistochemical staining was reliably evaluable in the majority 
of samples, varying from 92.0 – 99.1%. Examples of staining patterns are displayed in figure 1. 
Cytoplasmic IGF-1R expression was seen in 72% of aRMS and 61% of eRMS (ns).  Cytoplasmic 
ALK expression was more frequently observed in aRMS compared to eRMS (92% versus 39%, 
respectively, p<0.001). Nuclear expression was demonstrated for IGF-1R (eRMS 10%, aRMS 4%, 
ns) and ALK (eRMS 7%, aRMS 4%, ns). 
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Table 3
Frequency of ALK and IGF-1 receptor expression in RMS
Immunohistochemistry scoring system
Nuclear and cytoplasmic staining was scored separately by three independent investigators 
(UEF, YMHV, JCG). Staining intensity was compared to positive control and scored as negative 
(0), weak (1), strong (2) or very strong (3), with a cut-off at ≥10% of cells. Cases with discordant 
results were re-evaluated and given a mean final score. Staining scores were binary recoded 
based on overall staining intensity of the protein (0 and 1 negative, 2 and 3 positive) (27).
Inhibitors
The TKI NVP-TAE684 against ALK was provided by Novartis (Basel, Switzerland). The fully human 
mAb R1507 against IGF-1R was provided by Roche Diagnostics (Penzberg, Germany).
Cell viability assay 
RMS cells were seeded into 96-well plates at 5000 cells (RD, Rh30 and Rh41) or 3000 cells (Rh18)/100 
µl/well and allowed to adhere. After 24 hours, a series of NVP-TAE684 (range 0.01-100.000 nM) 
and R1507 (0.1-100.000 ng/ml) doses were added and cells were incubated for 72 (RD and Rh30), 
120 (Rh41) or 144h (Rh18), based on estimated growth rates. All drug concentrations and controls 
were completed in quadruplicate. Subsequently, 20 µl of 5 mg/ml MTT (3-(4,5- dimethylthiazol-
2-yl)-2 ,5-diphenyltetrazolium bromide, Sigma-Aldrich, Zwijndrecht, the Netherlands) in PBS was 
added to each well and cells were incubated for another 3.5h at 37°C. Afterwards, the medium 
was carefully removed and the formazan crystals were dissolved in 150 µl of acidified isopropanol 
solution. Absorbance was read at 560 nm using an ELISA reader. The experiments were repeated 
in triplicate and IC50 values were calculated with GraphPad Prism Version 4.00 software. 
Combination indices
To assess drug synergy, the combination index (CI) method as described by Zhao et al was 
used (32). Cell viability was measured using the MTT assay after treatment of Rh41 cells with 
NVP-TAE684 at concentrations 10, 50 and 100 nM combined with R1507 at concentrations 1, 5 
and 10 ng/ml. We next identified the concentrations of NVP-TAE684 and R1507 monotherapies, 
which resulted in a similar level of cell viability reduction to that observed with each of the 
combination treatments. Subsequently, CI for the combination treatments was calculated as 
follows: CI = [Ca,x/ICx,a] + [Cb,x/ICx,b]. Ca,x and Cb,x are the concentrations of drugs A and B 
used in combination to achieve x% drug effect, ICx,a and ICx,b are the concentrations for single 
agents to achieve the same effect. A CI <1 indicates synergy of the combination therapy. The 
CI method could not be applied to RD, Rh18 and Rh30 cell lines, since monotherapy treatment 
with R1507 showed too little inhibitory effect. Instead, the IC50 of NVP-TAE684 of all three cell 
lines was combined with the highest R1507 concentration of 100 µg/ml. Cell viability was again 
assessed by MTT assay and the inhibitory effect of the combination treatment was compared 
with no treatment, monotherapy  of NVP-TAE684 (IC50) and monotherapy of R1507 (100 µg/ml).
Statistical methods
A potential relation between categorical parameters was assessed by Chi-square or Fisher’s exact 
(FE) testing when appropriate. A potential relation between categorical and continuous data 
was assessed by Mann-Whitney U test. The influence of parameters of interest on relapse-free 
A siginificant difference (asterisk) in expression between eRMS and aRMS was seen for ALK (p<0.001). Percentages are presented 
as part of the reliably scored samples for each staining
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IGF-1R/ALK inhibition in vitro
Immunohistochemistry revealed ALK expression in aRMS cell lines Rh41 (++) and Rh30 (+) and to 
a lesser extent in eRMS cell lines Rh18 (±) and RD (±). The ALK TKI NVP-TAE-684 as monotherapy 
resulted in diminished cell growth in aRMS cell lines Rh41 (IC50 103 nM) and Rh30 (IC50 211 nM), 
and to a lesser extent in eRMS cell lines Rh18 (IC50 585 nM) and RD (IC50 734nM) (figure 3A). 
IGF-1R expression was detected in Rh41 (+) and to a lesser extent in cell lines Rh30, Rh18 and RD 
(±). Inhibition of IGF-1R by mAb R1507 as monotherapy resulted in decreased cell growth only 
in aRMS cell line Rh41 (IC50 11 ng/ml). In the other cell lines the IC50 was not reached, and the 
maximum concentration of 100 µg/ml induced cell death in 41.2% of Rh30 (aRMS), in 17.5% of 
Rh18 (eRMS) and only in 6.9% of RD (eRMS) cells (figure 3B).  
Simultaneous treatment in Rh41, indicates a synergistic effect with the combination of NVP-
TAE684 and R1507 at all tested concentrations (combination index <1) (figure 3C). In the other 
cell lines, the maximum concentration of 100 µg/ml of R1507 and the IC50 of NVP-TAE684 was 
added simultaneously (figure 3D to F). In aRMS cell line Rh30, the bargraph indicates that a 
combination of both agents causes increased cell death (figure 3D). 
Relation between IGF-1R and ALK
 In eRMS, a significant co-expression of cytoplasmic IGF-1R and ALK was observed (n=81, 26/51 
(51%) of IGF-1R positive samples versus 7/30 (23%) of IGF-1R negative samples display ALK 
expression, p= 0.019, co-expression in 32% of tumours). We furthermore observed a negative 
correlation between nuclear and cytoplasmic IGF-1R (n=83, nuclear IGF-1R expression present 
in 7/32 (22%) cytoplasm negative versus only 1/51 (2%) cytoplasm positive tumours, p=0.005). 
In aRMS, as the great majority of samples (92%) expressed ALK, no significant relation could be 
observed, although frequent co-expression of cytoplasmic ALK and IGF-1R (68%) was present. 
Outcome
Follow-up data was complete for 72 patients (eRMS 54, aRMS 18), with a median follow-up of 
46.9 months (range 0.5-292.3 months). For eRMS median follow-up time was 60.3 months (1.5-
292.3), for aRMS 24.7 months (0.5-254.3). 
The presence of nuclear IGF-1R was shown to be an adverse prognostic factor in eRMS (n= 53, 
5-yr disease specific survival 46.9±18.7 versus 84.4±5.9%, p=0.006, figure 2). For aRMS, there was 
no significant prognostic effect of receptor expression, possibly due to small numbers (n=18). 
Figure 2
Survival eRMS by nuclear IGF-1R expression
Figure 1 (color figure page 197)
Immunohistochemistry of the ALK and IGF-1R receptor
Immunohistochemical staining (magnification 20x), A eRMS displaying very strong predominant nuclear IGF-1R staining; B aRMS 
displaying very strong cytoplasmic IGF-1R staining; C eRMS displaying strong cytoplasmic ALK staining; and D aRMS displaying 
very strong cytoplasmic ALK staining. 
The presence of nuclear IGF-1R (red line) was shown to be an adverse prognostic factor in eRMS (n= 53, 5-yr disease specific 
survival 46.9±18.7 versus 84.4±5.9%, p=0.006
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DISCUSSION
We showed that co-expression of IGF-1R and ALK is detected in eRMS and particularly in aRMS 
and that combined inhibition reveals synergistic cytotoxic effects in vitro in aRMS. Furthermore, 
we detected nuclear IGF-1R expression to be an adverse prognostic factor in eRMS.  
The current study adds relevant data to the clinical importance of the IGF-1R and ALK receptor 
pathway and its potential as a therapeutic target in RMS. The ALK expression data (>90% of poor 
prognostic aRMS) as well as the in vitro experiments of the ALK inhibitor NVP-TAE684 suggest that 
ALK represents a very interesting therapeutic target in these tumours. To our knowledge, we are 
the first to report that NVP-TAE684 is effective against RMS in vitro as monotherapy (aRMS>eRMS) 
and that the amount of responsiveness upon inhibition correlates with immunohistochemical 
expression of ALK in these cell lines. However, it should be considered that the presence of 
genetic alterations of the ALK gene (amplification, mutation and exon deletions) as we observed 
previously, might alter the sensitivity of RMS tumours (27).
Despite the promising preclinical results of IGF-1R directed treatment in xenograft models 
(16-18;33), clinical trials up till now have not shown optimal results in sarcoma patients. Only a 
limited number of dramatic clinical responses in recurrent/refractory sarcomas were observed, 
while the majority of patients showed only a modest and temporarily anti-tumour effect (10-
40% response rate) (19-21). We still are convinced that IGF-1R as a therapeutic target deserves 
further clinical investigation, especially in combination studies (34). 
Interestingly, we detected the presence of IGF-1R not exclusively in the cytoplasm but also in 
the nucleus in 10% of eRMS and 4% of aRMS. Recently, nuclear localization of IGF-1R was also 
identified in multiple malignant and non-malignant epithelial cell lines, in a substantial part of 
clear cell renal carcinoma (48%) and also in a small cohort of sarcomas (different liposarcomas, 
pleomorphic RMS, synovial sarcoma, desmoplastic small round cell tumor, Ewing sarcoma and 
osteosarcoma, total n=16, 75% nuclear staining) (35-36). Nuclear IGF-1R shows a predilection 
for localization to less dense DNA regions and it co-localizes with RNA polymerase II and binds 
to chromatin. It was therefore proposed that it is directly involved as a gene transcription factor 
(37), as was also observed for multiple other RTKs (38-39). The negative correlation between 
cytoplasmic and nuclear IGF-1R as observed in our cohort is in line with the hypothesis that 
nuclear translocation of IGF-1R takes place in certain conditions, which can be the result of 
import of the full-length receptor or by enzymatic release of the intracellular domains of the 
receptor, both initiated by ligand binding. This finding may be of great clinical importance, even 
more since nuclear IGF-1R was associated with adverse prognosis in eRMS. 
A recent clinical study indicates that the exclusive presence of nuclear IGF-1R serves as a biomarker 
to predict increased sensitivity of sarcomas (osteosarcoma, Ewing sarcoma, liposarcoma, 
pleomorphic RMS, desmoplastic tumour, and synovial sarcoma) when treated with  IGF-1R 
mAbs IMC-A12, SCH 717454 and CP-751.871 (36). Although, this represents a small (n=16) 
heterogeneous cohort with regard to histology and Ab treatment given - if these findings can 
Figure 3
In vitro experiments of NVP-TAE684 and R1507 in rhabdomyosarcoma cell lines (RD, Rh18, Rh30, Rh41)
A: Cell viability assays of NVP-TAE684 as monotherapy. On the X-axis the different concentrations of NVP-TAE684 in nM, on the 
Y-axis the percentage of viable cells; B: Cell viability assays of R1507 as monotherapy. On the X-axis the different concentrations of 
R1507 in ng/ml, on the Y-axis the percentage of viable cells; C: Result of synergy experiment for Rh41. The x- and y-axis, respectively, 
show the relative concentrations of R1507 and NVP-TAE684 in synergy compared to the concentrations required in monotherapy. 
If synergy is absent, the resulting asterisk will be located on the bold line. Asterisks located below this line represent synergy 
(Combination Index <1). Numbers next to the asterisks indicate the concentrations of R1507 (µg/ml) and NVP-TAE684 (nM); D-F 
display the bargraphs of cell viability assays of monotherapy and combinations of the IC50 of NVP-TAE684 and the maximum 
concentration of R1507 (100 µg/ml) in Rh30 (D), Rh18 (E) and RD (F). 
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be confirmed in larger studies and extrapolated to RMS- nuclear expression of IGF-1R might 
predict a benefit of IGF-1R inhibition for eRMS patients with poor prognosis (18;40). Obviously, 
we need to increase our knowledge concerning the potential of combined targeted treatment. 
This is underlined by the synergistic effect we observed upon ALK/IGF-1R inhibition in Rh41 in 
the present study, and by previous studies indicating that the primary presence or upregulation 
of other RTKs upon IGF-1R inhibition facilitates resistance via alternative cell survival pathway 
activation, for example via the insulin receptor (IR) in Ewing sarcoma (24), platelet derived 
growth factor receptor a (PDGFRa) in a human RMS model (Rh41) (22), and human epidermal 
growth factor receptor 2 (HER2/EGFR) in RMS (RMS cell line Rh36 and a transgenic PAX3-FKHR 
aRMS mouse model) (25). A subsequent rising question is the optimal timing and combining 
strategy of targeted agents with conventional cytotoxic agents.  
In conclusion, combined targeting of ALK and IGF-1R seems a rationale choice in (a)RMS and 
needs further investigation in xenograft models. 
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INTRODUCTION
Rhabdomyosarcoma (RMS) is an extremely rare type of soft tissue sarcoma (STS) that is thought to 
derive from mesenchymal stem cells and shows varying degrees of skeletal muscle differentiation 
(1). RMS occurs predominantly in children <7 years, has a second age peak in adolescence, and 
the incidence subsequently declines in older patients (2;3). 
The two main distinguishable histological subtypes that affects both adults and children 
are embryonal RMS (ERMS) and alveolar RMS (ARMS) (2;4;5). A third subtype, pleomorphic 
RMS occurs almost exclusively in adults, and there is growing evidence that this tumour type 
should be biologically considered rather a distinct type of adulthood soft tissue sarcoma than 
a subtype of RMS (2;6). Therefore, this subtype is beyond the scope of this review considering 
age in relation to RMS.
Over the past decades, the awareness of a dismal outcome for RMS patients with increasing age 
has grown. Improvement of survival rates in children over the past decades resulted in a current 
5-year survival rate of approximately 70-80% for children with RMS (7-9), while survival rates 
in adults are not exceeding 56% (range 21-56%) (2;4;5;10-18). Moreover, patients < 1 year and 
≥ 10 years fare worse than patients 1-9 years in paediatric study populations (19;20). Whether 
this effect of age on outcome is attributable to differences in treatment approach or in tumour 
biology is unknown. 
The centralization of cancer care in specialized childhood oncology centres, together with the 
standardized treatment of RMS within comprehensive trials, is considered the principal factor 
that is responsible for the gain in RMS survival in children in the western countries (7-9;21-23). In 
contrast to this centralization of RMS treatment in children, the relative rarity of RMS in (young) 
adults in the burden of all adult-type cancers led to dispersion of patients with RMS in adult 
oncology centres. Also, the relative lack of clinical trial participation in adolescents and (young) 
adults with sarcoma has been proposed as one of the major reasons of the consequential lack 
of survival improvement (24). 
RMS requires aggressive multimodality treatment which -as in many childhood cancers- results 
in a significant rate of acute toxicities and long-term effects (25). The “traditional” VAC/VAI-based 
(vincristine, D-actinomycin and cyclophosphamide or ifosfamide) regimens developed in the early 
seventies underwent only minor modifications over time, primarily resulting in improvements 
for patients with low-risk disease. Unfortunately, survival for high-risk patients (e.g. patients 
with irresectable ARMS at unfavourable sites, distant metastatic disease, and recurrent disease) 
remains poor, not exceeding 50% (19;26-30). Along with the increase of survival rates in the 
young population of RMS patients, prevention of long-term ’costs’ as late organ toxicity, infertility 
and second tumours becomes more important. Although there is an urgent need for new –less 
harmful- therapeutic options, an important limitation in childhood RMS trials conducted over 
the past decades is the relative lack of introduction of new (targeted) therapies. 
ABSTRACT
Rhabdomyosarcoma (RMS) is a rare type of soft tissue sarcoma that mainly affects children, but 
also occurs in adolescents and (young) adults (AYA). Despite dramatic survival improvements 
reported by international study groups in children over the past decades, the awareness of a dismal 
outcome for older patients with RMS has grown. In contrast to the world-wide organization of care 
for children with RMS, standard care in adults lags behind. A step forward in RMS management 
for patients of all ages is urgently needed. Both paediatric oncologists and medical oncologists 
are essential players in development of a concept of RMS care, but bringing these two worlds 
together seems not so easy. This review provides an overview which highlights the similarities 
and differences in children and adults with RMS. Furthermore, it comes up with a novel concept 
to overcome the virtual gap between the treatment approach of children and AYA with RMS.
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PREDISPOSITION AND ONCOGENESIS
Genetic syndromes
Genetic alterations seem to be a key player in the development of RMS. This is emphasized by 
the association between several genetic syndromes and early RMS development, including Li-
Fraumeni syndrome (p53 mutation), Costello syndrome (HRAS mutation), neurofibromatosis type 
1 (NF-1 gene mutation), and Beckwith-Wiedemann (mutation or deletion 11p15.5 chromosomal 
region) (38;39).  Nevertheless, most RMS cases are considered sporadic, as only 9% of RMS cases 
are syndrome-related (40). Remarkably, an earlier study reported a much higher prevalence of 
minor or major congenital abnormalities (32%) in RMS patients on autopsy (involving mainly the 
central nervous system, genitourinary tract, gastrointestinal tract, and cardiovascular system) 
compared to 3% in the general population (41). Thus, it seems that additional underlying genetic 
conditions still remain to be revealed. 
Oncogenesis
Oncogenesis in RMS is still not completely understood, but different mechanisms seem to be 
involved in ERMS and ARMS (42). In ERMS, oncogenesis is proposed to act via a mechanism in 
which myogenic progenitor cells of postnatal muscle, satellite cells, potentially give rise to ERMS 
(43-45). These myogenic progenitor cells are present in all muscle tissues throughout the body, 
and are supposed to be activated in a myogenic regulatory factor- regulated way for growth or 
remodelling after tissue injury (46;47).  
Although experts in paediatric RMS treatment have proposed that treatment of adults should 
be based on the current paediatric treatment protocols (5), bringing the two worlds together 
seems not as easy as that. This review provides an overview highlighting the similarities and 
differences in epidemiology, tumour biology, diagnosis, treatment approach, and accrual to 
clinical trials with new agents together with a concept to overcome the existing virtual separation 
line between treatment approach in children, adolescents and (young) adults (AYA) with RMS. 
EPIDEMIOLOGY
Within the total cancer burden in the western countries which is almost 300/100,000 (Western 
Europe and United states of America (USA), 2008), RMS is an extremely rare tumour with an 
average incidence of 4.5-6.9/1,000,000 (age standardized incidence rate in children, and AYA) 
(31-34). RMS accounts for up to 57-70% of STS (corresponds to 3.4-3.7% of all cancers) in children 
0-14 years, whereas it accounts for only 5.2-6.5% of STS (corresponds to 2.9% of all cancers) in 
AYA aged 15-29 years (35;36). The incidence subsequently declines, as within the overall burden 
of cancer incidence only 1.3% comprises STS and within this group only 6.3% is RMS (36).
Figure 1 displays the incidence of RMS in patients 0-29 years in Europe (data retrieved from 1978-
1997) and the USA (1975-2000) (35;37). Data concerning RMS incidence in patients >14 years in 
Europe could not be retrieved from literature. RMS incidence shows a characteristic age peak 
in young children 0-4 years after which the incidence declines, followed by a second smaller 
age peak in adolescents 15-19 years. There is a typical age-distribution of ERMS and ARMS in 
children (displayed in figure 1b). After the age of 19 the incidence declines rapidly to 1.6 per 
million in the age group 20-24 years and 0.8 per million in the age group 25-29 years. In contrast 
to the widely available information on incidence rates in children, the data on incidence rates 
in adults are scarce. Besides, an important limitation to consider is the inclusion of pleomorphic 
RMS in adult series. In a large series of patients retrieved from the SEER database from 1973-
2005 (N=2,600 patients), ERMS (20.4%) and ARMS (14.5%) comprised approximately one third 
of RMS diagnoses in adults (>19 years) (2). 
Figure 1a (color figure page 197)
Incidence rates of all subtypes of RMS in patients 0-29 years of age. 
Figure 1b (color figure page 198)
Incidence of ERMS and ARMS in the childhood population.
*Data regarding patients with RMS >14 years in Europe  were not available
(33) CANCER, Vol. 115, No. 18, 2009, pages 4218-4226. Copyright 2011 American Cancer Society.  
This material is reproduced with permission of Wiley-Liss, Inc., a subsidiary of John Wiley & Sons, Inc.
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In ARMS, oncogenesis is thought to be initiated in a mesenchymal stem cell undergoing a 
PAX3/7-FOXO1 translocation as key event and subsequently (an) additional (second) hit(s) results 
in ARMS formation (48-51). These mesenchymal precursor cells are found throughout the body 
(predominantly in bone marrow), and the recent description of a “leukemic” variant of RMS 
in the bone marrow in the absence of a primary tumour strengthens this hypothesis (52;53). 
Contradictory, mature muscle cells also have shown the ability to give rise to ARMS after PAX3-
FOXO1 introduction by dedifferentiation in maturing myoblasts (54). The PAX3-FOXO1 translocation 
is the main genetic feature in ARMS as it is present in the majority of ARMS (55%), whereas a 
PAX7-FOXO1 translocation occurs in a lesser amount of ARMS cases (22%) (55). Translocation-
negative ARMS (23%) is currently under discussion as it potentially shows favourable clinical 
outcome (56;57) and is genetically more identical to ERMS than to translocation-positive ARMS 
(56;58;59). These differential patterns of oncogenesis have led to numerous investigations 
concerning genetic events in RMS. Major genetic events are summarized in table 1a and b. 
Age predisposition and oncogenesis
The complexity of mechanisms involved in RMS development together with the typical age-pattern 
observed, pose questions to age-related biological differences in ERMS and ARMS. Except for 
syndromes that are generally associated with young onset of disease, little is known concerning 
the aetiology of RMS at different ages. Biologically, the PAX7-FOXO1 fusion is associated with 
younger onset of disease, extremity primaries and a lower rate of metastatic disease, whereas 
the PAX3-FOXO1 positive RMS shows an association with higher age and represents a highly 
malignant phenotype which encompass bone marrow involvement and is therefore associated 
with adverse outcome (55;67). However, a recent study confirmed the relation of PAX3-FOXO1 
with metastatic disease and higher age at diagnosis, but did not find a relation with bone 
marrow involvement survival (57). The scarcity of data regarding age-dependent mechanisms of 
oncogenesis and tumour biology warrants further biological studies in RMS patients of all ages. 
DIAGNOSIS
Histological diagnosis 
Histological diagnosis is the cornerstone in establishing the diagnosis and making the 
consequential treatment decisions in RMS. The first well-developed classification was grounded 
in 1964 by Horn and Enterline, who distinguished embryonal, botryoid, pleomorphic and 
alveolar RMS (‘conventional scheme’) (68). Since then, refinements of the available techniques 
have increased accuracy of classification and the identification of new subtypes, i.e. the spindle 
cell variant of ERMS. The most recent ‘prognosis-tailored’ International classification of RMS (ICR) 
was developed in 1995 (table 2) (69). 
Immunohistochemically, RMS shows intranuclear expression of the myoregulatory proteins 
myogenin and myoD1, with myogenin showing the highest specificity (up to almost 100%) and 
sensitivity (approximately 90%) (70;71). Myogenin expression is seen more extensively in ARMS. 
With a cut-off point at 50% of the cells showing nuclear staining of myogenin, a sensitivity of 
0.82, and a specificity of 0.75 for distinguishing ARMS from ERMS was reported (72). 
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(76). Generally, ARMS shows a clinically more aggressive phenotype with unfavourable clinical 
presentation (e.g. stage of disease) when compared to ERMS. Lymph node involvement (LNI) is 
seen in roughly 15-20% of RMS patients at diagnosis. However, ARMS histology as well as extremity 
and paratesticular primaries show a predilection for LNI, demonstrating rates of LNI in up to 
40% (77-80). Approximately 20% of all RMS patients will present with distant metastatic disease 
at diagnosis, and the main metastatic sites involve the lungs and bone marrow but metastases 
may arise throughout the body (28). Children with ERMS seldom present with metastases (9 and 
13% in IRSG II and IRSG III respectively), whereas children with ARMS present more frequently 
(27 and 28%) with metastatic disease (23).
Although clinical data on adults with RMS are relatively scarce, increasing age was found to be 
related to unfavourable clinical presentation, i.e. a relatively higher rate of invasive tumours, 
tumours at unfavourable sites and a higher metastatic potential (loco regional lymph nodes 
and distant metastases) (2;4;5;12;14).  These clinical features can at least partly -but not fully- be 
explained by the different distribution of the histological subtypes with increasing age (table 
2). Besides a higher rate of metastatic disease in older patients due to a relatively higher rate of 
ARMS, a higher rate of metastatic disease is observed with increasing age in ERMS as well (18). 
Staging
Staging of RMS is based on the schemes developed by the paediatric study groups and should 
include evaluation of the local extent of the primary tumour (site, size, invasiveness in surrounding 
tissues), the presence of lymph node metastases and the presence of distant metastases. The 
most extensively used staging techniques in RMS comprise magnetic resonance imaging (MRI) 
to visualize size and local extension of the primary tumour, chest computed tomography (CT) 
scanning to evaluate the presence of lung metastasis or lymph node involvement, and bone 
scintigraphy for the detection of bone metastases. These techniques are extensively investigated 
and widely available, and therefore have taken a stable place into clinical practice. Optimal use 
and implementation of (novel) staging techniques in RMS is dependent on clinical appearance 
and thus should ideally be approached in an age-dependent manner. Therefore, we will discuss 
two existing age-related staging issues; lymph node detection and novel imaging techniques. 
The awareness of the clinical importance of lymph node involvement in RMS has grown, as lymph 
node metastases were recently reported as predictor for poor outcome, especially in ARMS 
(81). Conventional staging for detecting lymph node involvement is unsatisfactory and thus of 
particular interest in certain RMS subgroups. For example, in clinical group 1 paratesticular RMS 
in patients >10 years (LNI 30-40%) abdominal CT scan instead of ipsilateral retroperitoneal lymph 
node dissection (RPLND) led to suboptimal treatment (no radiotherapy) and consequently a high 
rate of lymph node failure (7). Therefore, in paratesticular RMS in boys >10 years RPLND is part 
of the current diagnostic standard (82;83). However, less invasive strategies in order to reduce 
morbidity of radical lymph node dissection are preferable in these patients (84). 
Although the value of sentinel lymph node sampling procedure (SLN) is established in adult 
oncology for a great variety of cancer types, in children with RMS this has not been performed 
Besides immunohistochemistry, optimization of molecular techniques in the past two decades 
led to optimization of diagnosis of ARMS, as 80% of the histomorphological diagnosed ARMS 
harbour detectable translocations (55). 
Still, histopathological diagnosis of RMS is a challenge, in which age is an extremely important 
factor providing a rationale for the diagnostic procedures to be undertaken. For a detailed 
description of histomorphological features we refer to Weiss and Goldblum (1). The greatest 
diagnostic challenge in RMS is the distinction from other poorly differentiated small blue 
round-cell tumours, including neuroblastomas, Ewing’s sarcoma, and primitive neuroectodermal 
tumours. But sporadically, poorly differentiated angiosarcomas, synovial sarcomas, malignant 
melanomas, melanocytic neuroectodermal tumours of infancy, granulocytic sarcomas, malignant 
lymphomas, and even bladder small cell carcinoma might mimic RMS (1;73;74). Furthermore, 
RMS in adults can occur as a heterologous component of epithelial, germ cell, sarcomatous or 
neuroectodermal derived tumours (75). The clinical relevance of this broad range of differential 
diagnostic options should be considered as this results in difficulties in clinical management of 
these tumours, especially in terms of (choice of ) adjuvant systemic treatment. 
Due to its rarity, an important complicating factor concerning histopathological diagnosis 
of RMS is that most pathologists are relatively unfamiliar with this diagnosis. In children, all 
pathological diagnoses are confirmed by central review of a specialized pathologist prior to 
inclusion into a clinical trial. Central pathological review for adult STS is also available in most 
developed countries, but its infrastructure could still be improved.
CLINICAL PRESENTATION AND STAGING
Clinical presentation
RMS can arise in a variety of sites throughout the body. The most common primary site includes 
the head and neck region (35%), followed by genitourinary (24%), and extremity primaries (19%) 
Table 2
International Classification of RMS (1995) (69)
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RISK STRATIFICATION
Investigations carried out over the past decades in large European and North American consecutive 
trials resulted in the development of two solitary risk-based staging systems for clinical use in 
children (summarized in table 3) (104;105). As this staging is closely related to outcome, patients 
are classified into low-, intermediate-, high- and very high-risk (the latter only in European 
scheme). The remarkable differences between these stratifications are relative “up-staging” of 
patients >10 years of age with embryonal tumours >5 cm with a postsurgical group I in the 
European schemes, as well as “down-staging” of metastatic ERMS in patients <10 years in the 
IRSG scheme, whereas all metastatic RMS in the European scheme are considered as identical 
risk group. Because of the lack of a risk-based staging system for adults with RMS, a TNM system 
is used in this respect (106).
at a regular basis in the past. Since two recent studies, however, indicated that sentinel node 
procedure in childhood malignancies is technically feasible, safe, and reliable, the technique may 
obtain a standard place in the staging of RMS in the future in both children and adults (85;86). In 
extremity ARMS, SNL has already been proven beneficial on outcome in a retrospective study, 
and seems especially feasible in ARMS patients older than 10 years with a tumour size >5 cm 
(87-89). Contradictory, in-transit lymph node sampling followed by altered treatment resulted 
in prevention of LN failure, but had no effect on final outcome in extremity RMS (78). SNL also 
might be allocated routinely in head and neck as well as gynaecologic RMS in the future. The 
development of a SLN protocol might thus be of great benefit in order to reduce morbidity and 
optimize staging in particular RMS patients, as is currently under investigation in paratesticular 
RMS the IRS-V trial of the COG. Additional prospective evidence concerning an age-defined 
approach in lymph node staging in RMS subgroups is urgently needed.   
Novel functional imaging techniques as Positron Emission Tomography (PET) are upcoming 
in oncology today. These new imaging techniques provide non-invasive information on the 
functional/metabolic status of a primary tumour, rather than only structural information. The 
most common used radiotracer over the past years is 18F-fluordeoxyglucose (18F-FDG), which 
has the capacity to monitor the glucose metabolism (90).
In adults with sarcoma, FDG-PET has been prospectively studied and resulted in evidence 
for its use in evaluation of tumour grade, in monitoring malignant transformation in patients 
with neurofibromatosis type I, for initial staging and re-staging, for treatment monitoring, as 
well as in predicting survival (91). In contrast to this widely obtained evidence for a successful 
role of PET in adults with soft tissue sarcoma, there is a scarcity of data in children. Although a 
number of PET studies in children consider PET as feasible and promising, all except one of these 
studies are retrospective and hold a maximum of 60 patients from a single institution including 
multiple paediatric tumour types (92-97). FDG-PET might also be optional for early detection 
of leptomeningeal involvement of parameningeal RMS (98). 
Limitations to consider regarding PET/CT include its limited role in detection of lesions smaller 
than 5 mm, well-differentiated tumours and tumours with low metabolic rate. Furthermore, 
many infections and inflammatory processes throughout the body can lead to false-positive 
PET/CT results. Careful considerations regarding cumulative radiation dose in children should 
be made, but this should not outweigh the importance of appropriate monitoring of treatment 
effects potentially leading to clinical decision making consequences (99). 
Furthermore, promising new tracers capable of monitoring angiogenesis (100), apoptosis 
(101), hypoxia (102), and other aspects of tumour metabolism (103)  are being developed. The 
possibilities of advanced staging modalities to current standards hold a great opportunity in 
optimization of RMS diagnostics and for selecting patients for targeted treatments in the near 
future. However, there is still an urgent need for decent prospective clinical trials including 
patients -regardless of age- to establish the use of these staging modalities into RMS daily practice. 
Table 3 IRSG and EpSSG risk stratification
IRSG (including patient up to 49 years) and EpSSG (including patients up to 20 years) risk stratification, with concurrent treatment and estimated 
survival rates. Survival rates are based on previous studies. ERMS= embryonal rhabdomyosarcoma, ARMS= Alveolar rhabdomyosarcoma NOS= not 
otherwise specified Favourable sites include: urogenital (non-bladder, non-prostate), head and neck (non-parameningeal), orbit, unfavourable includes 
all other sites. N0= lymph node involvement absent, N1= positive lymph nodes, Nx= unknown involvement lymph nodes. M0= No distant metastases, 
M1= distant metastases present.  I= ifosfamide, Do= doxorubicin, V=Vincristine, A=D-actinomycin, C= Cyclophosphamide, Topo= topotecan, CPT-11 
= irinotecan, XRT= radiotherapy RT= radiotherapy Asterix* post-surgical Clinical Grouping system.
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and EFS 78 versus 57%). The most striking differences in overall survival between the treatment 
strategies in the IRS-IV versus MMT-89 were observed in ARMS (5-year OS 71 versus 38%), limb- 
(5-year OS 71 versus 46%), and head and neck (head& neck non-parameningeal; 5-year OS 89 
versus 64%; and orbital RMS 100 versus 85%) RMS. Survival was nearly identical for genitourinary 
primaries (5-year OS 86 versus 80% in bladder and prostate primaries and 90 versus 94% other 
primaries) and parameningeal RMS (5-year OS 64 versus 59% in patients <3 years and 78 versus 
65% in patients ≥3 years). Although -based on these findings and cooperation between both 
groups- the current protocols more seem to converge, both strategies learned us much about 
local management of RMS. Long-term follow-up data are needed to evaluate the costs (e.g. 
acute and long-term morbidity and mortality)of both strategies. 
Besides initial treatment, local treatment of recurrent disease might increase survival rates from 
<10% to 30-40% (108). Lung metastectomy is rarely performed in RMS patients, as there is very 
little clinical evidence for its benefit in RMS (109). It might be that the number of patients with 
metastatic disease in childhood studies is too small, and that addition of adult RMS patients 
enables more extensive evaluation of the value of metastectomy in RMS. 
Another issue which might potentially compromise surgical management of RMS is decentralization 
of care. While most children presenting with an enlarging mass suspicious for a malignant disease 
are generally referred to a paediatric oncology unit in a specialized centre, adults may scatter out 
over a variety of surgical departments in sometimes even local hospitals. This may potentially 
result in an essential lack of experience, resulting in suboptimal surgical management by means 
of under- or over-treatment. 
Radiotherapy
Radiotherapy (RT) plays a significant role in treatment of RMS patients with 1) irresectable tumours 
at diagnosis (e.g. parameningeal or abdominal primaries); 2) microscopic residual disease after 
resection, and 3) completely resected disease but alveolar histology or lymph node involvement 
(110). The evaluation of the benefit of RT is hard to reflect since RT has been incorporated for 
a long time in RMS treatment protocols. RT at an early time point (within 9 weeks in the IRS-IV 
study) seems preferable over delayed RT, but delayed RT may be feasible in particular subsets 
of patients without compromising overall survival (i.e. in orbit or bladder/prostate primaries) 
(107). In patients with intracranial extension of parameningeal RMS, early administration of 
RT within 2 weeks resulted in a significant survival benefit, showing a local failure rate of only 
16% versus 37% in patients who received RT after >2 weeks from diagnosis (111). Furthermore, 
elimination of RT by the MMT studies was attempted in children <3 years with parameningeal 
RMS, resulting in a decreased OS from 62 to 44% (112). After radical surgical excision of RMS, 
ARMS seems to benefit modestly from RT with an increase in 10-year FFS from 25% to 30% 
(110). Furthermore, non-compliance to RT treatment schedules (i.e. omission/dose reduction 
or volume reduction) results in a higher rate of local recurrences in postsurgical group II disease 
(113). The most recent reported IRS V (D9620) trial, showed that RT dose reductions to 36 Gy 
(instead of 41.1 Gy in IRS-IV) do not result in lower local control rates in VA-treated stage 1/group 
IIA patients and group III orbital patients. Remarkably, RT reduction in patients treated with VAC 
An attempt for development of a uniform staging method should be undertaken to prospectively 
facilitate comparison. It is questionable whether the current childhood risk classification is 
suitable for guiding treatment decisions in adult patients because of the previously discussed 
differences in clinical presentation and tumour biology. As metastatic disease is seen more often 
in adult patients, combined studies could serve to enlarge the knowledge and to consequently 
optimize care for all patients with metastatic disease. This accentuates the need for inclusion of 
both children and adults in risk assessments, as this expanded population might provide new 
insights concerning risk stratification for all RMS patients. 
TREATMENT
Children with RMS are treated within multidisciplinary, risk adapted, cooperative multi-institutional 
trials. This provides a world-wide infrastructure in which RMS treatment in children is embedded. 
The groups conducting these trials are the Soft tissue Sarcoma committee of the children’s 
oncology group (COG, formerly intergroup RMS study group, IRSG) in the United States, and the 
recently formed European paediatric Soft tissue sarcoma study group (EpSSG). The latter was a 
result of joined forces of the International Society of Paediatric Oncology- Malignant Mesenchymal 
Tumor committee (SIOP-MMT), the German soft tissue sarcoma cooperative group (cooperative 
Weichteilsarkomen study, CWS), and the Italian Cooperative Group (ICG; associazione Italiana 
Ematologia Oncologia Pediatrica-Soft Tissue sarcoma committee, AIEOP-STSC). 
Controversially, the rarity of RMS in adults has resulted in a dispersion of patients over different 
centres. Despite adult sarcoma treatment collaborations (e.g. European Organization for Research 
Treatment in Cancer, EORTC) do exist; there is a general assumption that there is a lack of clinical 
trial availability and inclusion for adult patients with ERMS/ARMS. Adolescents (15-19 years) with 
RMS might be treated either in a paediatric or an adult oncology unit, dependant on referral 
pattern. In children, treatment is coordinated by a paediatric oncologist. Adults will be referred 
to different departments for the different treatment modalities, and will thus be surrounded by 
multiple specialists without a central point of care. 
Local treatment
Surgery
Although surgery is considered the mainstay of treatment for RMS in both adults and children, 
the optimal timing of local treatment (e.g. surgery and radiotherapy) has been under discussion. 
There was an essential difference in philosophy on optimal local treatment approach between 
the childhood study groups in Europe and the United states that reflect the current difficulties in 
treatment of RMS (107). The SIOP-MMT studies attempted to reduce aggressive local treatment, 
including avoidance of local treatment up to a time point after initial first-line or in the case 
of poor response even after second-line chemotherapy. On the contrary, the COG guidelines 
recommend aggressive local treatment (surgery and radiotherapy) at initial diagnosis, regardless 
of the potential side-effects. As a result, the MMT trial had to cope with an increased need for 
aggressive salvage treatment in the case of recurrence. Comparison of the COG IRS-IV study and 
the MMT-89 study shows an advantage of survival in the COG IRS-IV study (OS: 84 versus 71 % 
140 141
Building the bridge
stem cell rescue) failed to improve outcome (127). In adulthood soft tissue sarcoma treatment, 
controversial findings and opinions regarding the use of adjuvant chemotherapy still exist. As 
a result, aggressive local treatment is the mainstay of treatment in adult STS and information 
regarding the use of neo-adjuvant chemotherapy in adults with RMS is nearly absent. Additionally, 
when metastatic disease occurs, the adult patient is treated with palliative chemotherapy (either 
a single agent or a combination) when feasible. 
Importantly, a retrospective analysis of adult RMS patients by Ferrari et al in 2003, pointed 
out that older patients with ERMS and ARMS could benefit equally from adjuvant treatment 
as children do. Polychemotherapy schedules resulted in nearly identical survival rates as had 
been reported in children (61% overall and 72% for ERMS) (5). Nevertheless, there is an evident 
heterogeneity in chemotherapeutic agents and dose intensities administered over the past years 
for adult RMS impairing true comparison with the protocols used in childhood RMS. Due to the 
rarity of RMS in adults; there are no prospective studies available considering the feasibility of 
childhood regimens in older patients up to now. 
When an attempt is made to design a uniform protocol for children as well as AYA the potential 
differences in pharmacokinetics and pharmacodynamics should be considered, as this potentially 
results in different response rates, toxicity profiles and severity of toxicities with increasing age 
(128;129). 
With regard to RMS pharmacology in particular, vincristine clearance was shown to be lower 
in adolescents compared to younger children (age range 0.2-18 years, N=54), whereas another 
study could not establish this relationship between pharmacokinetics and age (age range 
1.2-17.3 N=98) (130-132). Furthermore, d-actinomycin shows a higher area under the curve in 
patients who were younger (<40 kg) when compared to adolescents potentially leading to a 
higher toxicity risk (133). However, another study of 33 patients (age 1.6-20.3 yrs) found that 
age had no discernible effects on D-actinomycin pharmacokinetics (134). Cytochrome p450, 
important for the metabolism of alkylating agents (cyclophosphamide, ifosfamide), has been 
shown to be increased in children when compared to adults, potentially resulting in modification 
of the therapeutic effect (135). Doxorubicinol, a toxic metabolite of doxorubicin has a decreased 
clearance if body fat is greater than 30% which might result in age-related cardiac toxicity risk 
as there is a change in body fat disposition from young childhood up to adult age (136).
In a large retrospective study concerning children with RMS, the acute toxicity profile of systemic 
treatment was shown to be age-related. Children aged <1 year are the most susceptible for 
D-actinomycin hepatotoxicity, whereas older patients are more susceptible to vincristine 
neurotoxicity. Consequently, a rate of over 50% grade 3 or 4 CTCAE v3.0 toxicity in patient > 
12 years with RMS was observed (137). Although this was confirmed by a second study (138), 
still the number of patients is low and further research into this harmful effect of vincristine in 
AYA is needed. Surprisingly, the latter study found a lower rate of haematological side effects 
in patients >15 years than in their younger counterparts (138). Alkylating agents, particularly 
cyclophosphamide and to a lesser extent ifosfamide, have shown a dose-dependent harmful 
showed worse survival in D9602 when compared to IRS-IV, indicating that cyclophosphamide 
in combination with higher RT dose results in higher local control rates (114).  
With regard to late toxicity, RT is one of the most harmful treatment modalities in cancer treatment 
resulting in a high rate of late morbidity such as development of fibrosis and secondary tumours 
(25;115). Because of its harmful effect on growing tissues, RT is generally administered with more 
caution in children. Besides, adults can also be very vulnerable to RT, for example in treatment 
for parameningeal RMS where older patients show an increased susceptibility for spinal cord 
injury following craniospinal irradiation and/or intrathecal treatment (116).
Promising techniques as intensity-modulated RT (IMRT), brachytherapy (BT) and proton beam 
RT are upcoming modalities for the local control of RMS. These techniques reduce loco-regional 
side effects and can thus reach a higher tumour dose without an increase of toxic side effects. 
The use of novel radiotherapeutic techniques has been investigated for various indications in 
adults but to a lesser extent in children. In RMS, these opportunities have been investigated in 
small cohorts and seem most promising in head and neck tumours, illustrated by the consecutive 
Ablative Surgery, MOld technique with afterloading brachytherapy and immediate surgical 
REconstruction protocol (AMORE-protocol, developed in 1993) (110;117-120). Importantly, a 
higher target dose coverage of IMRT when compared with conventional 3-dimensional conformal 
radiotherapy was recently reported in a decent cohort (N=375, COG-D9803) of intermediate 
risk childhood RMS, which did however not lead to an improved locoregional control or failure-
free survival rate (121). Brachytherapy also serves as a way to obtain bladder preservation and 
in order to reduce morbidity (i.e. incontinence, sexual function) in prostate/bladder RMS and 
female genital tract RMS (122-125).
Although the newer techniques seem less harmful, no data regarding long term effects are 
available yet. IMRT for example leads to a higher scattered dose to the whole body. Therefore, 
considerations concerning the use of these technique in children compared to adults should 
be made; 1) a smaller relative body volume will be exposed to the high scattered dose of IMRT; 
2) children are more sensitive to radiation-induced cancer compared to adults because of their 
longer life span; and 3) children with genetic susceptibility (for example germ line mutations) 
are also at higher risk for radiation-induced tumours (126). Although prospective information 
regarding long-term safety is widely unknown, IMRT, BT and PT are promising techniques in 
reducing acute toxicity of RT in RMS treatment and might be introduced as part of the standard 
treatment protocols in the near future. 
Systemic treatment
Chemotherapy has been the main topic of discussion in RMS treatment controversies in adults 
versus children in the past years. With the introduction of chemotherapy in the seventies, a 
dramatic improve in RMS survival in children was seen. The current strategies of the European 
as well as the North American RMS study groups are shown in table 3. Although optimization of 
these regimens has been performed, no revolutionary changes in current regimens for children 
have taken place since all proposed treatment protocols (including high-dose-chemotherapy with 
142 143
Building the bridge
effect on testicular function (FSH levels) and fertility (infertility occurring in up to 90% of male 
patients treated with cyclophosphamide for Ewing’s sarcoma/STS or Hodgkin’s lymphoma) (139-
141), and it seems that prepubertal age is related to a lower rate of gonadal toxicity in males 
when compared to older age (142). In females, age- and dose-dependent effects of alkylating 
agents on infertility and premature ovarian failure are reported as well, i.e. increasing age (post 
menarche) at the time of treatment increases the risk (143-146). 
The knowledge on age-related pharmacology needs to be expanded in order to develop 
appropriate protocols of chemotherapy in children, AYA and adult patients with RMS. Close 
collaboration with pharmacologists for monitoring of RMS patients providing information 
regarding pharmacokinetics and pharmacodynamics is therefore essential in future RMS treatment 
for monitoring and optimizing safety and efficacy. Furthermore, there is an urgent need for new 
therapeutic options in RMS patients of all ages in order to optimize the balance between costs of 
cure (e.g. acute and long-term morbidity and mortality) and potential benefit of RMS treatment. 
At the moment, there is a remarkably high incidence of treatment related (late) toxicity and a 
subsequent risk of a second tumour after RMS (observed-to-expected (O/E) ratio 7.7), caused 
mainly by radiation and chemotherapeutic treatment (O/E ratio of 15.2 in patient treated with 
chemo-RT versus 1.4 for surgery alone in all childhood STS) (147). 
NEW TREATMENT POSSIBILITIES
Potential targets
Potential targets for RMS treatment imply the different tumorigenic mechanisms. There are 
currently many new drugs available against receptors/growth factors, intracellular signalling 
molecules, cell cycle apoptosis proteins, proteasome, Hsp90 and Histone deacetylase (HDAC), 
angiogenic proteins, as well as the fusion protein in ARMS (PAX3-FOXO1). This was also reviewed 
by Wachtel and Schäfer in 2009 (table 4) (148).
Table 4
Possible treatment targets in RMS. 
Clinical trials
Trial availability 
To get proper insight in the availability of clinical trials for RMS patients, we performed a 
search for clinical trials over a period of ten years on www.clinicaltrials.gov (search criteria 
“rhabdomyosarcoma” and “sarcoma” N=761). We selected trials which started from the 1st of 
January 2001- 1st of January 2011, had actually been open for inclusion, studied an “intervention”, 
and indeed included RMS or soft tissue sarcoma patients. For the selected trials (N=221), specific 
data on ERMS and ARMS inclusion, minimum and maximum age at the moment of inclusion, and 
type of intervention (cytotoxic, targeted, immunotherapy, stem cell transplantation related, RT or 
other) were documented. An overview of trial availability by age and trial phase is summarized 
in figure 2a -2c. 
A focus on phase I and I/II combined trials revealed a total of 106 trials available over a 10-year 
period which explicitly included sarcomas/RMS. A substantial part (N= 43; 40,6 %) of sarcoma/
RMS phase I trials included children <18 years. Secondly, we looked in more detail to trials with 
targeted treatment (N=34), or tumour immunology related treatment (N=6) in patients <18 years 
(table 5a and table 5b). Obviously, an increase in availability of trials with targeted treatment 
is seen over time, as the number of trials conducted from 2006-2011 doubled when compared 
to 2001-2005 (N=23; 67.6 % versus N=11; 32.4%, respectively). 
A focus on phase III availability revealed a total of 14 trials for the period 2001-2011 (displayed 
in table 5c). These included first-line treatment (10), maintenance treatment (1) and treatment 
of refractory/recurrent RMS (3). First-line studies focussed on image-guided IMRT (1), and 
chemotherapy (9). Six of the first-line chemotherapy trials represent the IRSG and European 
childhood study groups protocols. The other first-line chemotherapy studies (3) included one 
EORTC study which administered doxorubicin/ifosfamide including metastatic/advanced ARMS 
(age ≥18 years),  one industry-sponsored study testing trabectedin versus doxorubicin including 
ARMS patients ≥18 years, and one study of doxorubicin with palifosfamide in patients ≥18 years 
(ERMS/ARMS inclusion was not exclusively mentioned). 
It is remarkable that IRSG study protocols include patients up to age 50 years, whereas the 
European study protocols (EpSSG, CWS) have an upper age limit of 20 years. However, despite 
inclusion criteria up to 50 years, the recent D9602 (low risk) study only managed to include 
one patient aged 27, and all others were younger than 21 years (114). Importantly, ERMS was 
excluded in two out of three adult STS phase III trials involving chemotherapy. This clearly reflects 
the urgent need for cooperation between these groups. 
Clinical trial design and infrastructure
In general, there is a lack of availability of new therapeutic agents in children when compared 
to adults. This is probably a result of the rarity of paediatric malignancies in general, which 
makes cooperation with pharmaceutical agencies a much greater challenge when compared 
to the large patient numbers available in adult oncology. At the moment, regulations of the 
European Medicines Agency (EMA) ‘Paediatric committee’ as well as the U.S. food and drug 
Modified from Wachtel et al (148). Bold= targets under investigation in phase I/II clinical trials.
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Figure 2 (color figure page 199)
Clinical trial availability explicitly for sarcoma/RMS
Clinical trial availability explicitly for sarcoma/RMS by phase (I/II/III) , type of intervention (chemotherapy, targeted therapy, 
immune-related therapy, stem cell transplantation (SCT), Radiotherapy, and other) and for each year of age 0-55 years over the 
ten-year period  1st January 2001- 1st January 2011. It is of note that our search on sarcoma/rhabdomyosarcoma results in a 
major underestimation of phase I trials available in these patients of adult age, because this indication is often not mentioned 
explicitly in study description. 
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administrations’ ‘Best Pharmaceuticals for Children Act’ (BPCA) and the ‘Pediatric Research Equity 
Act’ (PREA), encourages and forces pharmaceutical companies to test new agents in children as 
well (149;150). This hopefully provides a basis for a wider availability of novel treatment options 
in children with cancer as well as their older counterparts. However, the availability of multiple 
targeted treatments in phase I and II studies for a relatively low number of patients might 
controversially discourage enrolment, as selection of the appropriate trial for a patient becomes 
too complicated. Furthermore, due to national governments’ regulations on drug administration 
in children and ethical complaints in many countries the enrolment of children in phase I trials is 
extremely difficult. Worldwide collaboration is needed to provide an infrastructure and regulate 
the optimal balance between trial availability and enrolment. 
Besides trial availability issues, an extremely important issue to consider is the world-wide low 
accrual of AYA patients into clinical trials. Although an increase in inclusion rate is reported by 
recent studies, still, improvements have to be made for this group (151). The National Cancer 
Institute (NCI) network shows to be extremely important in providing clinical trials and providing 
the network for centres to participate in these trials in the United States (148). Furthermore, the 
NCI supports the multicenter drug development initiative “Pediatric preclinical testing program” 
(PPTP) which has provided important (preclinical) translational research aiming at the usefulness 
of the introduction of targeted agents in children (152). 
CRITICAL ISSUES IN RMS PATIENT CARE
Table 6 summarizes the critical points in design of RMS care. In general, the rarity of RMS 
illustrated by its incidence rates clarifies the scope of the problem, given that the incidence 
declines very fast after the age of 20 years and true information regarding ERMS and ARMS 
incidence in adult populations is scarce. Furthermore, the etiological and biological diversity 
in RMS in adults versus children remains to be revealed. Therefore, epidemiologic and genetic 
studies in both children and adults are indispensable in order to increase knowledge about the 
different etiologic patterns and nature of RMS at different ages.
Histological diagnosis is the corner stone of diagnosis of RMS. The infrastructure for histological 
RMS diagnosis in children already exists, as this must be confirmed by a central review pathologist 
prior to inclusion into a clinical trial. Although boards for pathological review of RMS in adult 
do exist, probably not all diagnoses are truly confirmed and the differential diagnosis is 
challenging. 
There is an essential deficit of prospective information concerning staging and risk stratification in 
adult versus children with RMS. As clinical presentation in adults seems more unfavourable than 
reported in children, it is questionable whether the current childhood risk classifications as well 
as the staging procedures are appropriate in adults as well. An attempt for the development of 
uniform staging methods as well as appropriate risk assessments should however be undertaken 
to facilitate comparison. Besides optimization of current standards, additional efforts should aim 
at trial availability for prospective testing of novel staging techniques in RMS patients of all ages.
Treatment in adults versus children with RMS has been incomparable up to now, and even 
within the childhood RMS study groups controversies do exist. Age is an important factor 
to consider as it greatly influences treatment decisions and possibilities.  The major existing 
controversy in treatment of adult and childhood RMS is the use of chemotherapy. Increased 
knowledge concerning age-related pharmacology has to be obtained in order to develop feasible 
chemotherapy protocols in adults. Close collaboration of both paediatric and adult oncologists 
with pharmacologists for close monitoring to provide information regarding pharmacokinetics 
and –dynamics are therefore essential in future RMS treatment to monitor and optimize safety 
and efficacy. 
Still, there is an urgent need for new therapeutic agents in RMS. Despite extensive preclinical 
research, the availability of clinical implementation of these targeted therapies is essentially 
compromised by the low incidence of RMS and pre-clinical research is performed scattered around 
the world which prohibits a quick move of new potential active drugs from bench to bedside. 
Table 6
Critical issues in RMS management
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Key players in the “global RMS treatment group” should involve a panel of experts involved in 
RMS, i.e. paediatric and adult sarcoma pathologists, paediatric oncologists as well as medical 
oncologists, radiotherapists, and paediatric as well as adult surgeons of different specialties, 
as well as representatives from pharmaceutical companies. Furthermore, cooperation might 
highlight differences in needs for different age groups (RMS-specific as well as non-RMS-specific); 
for example fertility issues, long term follow-up methods, and the transition from paediatric 
to adult oncology (156). It could be very helpful to involve patient/parent advocacy groups 
in order to achieve global collaboration, since these groups often work in close international 
association. Moreover, to deliver age-adjusted healthcare for all patients with RMS, it is crucial 
letting the patients and their parents participate in this process and making us clear what they 
are in need of. Due to involvement and participation of patient and parent advocacy groups an 
impulse can be given to both cure and care. 
Infrastructure and clinical trials
The currently available infrastructure for RMS treatment is mainly that of the childhood RMS 
treatment groups; the EpSSG and the COG. Preferably they should collaborate on RMS protocols 
within existing networks for adult sarcoma patients such as e.g. SARC and EORTC, and the 
World Sarcoma Network. This would enhance attractiveness for pharmaceutical partners to do 
studies in even this rare group of tumours and would increase the speed of accrual in clinical 
trials. Improvement of clinical trial availability and accrual is essential to make a step forward in 
the optimization of the current staging and treatment standards as well as the implementation 
of new diagnostic and therapeutic options for RMS patients of all ages. Nationwide as well as 
global awareness for the need of trial accrual of patients should be aimed at, in order to enlarge 
the trial accrual especially in young RMS patients. Although improvements concerning the 
availability and accrual to clinical trials in AYA have been made, within this respect AYA patients 
need ongoing attention. 
Future perspectives 
The outlined concept might also provide a rationale for the management of additional rare 
tumour types in which there is overlap between children, adolescents and (young) adults, i.e. 
Ewing’s sarcoma, osteosarcoma and certain brain tumours. Some economy of scale can be 
reached by grouping the management of these tumours as happens already in certain network 
organisations. Although it probably will take quite a couple of years if we start from now, a steep 
increase in knowledge of RMS and other rare tumours of AYA age can be generated in order to 
develop world-wide standardized treatment, and to achieve the best quality of care and cure 
for patients of all ages.
FACILITATING THE ROAD AHEAD
Despite its rarity, there is no doubt that AYA patients with RMS do deserve equal attention as well 
as established standardized treatment as their younger counterparts currently do. The virtual 
distinction between RMS treatment in children and adults not only impairs optimization of 
treatment, but also of diagnosis, staging, new drugs, and organization of patient care. Therefore, 
bringing the knowledge obtained from both worlds together is essential to provide a basis for 
development of standardized treatment protocols, facilitation of introduction of new treatment 
possibilities and optimization of care for RMS patients of all ages in the near future.
 
Centralization and concentration
The number one challenge concerning RMS we have to overcome is the rarity of this tumour 
in children as well as adults. The solution from paediatric oncologists to this problem involves 
treatment concentration and global collaboration as fundamental strategy as reflected by the 
existing large childhood cooperative groups. RMS care in adults is seriously compromised by a 
relative lack of concentration and collaboration, resulting in the dispersion of patients treated at 
numerous adult oncology centres and departments.  In general, it seems that RMS care should 
ideally take place in a specialized centre with experienced clinicians in order to obtain the best 
survival rates. 
Cooperation and collaboration
The key players in RMS treatment are both paediatric and medical oncologists. Ideally, this 
cooperation will lead to an increase in knowledge by learning from each other’s experiences 
and treatment concepts. An example of a project improving the awareness of clinicians with 
regard to treatment of rare tumours that are underrepresented in their daily practice population 
is the Tumori Rari in Eta` Pediatrica “TREP” project, which was grounded in Italy in 2000. The TREP 
project was initiated by paediatric oncologists to reach national collaboration of paediatric and 
medical oncologist for treatment of tumours which are very rare in children but common in 
adults. The intent for a call for guidelines came from paediatric oncologists not familiar with these 
tumours, which are rare-but not absent- in children, and were provided by medical oncologists. 
Such an approach might be feasible for RMS; however, one should add a critical side-note as 
the TREP project was embedded in the existing infrastructure and centralized care for children 
with cancer (153). In 2002, the COG followed with a committee for rare tumours at paediatric 
age. Their specific purposes were to develop an organizational framework to facilitate the 
study of infrequent tumours and create registries, biospecimen banks, and clinical trials (154). 
Centralization of informational support concerning rare diseases was facilitated by grounding 
of the National Organization of Rare Disorders Network (NORD; http://www.rarediseases.org). 
The global cooperation of medical oncologists in European, USA and Australian study groups 
in treatment of gastro-intestinal stromal tumour (GIST) is the example that collaboration in a 
rare adult-type tumours can also be very successful (155). These collaborations might serve as 
a starting point of RMS treatment design. 
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Summary
Over the past decades, there has been a relative lack of awareness of adolescent and young adult 
(AYA) patients with cancer. This is reflected by the relatively low accrual and participation of this 
subpopulation in clinical trials, which is held as one of the factors responsible for a consequent 
lack in survival benefit when compared to their younger counterparts. Importantly, the AYA cancer 
population is unique in ways of a typical tumour type distribution, overlapping both child- and 
adulthood cancers. Furthermore, the awareness of the AYA population being distinct in terms of 
specific needs and concerns (e.g. fertility, insurance, employment, psychosocial issues) is rising. 
The basis to increase awareness and facilitate the development of tailored treatment and care 
of this young cancer population is a throughout description of the epidemiological features 
(e.g. incidence, distribution, survival) of cancers affecting this population. Another important 
feature to consider in both children and AYA with cancer is their generally long life-expectancy 
after surviving cancer, accompanied by an increased risk of development of long-term cancer 
related issues, including long term morbidity/mortality and second malignancies.
In chapter 2 we characterized the population-based incidence and survival of 1,118 AYAs (12-
24 years) with cancer diagnosed in the Northern Netherlands between 1989 and 2003. The 
main tumour types represented in AYA males were germ-cell tumours (predominantly non-
seminomatous testicular cancer), lymphoma, and central nervous system tumours. In females, 
lymphoma showed the highest incidence, followed by carcinoma and melanoma. The total 
incidence of cancer in AYA increased (estimated annual percentage change, EAPC 2.2%). Survival 
did not change over the study period (overall 5-years survival 80.8%). Survival was high for 
lymphoma, germ cell tumours, carcinoma and melanoma, while survival was poor for leukaemia, 
soft tissue and bone sarcoma and central nervous system tumours. The Standardized Incidence 
Ratio (SIR) of a second primary tumour in this young cohort was high (30.6), corresponding to 
a cumulative incidence at ten years of 2.8%. 
In chapter 3 we reported an extended study concerning 23,161 AYAs (15-29 years) diagnosed 
with cancer in the Netherlands between 1989 and 2009. This study confirmed a significant 
increase in incidence over time, predominantly in males (EAPC 1.9%) when compared to females 
(EAPC 1.4%). The tumour type distribution as well as the overall survival rates (82.0 and 83.0% 
in males and females, respectively), were nearly identical compared to the study described in 
chapter two. With a median follow-up time of 6.8 years, 412 AYAs experienced a second primary 
tumour (1.8%). The SIR of a second primary tumour was lower than in the previous study in the 
Northern Netherlands; males 5.5 and females 5.3. The most striking result was the more than 
seven times increased risk of breast cancer after Hodgkin’s lymphoma (n=26, SIR 7.4).
Rhabdomyosarcoma (RMS) is a rare type of soft tissue sarcoma that represents an ultimate example 
of a typical childhood malignancy which also occurs across the AYA age-spectrum and shows 
inferior survival rates in the older population. Despite the successive survival rates reported in 
children with RMS, the survival in particular subgroups of patients (e.g. those primarily diagnosed 
with alveolar histology, distant and/or lymph node metastases at diagnosis, diagnosed at older 
age, or with refractory/recurrent disease) remains disappointing. This urges the need for new 
therapeutic treatment strategies.
In chapter 4 we reported that age is an independent prognostic factor of survival in 
rhabdomyosarcoma (RMS) patients based on a multivariate analysis in a multi-center retrospective 
cohort study of 169 patients (aged 0-73 years). As expected we observed a typical age-distribution 
of the two main histological subtypes of RMS; embryonal RMS (favourable prognosis, median 
age 7 years) and alveolar RMS (unfavourable prognosis, median age 15 years). Furthermore, 
older age was related to unfavourable clinical presentation (e.g. metastatic disease in embryonal 
RMS and parameningeal location of alveolar RMS). Survival for patients under 16 years of age 
was significantly better when compared to patients age 16 or older in the whole cohort, as well 
as in embryonal RMS, alveolar RMS, and non-metastatic embryonal RMS. Metastatic disease 
was also an important adverse prognostic factor for all patients with RMS (survival of patients 
diagnosed with metastatic disease did not exceed 10%). In multivariate analysis, age was a 
significant prognosticator of disease specific survival in all subgroups (all patients, embryonal, 
alveolar and non-metastatic embryonal RMS).
In chapter 5 we reported that anaplastic lymphoma kinase (ALK) protein expression and ALK gene 
copy number gain was detected in the vast majority of alveolar RMS (80-90%), compared to 30-
50% of embryonal RMS (p<0.001), thereby providing a potential treatment target. Furthermore, 
ALK copy number correlated with ALK protein expression in all primary tumours. ALK gene 
translocations were not observed. Importantly, we identified a novel missense mutation, as well 
as whole exon deletions in 7/43 patients and in one RMS cell line. Linkage of ALK status with 
clinical characteristics and outcome revealed that specific ALK gain was related to metastatic 
disease at diagnosis and consequently worse survival in embryonal RMS. 
In chapter 6 we reported a study on both insulin-like growth factor 1 receptor (IGF-1R) and ALK 
as potential targets for combined treatment in RMS. Expression of IGF-1R was seen in an equal 
amount of alveolar RMS (72%) and embryonal RMS (62%). Interestingly, we observed nuclear 
expression of IGF-1R in up to 10% of RMS, and this was related to worse survival in embryonal 
RMS. ALK expression was already described in chapter 5. Co-expression of IGF-1R and ALK was 
observed in a significant amount of alveolar RMS (68%) and embryonal RMS (32%). Therefore, 
these targets might be of major interest for simultaneous inhibitory treatment in RMS. We 
consequently tested the potential of IGF-1R-, ALK- and simultaneous inhibitory treatment in vitro. 
Inhibition of IGF-1R (R1507) resulted in diminished cell growth only in alveolar RMS cell line Rh41. 
The ALK inhibitor NVP-TAE-684 resulted in diminished cell growth in aRMS cell lines Rh41 and 
Rh30, and to a lesser extent in eRMS cell lines Rh18 and RD. Simultaneous treatment revealed a 
synergistic effect of R1507 and NVP-TAE684 in Rh41.  Based on these results, we conclude that in 
RMS targeting of the ALK receptor, as well as simultaneous targeting of IGF-1R and ALK warrant 
further research, especially in patients with alveolar RMS and metastatic embryonal RMS. 
In chapter 7 we review the current data available concerning RMS treatment in children, 
adolescents and (young) adults. It provides a profound overview which highlights the similarities 
and differences in children and adults with RMS in terms of epidemiology, tumour biology, 
diagnosis, treatment approach, and accrual to clinical trials with promising new agents. The 
findings as provided in this review consequently lead to a concept for a global cooperation 
and centralization of treatment of patients of all ages, thereby facilitating progress in scientific 
knowledge and in the introduction of new agents in the future.
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of a handful of studies mostly concerning late effects after a single type of malignancy at AYA 
age (5). Long-term follow-up studies focusing on the specific issues after surviving AYA cancers, 
should therefore be a fundamental part of improvement of AYA cancer care. 
Last but not least, AYA with cancer are unique in ways of their specific needs including psychosocial 
care, fertility issues, work and employment, relationship and society related issues. Therefore, 
multiple initiatives have recently been taken world-wide to ensure specialized care for AYA cancer 
patients, including the development of AYA cancer departments/clinics/programs facilitating 
concentration of care and giving the opportunity to focus on their short- and long-term needs 
(1). The basis of tailored AYA cancer care is thus seeded, but the following years will point out 
whether we can harvest the effect of all effort. 
Rhabdomyosarcoma (RMS) represents an ultimate example of a childhood tumour covering a 
wider age spectrum; children and AYA. Therefore, we performed a multi-center retrospective 
study which underlines the adverse outcome of this tumour type in AYA compared to children 
(chapter 4). This is in line with the observations in population-based studies concerning AYA (i.e. 
poor survival of childhood tumours in AYA compared to children, also highlighted in chapter 2 
and 3) (15). We observed that higher age at diagnosis was related to advanced stage of disease at 
diagnosis (e.g. metastatic disease and lymph node involvement), which might be contributable 
to an age-dependent difference in tumour biology (more aggressive tumour phenotype) but 
also a potential delay in diagnosis in older patients, which is either patient-related, doctor-related 
or both. As treatment differences have been held responsible for the difference in survival, we 
made an effort to include treatment variables into a multivariate prognostic model. However, we 
were confronted with the compromising effect of the generally existing differences in treatment 
approach (especially in chemotherapeutic regimens) in children versus adults. The importance 
of these unsatisfactory findings is strengthened by an earlier study which indicated that survival 
rates in adults with RMS may be equal to children when ‘appropriate’ treatment according to 
childhood standards is given (16). Because it remains unknown to what extent biological and 
treatment effects play a role in the observed survival difference in children versus adults, this 
remains to be elucidated in prospective studies after introduction of uniform treatment schedules, 
which requests centralization of care for adults with these very rare tumours.
Molecular targeted compounds are upcoming in cancer treatment and also in sarcoma (17). 
During the development of targeted agents, many compounds fail to reach clinical application in 
sarcomas, due to preliminary ending of clinical trials after being unsuccessful in more common 
tumour types, and because pharmaceutical partners face more complexity in trial organization 
in studies in rare (subtypes of ) sarcomas. Therefore, international collaboration is of utmost 
importance in the field of sarcoma, which is currently the case in Europe via the European 
Organization for Research and Treatment of Cancer (EORTC) and for which the World Sarcoma 
Network has been raised. In this way we hope to prevent that for sarcoma treatment new and 
interesting drugs are thrown out as babies with the bathwater (18). 
GENERAL DISCUSSION AND FUTURE PERSPECTIVES
Adolescents and young adults (AYA) suffering from cancer are a very heterogeneous group 
of patients with specific needs and tumourtype specific treatment-related care issues during 
and after treatment. Although the age group to which AYA refers is still a world-wide topic of 
discussion, it usually refers to patients aged 15-39 years or smaller intervals within this range 
(1). Although cancer in AYA is relatively rare (2-3% of all cancers), the incidence is nearly three 
times higher than in children (2). In contrast to the world-wide improvements of both pediatric 
and adult cancer care over the past decades, the awareness has grown that there has been a 
relative lack of attention for this age group resulting in the “adolescent and young adult gap 
in cancer care” (3).
Epidemiological knowledge concerning the AYA cancer population is of major importance 
for the development of tailored cancer care programs for this particular group of patients. 
Population-based studies (as described in chapter 2 and 3 of this thesis) reveal that there is a 
typical age-related shift in incidence pattern of cancer types in AYA. Patients up to age 20 show 
the tail of childhood tumours (including acute lymphoblastic leukemia, Wilms tumours, certain 
subtypes of central nervous system tumours, and typical age-related sarcoma subtypes as 
rhabdomyosarcoma which will be discussed in more detail later on), while in older AYA patients 
adulthood tumours as breast carcinoma, thyroid carcinoma and melanoma are emerging. In 
between, the typical tumours of AYA age occur, such as testicular germ cell tumours and Hodgkin’s 
disease. This unique distribution of tumour types causes them to be a heterogeneous group of 
patients which doesn’t belong to specific childhood or adult cancer services.
The resulting effect is of major concern; although overall AYA show a relatively high survival rate 
of 80%, those diagnosed with typical childhood tumours show a fairly poor survival and there is 
an obvious deficit in survival improvement over the past decades when compared to children 
(2). Although a relatively low accrual to, and availability of, clinical trials in this subpopulation has 
been held responsible for this lack in survival, the most reasonable explanation is with certainty 
multifactorial and is supposedly tumour-related (differences in tumour biology), patient-related 
(delay in seeking medical help, worse tolerance of therapy, worse compliance), and health-care 
related (delay in diagnosis, treatment by professionals who are not familiar with the disease, 
decentralized care, and as earlier mentioned a lack of clinical trial availability and enrollment) (4). 
“The cancer is over, now what?” (5). Late effects after suffering from AYA cancer are of major 
concern in these young cancer survivors with a generally long life expectancy. This is underlined 
by the high incidence of second tumours that we observed in both AYA studies, which probably 
even underestimates the real incidence due to relatively short follow-up. Besides second 
tumours, we should pay attention to other long-term morbidity/mortality as seen after cancer 
treatment in AYA, for example coronary artery disease after chest irradiation (6), heart failure in 
anthracycline treated patients (7;8), cardiovascular disease after cisplatin-based chemotherapy in 
testicular cancer (9), and multiple health issues in allogeneic hematopoietic stem cell transplant 
recipients (5). In children, major cancer survivor studies have been conducted with long-term 
follow-up data (10-14), while AYA cancer survivor studies are relatively scarce, with the exception 
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In a search for new targets of treatment for rhabdomyosarcoma, two earlier studies (19;20) pointed 
towards a potential role of anaplastic lymphoma kinase (ALK) in RMS. This consequently formed 
the basis for chapter 5, where we describe anaplastic lymphoma kinase (ALK) as a potential target 
for treatment of RMS. We identified genetic alterations of the ALK gene (e.g. gain or amplification, 
whole exon deletions, and one novel mutation). The most important clinical finding was the 
observed relation between specific ALK gain (primary tumour) and metastatic disease as well as 
poor survival in embryonal RMS. Our observations and those previously reported by others, pose 
questions to a potential oncogenic role of ALK in RMS. Also, our study gives direction towards 
ALK as an important target for future RMS treatment (especially in patients with alveolar RMS 
and patients with advanced disease). We are therefore looking forward to the clinical outcomes 
of the planned phase II CREATE trial of the EORTC (NCT01524926), testing Crizotinib (ALK-MET 
inhibitor) in patients with advanced sarcoma, including locally advanced/metastatic aRMS. 
The most extensively investigated target in RMS is probably IGF-1R (21). Although the first 
clinical results for IGF-1R inhibitors in sarcoma have been less promising than expected based 
on pre-clinical studies, we still feel that IGF-1R signalling is important in RMS. Therefore, we are 
convinced that IGF-1R inhibitors, maybe in combination with conventional chemotherapy or 
other targeted drugs, deserve further investigation. 
In chapter 6 we investigated combined inhibition of IGF-1R and ALK. We observed that co-
expression of ALK and IGF-1R was frequently seen in RMS tumour samples and that simultaneous 
ALK and IGF-1R inhibition in vitro revealed a synergistic effect in one alveolar RMS cell line. 
Remarkably, we also identified a negative prognostic value of nuclear IGF-1R in embryonal RMS, 
however the functional effect of nuclear localization of the receptor is still unknown. 
Besides the general obstacles to overcome in the development and implementation of targeted 
agents (clinical trial design, patient selection, biomarkers, development of potential combination 
strategies), the rarity of these tumours represents an additional compromising factor. Therefore, 
we recommend global cooperation for the introduction of standardized (comparable) treatment 
regimens for RMS in children and adults, as well as optimization of the prior conditions for the 
introduction of promising new treatment strategies, as was subject of the review in chapter 7. 
Moreover, this review also can serve as a basis for other rare pediatric solid tumours occurring in 
the AYA population such as for example Ewing sarcoma, osteosarcoma, and medulloblastoma. 
General conclusion
In this thesis, we address two major issues in young cancer patients. First, we aim to provide 
a step forward to increase the worldwide awareness of the existence and unmet needs of the 
AYA cancer population. And we use RMS as a specific cancer type to discuss the position of AYA 
within this population. Second, we give insight into potential new treatment strategies for RMS 
patients and a concept to pass the river between care and treatment for rhabdomyosarcoma 
in children and adults. Optimization of AYA cancer care, as well as optimization of care for RMS 
patients of all ages can only be reached by efforts of all key players in the treatment of these 
rare groups of patients, by the introduction of standardized treatment and care, as well as 
collaboration at a global level. 
“Because the people who are crazy enough to think they can change the world, 
are the ones who do.” 
Steve Jobs
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in oudere patiënten een slechtere overleving wordt zien. Ondanks de toegenomen overleving 
in kinderen met een rhabdomysarcoom, is ook in de overleving in bepaalde subgroepen nog 
steeds slecht (patiënten met tumoren met alveolaire histologie, lymfeklier- of afstandsmetastasen 
bij diagnose, of patiënten met therapie-ongevoelige ziekte of recidief van de ziekte). Daarom is 
er een urgente noodzaak voor het ontwikkelen van nieuwe therapeutische opties. 
In hoofdstuk vier beschrijven we dat leeftijd een onafhankelijke negatieve voorspeller van 
overleving is in een multivariate analyse van patiënten met een rhabdomyosarcoom in een 
retrospectieve cohort studie. De populatie in deze studie betrof 169 patiënten (leeftijdscategorie 
0-73 jaar), die werden behandeld in meerdere universitaire medische centra in Nederland over 
de afgelopen decennia. Hierbij werd een typische leeftijdsverdeling van de twee belangrijkste 
subtypen gezien; het embryonale rhabdomyosarcoom (gunstige prognose, mediane leeftijd bij 
diagnose 7 jaar) en het alveolaire rhabdomyosarcoom (ongunstige prognose, mediane leeftijd 
bij diagnose 15 jaar). Bovendien bleek een hogere leeftijd bij diagnose geassocieerd te zijn met 
ongunstige klinische presentatie (zoals gemetastaseerde ziekte bij het embryonale subtype 
en parameningeale lokalisatie bij het alveolaire subtype). De overleving voor patiënten onder 
de leeftijd van 16 jaar was significant beter vergeleken met patiënten van 16 jaar en ouder 
in het hele cohort, maar ook in de subgroepen embryonaal rhabdomyosarcoom, alveolair 
rhabdomyosarcoom en niet-gemetastaseerd embryonaal rhabdomyosarcoom. Bovendien was 
gemetastaseerde ziekte een belangrijke ongunstige prognostische factor in alle patiënten met 
een rhabdomyosarcoom (5-jaars overleving minder dan 10%). 
Ook in multivariate analyse bleek leeftijd een onafhankelijke voorspeller voor slechtere overleving 
in alle patiënten, evenals in patiënten met het alveolaire of embryonale subtype en in patiënten 
met een niet-gemetastaseerd embyonaal rhabdomyosarcoom. 
In hoofdstuk vijf beschrijven we anaplastic lymphoma kinase (ALK) eiwitexpressie en winst van het 
aantal kopieën van het ALK gen in het overgrote merendeel van de alveolaire rhabdomyosarcomen 
(80-90%) en tevens in een aanzienlijk deel van de embryonale rhabdomyosarcomen (30-50%). 
Hiermee vormt het een potentieel doelwit voor nieuwe therapieën. Bovendien correleerde het 
aantal kopieën van het ALK gen met ALK eiwitexpressie in het hele cohort. Translocaties van het 
ALK gen werden niet gezien. Tevens identificeerden we één nooit eerder gevonden mutatie, en 
deleties van hele exonen in het messenger RNA (mRNA) van 7/43 tumoren evenals in één van 
de vier onderzochte cellijnen. Het koppelen van de ALK gen en eiwitexpressie status met de 
klinische parameters en overleving, toonde aan dat specifieke winst van het ALK gen gerelateerd 
was aan de aanwezigheid van metastasen op afstand en daarmee een slechtere overleving in 
het embryonale rhabdomyosarcoom.  
Hoofdstuk zes beschrijft een studie die focust op zowel de insulin-like growth factor 
1 receptor (IGF-1R) en ALK als potentiële doelwitten voor gecombineerde therapie in het 
rhabdomyosarcoom. Expressie van IGF-1R werd zowel gezien in het alveolaire (72%) als in het 
embryonale rhabdomyosarcoom (62%). Opmerkelijk hierbij was de observatie van nucleaire 
IGF-1R expressie in ongeveer 10% van de tumoren, waarbij dit bovendien gerelateerd was aan 
een slechtere overleving in het embryonale subtype. Co-expressie van beide receptoren werd 
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Gedurende de afgelopen decennia zijn adolescenten en jong volwassenen met kanker relatief 
onderbelicht. Dit wordt onder andere weerspiegeld door de lage inclusiecijfers in klinische 
trials, wat tevens wordt gezien als een belangrijke oorzaak voor de relatief slechte overleving 
vergeleken met kinderen met kanker. Er is een groeiend bewustzijn dat adolescenten en 
jongvolwassenen een unieke populatie zijn met specifieke behoeften en zorgen (bijvoorbeeld 
fertiliteit, verzekeringen, werk, psychosociale problematiek). De basis voor het onder de aandacht 
brengen en faciliteren van patiëntgerichte behandeling en zorg voor deze populatie, is het in 
kaart brengen van de epidemiologische paramaters van kanker in deze populatie (incidentie, 
verdeling van tumoren, overleving). Gezien de relatief lange levensverwachting na de overleving 
van kanker, is een ander aandachtspunt in deze jonge populatie het verhoogde risico op het 
ontwikkelen van lange termijn effecten (morbiditeit, mortaliteit en tweede tumoren).
In hoofdstuk twee van dit proefschrift beschrijven we de incidentie en overleving van 1118 
adolescente en jong volwassen patiënten (leeftijdscategorie 12-24 jaar) met een maligniteit, 
gediagnosticeerd in de regio Noord-Nederland tussen 1989 en 2003. De meest frequente 
tumortypen bij mannen in deze populatie betroffen kiemceltumoren (vooral non-seminomen 
van de testis), gevolgd door lymfomen en tumoren van het centrale zenuwstelsel. Bij vrouwen 
werd de hoogste incidentie gezien voor lymfomen, gevolgd door carcinomen en melanomen. 
De totale incidentie van maligniteiten in adolescenten en jong volwassenen nam over de 
studieperiode toe met gemiddeld 2,2% per jaar. De 5-jaars overleving bleef gelijk gedurende de 
studieperiode (80,8%). De 5-jaarsoverleving was relatief gunstig voor patiënten met lymfomen, 
kiemceltumoren, carcinomen en melanomen, terwijl de overleving voor patiënten met leukemie, 
weke delen- en botsarcomen, en tumoren van het centrale zenuwstelsel ongunstiger was. De 
gestandaardiseerde incidentie ratio (SIR) van tweede tumoren in dit jonge cohort was hoog 
(30,6), wat overeenkomt met een absolute incidentie van 2,8% na 10 jaar.   
In hoofdstuk drie beschrijven we een meer uitgebreide studie betreffende 23161 adolescenten 
en jong volwassenen (15-29 jaar) gediagnosticeerd met een maligniteit in heel Nederland tussen 
1989 en 2009. Deze studie bevestigde de significante stijging in incidentie over de tijd zoals 
beschreven in hoofdstuk twee, waarbij deze stijging meer uitgesproken was bij het mannelijke 
geslacht (geschatte jaarlijkse incidentiestijging 1,9%) ten opzichte van het vrouwelijke geslacht 
(1,4%). De verdeling van tumortypen en de overlevingspercentages (82,0% en 83,0% in mannen 
en vrouwen respectievelijk) waren nagenoeg identiek ten opzichte van de studie beschreven 
in hoofdstuk twee. Met een mediane follow-up periode van 6,8 jaar, werd een tweede primaire 
tumor gevonden in 412 patiënten (1,8%). De SIR van tweede tumoren in dit cohort was echter 
lager dan in de voorgaande studie; 5,5 en 5,3 bij het mannelijke en het vrouwelijke geslacht 
respectievelijk. De belangrijkste bevinding was een meer dan 7 maal verhoogd risico op 
borstkanker na het Hodgkin lymfoom (26 patiënten, SIR 7,4). 
Het rhabdomyosarcoom is een zeldzame weke delen tumor die een expliciet voorbeeld vormt 
van een kindertumor die tevens in adolescenten en (jong) volwassenen kan optreden en waarbij 
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gevonden in 68% van het alveolaire en in 32% van het embryonale subtype. Gecombineerde 
remming van deze beide receptoren werd daarom onderzocht in rhabdomyosarcoom cellen 
in vitro (embryonale cellijnen Rh18 en RD, alveolaire cellijnen Rh30 en Rh41). Remming van de 
IGF-1R (met R1507) resulteerde in een evidente afname van groei in de alveolaire cellijn Rh41. De 
ALK remmer NVP-TAE-684 resulteerde in een afname van groei in de alveolaire cellijnen Rh30 en 
Rh41, en in mindere mate ook in de embryonale cellijnen Rh18 en RD. Combinatie behandeling 
kon worden getest in cellijn Rh41, waarbij een synergistisch effect van simultane remming van 
IGF-1R en ALK werd gezien. Al deze resultaten bij elkaar opgeteld, concluderen we dat ALK 
receptor remming, evenals gecombineerde remming van ALK en IGF1R verder moet worden 
onderzocht, en vooral veelbelovend kan zijn in patiënten met een alveolair rhabdomyosarcoom 
en in patiënten met een embryonaal rhabdomyosarcoom met ongunstige prognose. 
In hoofdstuk 7 beschrijven we de huidige kennis met betrekking tot de behandeling van 
kinderen, adolescenten en (jong) volwassenen met een rhabdomyosarcoom. We geven een 
gedetailleerd overzicht waarin we de overeenkomsten en verschillen beschrijven tussen kinderen 
en volwassenen met een rhabdomyosarcoom, waarbij we focussen op epidemiologie, tumor 
biologie, diagnostiek, behandeling en de inclusie in klinische trials met potentiële nieuwe 
behandelingen. De constateringen die hieruit voortkomen, leiden ons naar de beschrijving van 
een concept voor wereldwijde samenwerking en centralisatie van zorg voor patiënten met een 
rhabdomyosarcoom ongeacht de leeftijd bij diagnose. Hiermee beogen we de vooruitgang in 
wetenschappelijke inzichten en de vergemakkelijking van de introductie van nieuwe therapieën 
in de toekomst te bewerkstelligen.
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ADDITIONAL COLOR FIGURES
Additional color figures
Chapter 5 Figure 1A
ALK protein expression by IHC with the ALK1 antibody (DAKO) in RMS. 
Upper row: 1. ALK negative staining in ERMS, 2. ALK weak staining inERMS, 3. ALK moderately strong staining in ARMS, 4. ALK 
strong staining in ARMS. Lower row: corresponding heamatoxylin and  eosin (H&E) staining. Magnification: 20x 
Chapter 5 Figure 1B
Chromogenic in situ hybridization (CISH) of the ALK gene in RMS.
1. low level ALK gain up to 6 copies per nucleus (marked by black arrows) 2. Primary ARMS showing ALK amplification in all cells 
3. Amplification of the ALK gene with >30 ALK copies in an ERMS lymph node metastasis during treatment. Magnification: 40x.
Chapter 6 Figure 1
Immunohistochemistry of the ALK and IGF-1R receptor
Immunohistochemical staining (magnification 20x), A eRMS displaying very strong predominant nuclear IGF-1R staining; B aRMS 
displaying very strong cytoplasmic IGF-1R staining; C eRMS displaying strong cytoplasmic ALK staining; and D aRMS displaying 
very strong cytoplasmic ALK staining. 
Chapter 7 Figure 1a
Incidence rates of all subtypes of RMS in patients 0-29 years of age. 
*Data regarding patients with RMS >14 years in Europe  were not available
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Additional color figures
Chapter 7 Figure 1b
Incidence of ERMS and ARMS in the childhood population.
(33) CANCER, Vol. 115, No. 18, 2009, pages 4218-4226. Copyright 2011 American Cancer Society.  
This material is reproduced with permission of Wiley-Liss, Inc., a subsidiary of John Wiley & Sons, Inc.
Chapter 7 Figure 2
Clinical trial availability explicitly for sarcoma/RMS
Clinical trial availability explicitly for sarcoma/RMS by phase (I/II/III) , type of intervention (chemotherapy, targeted therapy, 
immune-related therapy, stem cell transplantation (SCT), Radiotherapy, and other) and for each year of age 0-55 years over the 
ten-year period  1st January 2001- 1st January 2011. It is of note that our search on sarcoma/rhabdomyosarcoma results in a 
major underestimation of phase I trials available in these patients of adult age, because this indication is often not mentioned 
explicitly in study description. 
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